Professor Christopher Sweeney
Director, SAiGENCI
SAIGENCI
College of Health
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Professor Christoper Sweeney MBBS is a Medical Oncologist and the inaugural Director of the South Australian immunoGENomics Cancer Institute (SAiGENCI) at the University of Adelaide.Professor Sweeney received his medical degree from the University of Adelaide, South Australia in 1992 and completed an internship at the Royal Adelaide Hospital. He did his residency in internal medicine at Gundersen Lutheran Medical Center (Wisconsin, USA) and a fellowship in Hematology/Oncology at Indiana University Medical Center (Indiana, USA), where he was later appointed Associate Director for Clinical Research for the Simon Cancer Center. Professor Sweeney joined the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute and Harvard Medical School (Massachusetts, USA) in 2009.Professor Sweeney's primary research interest is drug discovery and development. His academic focus is management of genitourinary malignancies, with a focus on prostate and testicular cancer. Professor Sweeney is a highly active contributor to his field, having served on the Editorial Board for ASCOs Journal of Clinical Oncology and the Program and Cancer Education Committees of the American Society of Clinical Oncology. He has received peer reviewed funding from the National Institutes of Health and the Department of Defense. Professor Sweeney is also a member of the Scientific Advisory Boards of biotech companies in the United States and Australia.He is a member of the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group-ACRIN, Alliance and the American Association for Cancer Research.
Professor Sweeney is a clinician researcher with a translational approach focussed on drug discovery and development. His primary research interest is on the management of genitourinary malignancies, in particular prostate and testicular cancer.
Professor Sweeney has over 25 years of experience in hematology and oncology and leading clinical trials as well preclinical drug discovery and translational research. He has either led or contributed to over 300 peer-reviewed original research publications as well as more than 50 peer-reviewed teaching papers and more than 25 review articles and book chapters. He has been a first or senior author on high-ranking journals such as the New England Journal of Medicine, Lancet, Nature and Nature Medicine, Journal of Clinical Oncology and Annals of Oncology. He has led several clinical trials (in the US, Australia, Canada, UK and Ireland) that have changed and/or informed the care of men with prostate and bladder cancer and germ cell tumours. He is also Principal Investigator of the ICECaP international collaboration that has led to new endpoints for prostate cancer trials that have been accepted by regulatory agencies in USA and Europe (icecap.movember.com).
As a result of 20 years of research, Professor Sweeney developed a novel prostate cancer therapy targeting nuclear factor kappa B in the laboratory, dimethylaminoparthenolide (DMAPT) and also identified tristetraprolin (TTP) as regulator of NF-kappa B and a biomarker of lethal prostate cancer. This discovery forms the basis of Professor Sweeney’s ongoing investigational drug development. The Sweeney group will continue exploring the role of NF-κB and its impact on prostate cancer progression and resistance to therapy with specific interest on phenotypic plasticity.
Other projects planned include the use of DMAPT with Radioligand Therapy (RLT), which targets the prostate specific membrane antigen (PSMA) which is a recent development in the treatment of metastatic castration resistant prostate cancer. The aim is to investigate the ability of pro-oxidative properties of DMAPT to increase efficacy of RLT in prostate cancer and understand the underlying mechanisms which has led to our previous observations that DMAPT enhanced anti-cancer activity of radiation while also protecting normal tissue from radiation.
Professor Sweeney is also overseeing a large collaborative project to develop an integrated cancer analytics repository which will create a globally accessible comprehensive and integrated data asset of immense clinical value combining clinical, molecular and imaging data from patients with mHSPC. Data from ~2000 patients from clinical trials already exist and will be utilised in the first instance. (Once the infrastructure is established, the team will look to expand this model to other cancers). The repository will link clinical, radiological, biological and social determinant data to better understand the causes of cancer, drivers of cancer progression and to identify new targets for the development of new cancer drugs.
The Sweeney group are also investigating MYBL2, a MYB family transcription factor, a physiological regulator of cell cycle progression, cell survival and cell differentiation. It is frequently found to be dysregulated in cancer. Professor Sweeney’s group will investigate strategies to block the docking of MYBL2 to the MuvB core to prevent upregulation of the downstream MYBL2-MuvB transcriptional network. The aim of this project is to investigate and validate candidate compounds from a virtual screening platform as novel MYBL2 inhibitors that can be used in treatment of aggressive PCa.
| Date | Position | Institution name |
|---|---|---|
| 2022 - ongoing | Director | University of Adelaide |
| 2018 - 2022 | Professor | Harvard Medical School |
| 2017 - ongoing | Associate Member | Massachusetts Institute of Technology |
| 2013 - ongoing | Honorary Associate | University of Sydney |
| 2010 - 2018 | Associate Professor | Harvard Medical School |
| 2010 - 2010 | Lecturer in Medicine | Harvard Medical School |
| 2009 - ongoing | Visiting Professor | University of Adelaide |
| 2008 - 2009 | Professor | University of Adelaide |
| 2007 - 2007 | Associate Professor | Indiana University Hospital |
| 2001 - 2023 | Assistant Professor | Indiana University Hospital |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 2018 | Harvard University | United States | Masters of Arts (MA) |
| 1993 | University of Adelaide | Australia | Bachelor of Medicine, Bachelor of Surgery (MBBS) |
| Date | Title | Institution | Country |
|---|---|---|---|
| 1997 - 2000 | Fellow | Indiana University Hospital | United States |
| 1994 - 1997 | Resident | Gundersen Lutheran Hospital | United States |
| 1994 - 1994 | Physician Trainee | Royal Adelaide Hospital | Australia |
| 1993 - 1993 | Internship | Royal Adelaide Hospital | Australia |
| Year | Citation |
|---|---|
| 2025 | Gillessen, S., Turco, F., Davis, I. D., Efstathiou, J. A., Fizazi, K., James, N. D., . . . Scher, H. I. (2025). Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). European Urology, 87(2), 157-216. Scopus56 WoS44 Europe PMC39 |
| 2025 | Mostaghel, E., Wang, V., Marck, B. T., Sharifi, N., Matsumoto, A. M., & Sweeney, C. J. (2025). Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer.. Endocrine-related cancer, 32(2), ERC-24-0140. |
| 2025 | Ravi, P., Xie, W., Gillessen, S., Tombal, B., Spratt, D. E., Nguyen, P. L., & Sweeney, C. J. (2025). Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer.. Prostate cancer and prostatic diseases, 3 pages. WoS1 |
| 2025 | Conduit, C., Inderjeeth, A. -J., Allen, R., Martin, A. J., Parulekar, W., Mulroe, E., . . . ANZUP Cancer Trials Group. (2025). Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).. Future Oncol, 21(6), 1-10. Scopus1 Europe PMC1 |
| 2025 | de Bono, J. S., He, M., Shi, Z., Nowicka, M., Bracarda, S., Sternberg, C. N., . . . Sweeney, C. (2025). Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.. European urology, 87(6), S0302-2838(24)02771-4. Scopus5 WoS3 Europe PMC5 |
| 2025 | Azad, A. A., Kostos, L., Agarwal, N., Attard, G., Davis, I. D., Dorff, T., . . . Fizazi, K. (2025). Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer. European Urology, 87(4), 455-467. Scopus11 WoS10 Europe PMC10 |
| 2025 | Sweeney, C., He, M., Wongchenko, M., Ferraldeschi, R., & de Bono, J. S. (2025). Reply to Felix Melchior, Andreas Pircher, and Isabel Heidegger's Letter to the Editor re: Johann S. de Bono, Meng He, Chen Shi, et al. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.12.015. European Urology, 87(6), S0302-2838(25)00193-9. |
| 2025 | Swanton, C., Madison, R. W., Tambaoan, C. F. B., Meric-Bernstam, F., Sweeney, C. J., Kurzrock, R., . . . Friedman, C. F. (2025). Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab.. Mol Oncol, 19(11), 3060-3078. Scopus2 WoS2 Europe PMC2 |
| 2025 | Lin, H. M., Scheinberg, T., Portman, N., Kim, R. M. N., Mellor, R., Huynh, K., . . . Horvath, L. G. (2025). Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304). Annals of Oncology, 36(9), 1068-1077. WoS1 |
| 2025 | Sentana-Lledo, D., Chu, X., Ryan, C. J., Gupta, A., Sweeney, C. J., Jarrard, D. F., . . . Morgans, A. K. (2025). Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial.. Eur Urol Oncol, S2588-9311(25)00089-6. |
| 2025 | Liu, X., Cortes, E., Ji, Y., Zhao, K., Ho, J., Liu, Y. S., . . . Tang, D. G. (2025). Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival.. bioRxiv. |
| 2025 | Meric-Bernstam, F., Raghav, K. P. S., Sweeney, C. J., Swanton, C., Spigel, D. R., Bose, R., . . . Kurzrock, R. (2025). ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.. Clin Cancer Res, 31(14), OF1-OF10. Scopus2 WoS2 Europe PMC2 |
| 2025 | Brown, D. W., Sun, D., Fine, A. D., He, S., McDevitt, M., Pontbriand, K., . . . Xu, C. (2025). Fragmentomic-based algorithm to computationally predict tumor-somatic, germline, and clonal hematopoiesis variant origin in liquid biopsy. Journal of Liquid Biopsy, 9, 100311. |
| 2025 | Phillips, R. M., Proudfoot, J. A., Davicioni, E., Liu, Y., Spratt, D. E., Simko, J. M., . . . Tran, P. T. (2025). Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial.. Eur Urol Oncol, 8(4), 968-976. Scopus1 WoS1 Europe PMC1 |
| 2025 | German, B., Morel, K. L., Noel, T., Boufaied, N., Burkhart, D. L., Chen, S., . . . Ellis, L. (2025). EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer.. bioRxiv. |
| 2025 | Tripathi, A., Chen, Y., Jarrard, D. F., Garcia, J. A., Dreicer, R., Liu, G., . . . Sweeney, C. J. (2025). Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.. Annals of oncology : official journal of the European Society for Medical Oncology, 36(11), S0923-7534(25)00924-X. |
| 2025 | Grist, E., Dutey-Magni, P., Parry, M. A., Mendes, L., Sachdeva, A., Proudfoot, J. A., . . . Attard, G. (2025). Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.. Cell, 188(20), 5717-5734.e10. Scopus2 WoS2 Europe PMC1 |
| 2025 | German, B., Morel, K. L., Noel, T., Boufaied, N., Burkhart, D. L., Chen, S., . . . Ellis, L. (2025). EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer.. Res Sq. |
| 2025 | Soon, Y. Y., Marschner, I. C., Schou, I. M., Sweeney, C. J., Davis, I. D., Stockler, M. R., & Martin, A. J. (2025). Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer. BJU International, 1-8. |
| 2025 | De Feria Cardet, R. E., Goodall, S., Laba, T. -L., Haas, M., Davis, I. D., Street, D. J., . . . De Abreu Lourenço, R. (2025). What matters to society when making decisions about reimbursing drugs for prostate cancer: a discrete choice experiment.. Journal of the National Cancer Institute, djaf315. |
| 2025 | Riaz, I. B., Ahmed Naqvi, S. A., Faisal, K. S., He, H., Rubab Khakwani, K. Z., Childs, D. S., . . . Bryce, A. H. (2025). Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis.. European urology, S0302-2838(25)00509-3. |
| 2025 | Cilento, M. A., Butler, L. M., Emmett, L., & Sweeney, C. J. (2025). Personalized intensification of treatment for hormone-sensitive prostate cancer. NATURE REVIEWS CLINICAL ONCOLOGY, 16 pages. |
| 2025 | Medina, S., Tokuyama, N., Hammouda, K., Pathak, T., Mirtti, T., Fu, P., . . . Madabhushi, A. (2025). A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. |
| 2024 | Soon, Y. Y., Marschner, I. C., Schou, M., Sweeney, C. J., Davis, I. D., Stockler, M. R., & Martin, A. J. (2024). Challenges of estimating treatment effects after a positive interim analysis. European Journal of Cancer, 209, 8 pages. Scopus1 WoS1 |
| 2024 | Markowski, M. C., Ren, Y., Tierney, M., Royce, T. J., Yamashita, R., Croucher, D., . . . Sweeney, C. J. (2024). Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer.. European urology oncology, 8(3), S2588-9311(24)00271-2. Scopus3 WoS3 Europe PMC1 |
| 2024 | Sharifi, N., Diaz, R., Lin, H. -M., Roberts, E., Horvath, L. G., Martin, A., . . . Sweeney, C. J. (2024). Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance. The Journal of clinical investigation, 134(18), e183583. Scopus5 WoS4 Europe PMC4 |
| 2024 | Pommier, P., Xie, W., Ravi, P., Carrie, C., Dignam, J. J., Feng, F., . . . Sweeney, C. (2024). Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 201, 110532. Scopus1 WoS1 Europe PMC1 |
| 2024 | Patrikidou, A., Saieva, C., Lee-Ying, R., Nuzzo, P. V., Zarif, T. E., McClure, H., . . . Francini, E. (2024). Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study. Clinical Genitourinary Cancer, 22(6), 11 pages. |
| 2024 | Morel, K. L., Germán, B., Hamid, A. A., Nanda, J. S., Linder, S., Bergman, A. M., . . . Ellis, L. (2024). Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.. Journal of Clinical Investigation, 135(2), e175680-1-e175680-18. Scopus2 WoS2 Europe PMC5 |
| 2024 | Fotia, G., Saieva, C., Lee-Ying, R., Patrikidou, A., Nuzzo, P. V., Zanardi, E., . . . Francini, E. (2024). Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study. Clinical Genitourinary Cancer, 22(5), 8 pages. |
| 2024 | Weiner, A. B., Agrawal, R., Wang, N. K., Sonni, I., Li, E. V., Arbet, J., . . . Reiter, R. E. (2024). Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. European Urology, 86(6), 579-587. Scopus8 WoS9 Europe PMC5 |
| 2024 | Brookman-May, S. D., Buyse, M., Freedland, S. J., Miladinovic, B., Zhang, K., Fendler, W. P., . . . Sweeney, C. J. (2024). Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer. European Urology, 86(2), 81-87. Scopus2 WoS2 Europe PMC2 |
| 2024 | Ravi, P., Xie, W., Buyse, M., Halabi, S., Kantoff, P. W., Sartor, O., . . . Sweeney, C. J. (2024). Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials.. Eur Urol, 87(2), 217-224. Scopus5 WoS3 Europe PMC3 |
| 2024 | Cilento, M. A., Sweeney, C. J., & Butler, L. M. (2024). Spatial transcriptomics in cancer research and potential clinical impact: a narrative review. Journal of Cancer Research and Clinical Oncology, 150(6), 296-1-296-16. Scopus21 WoS19 Europe PMC19 |
| 2024 | Halabi, S., Guo, S., Roy, A., Rydzewska, L. E., Godolphin, P., Hussain, M., . . . Sweeney, C. J. (2024). Reply to J.A. Garcia et al.. J Clin Oncol, 42(24), JCO2400625. |
| 2024 | Basaria, S., Taplin, M. -E., McDonnell, M., Simonson, D. C., Lin, A. P., Dufour, A. B., . . . Travison, T. G. (2024). Insulin resistance during androgen deprivation therapy in men with prostate cancer.. Cancer, 130(21), 3671-3685. Scopus5 WoS2 Europe PMC2 |
| 2024 | Sweeney, C. J., Petry, R., Xu, C., Childress, M., He, J., Fabrizio, D., . . . Powles, T. (2024). Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration Resistant Prostate Cancer.. Clin Cancer Res, 30(18), 4115-4122. Scopus14 WoS14 Europe PMC14 |
| 2024 | Xie, W., Ravi, P., Buyse, M., Halabi, S., Kantoff, P., Sartor, O., . . . Sweeney, C. J. (2024). VALIDATION OF METASTASIS-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN LOCALIZED PROSTATE CANCER IN THE ERA OF DOCETAXEL FOR CASTRATION RESISTANT PROSTATE CANCER.. Ann Oncol, 35(3), 285-292. Scopus7 WoS8 Europe PMC7 |
| 2024 | Halabi, S., Roy, A., Rydzewska, L., Guo, S., Godolphin, P., Hussain, M., . . . Sweeney, C. (2024). Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology, 42(9), 1044-1054. Scopus14 WoS16 Europe PMC16 |
| 2024 | Kwak, L., Ravi, P., Armstrong, J. G., Beckendorf, V., Chin, J. L., D'Amico, A. V., . . . Sweeney, C. J. (2024). Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials.. J Clin Oncol, 42(18), JCO2300762. Scopus11 WoS15 Europe PMC12 |
| 2024 | Bührer, E., D'Haese, D., Daugaard, G., de Wit, R., Albany, C., Tryakin, A., . . . Beyer, J. (2024). Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.. European journal of cancer (Oxford, England : 1990), 202, 114042. Scopus3 WoS2 Europe PMC3 |
| 2024 | Choudhury, A. D., Kwak, L., Cheung, A., Allaire, K. M., Marquez, J., Yang, D. D., . . . Fong, L. (2024). Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.. Cancer immunology research, 12(6), 704-718. Scopus16 WoS16 Europe PMC21 |
| 2024 | Hamid, A. A., Sweeney, C. J., Hovens, C., Corcoran, N., & Azad, A. A. (2024). Precision medicine for prostate cancer: An international perspective. Urologic Oncology: Seminars and Original Investigations, 42(12), 392-401. Scopus1 Europe PMC2 |
| 2024 | Sentana-Lledo, D., Chu, X., Jarrard, D. F., Carducci, M. A., DiPaola, R. S., Wagner, L. I., . . . Morgans, A. K. (2024). Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED).. European urology oncology, 8(1), S2588-9311(24)00102-0. Scopus3 WoS4 Europe PMC4 |
| 2024 | Sutera, P., Shetty, A. C., Song, Y., Hodges, T., Hoang, T., Rana, Z., . . . Tran, P. T. (2024). Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.. European urology oncology, 7(2), 241-247. Scopus8 WoS8 Europe PMC5 |
| 2024 | Rosen, D. B., Ghosh, A., Niemierko, A., Beard, C. J., Ravi, P., Tewari, A., . . . Kamran, S. C. (2024). Clinical outcomes of de novo versus relapsed early metastatic testicular seminoma treated with contemporary radiation therapy.. International journal of radiation oncology, biology, physics, 118(3), 706-711. Scopus2 WoS2 |
| 2024 | Sweeney, C. J., Hainsworth, J. D., Bose, R., Burris, H. A., Kurzrock, R., Swanton, C., . . . Meric-Bernstam, F. (2024). MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. Journal of clinical oncology, 42(3), 258-265. Scopus38 WoS34 Europe PMC36 |
| 2023 | Parry, M. A., Grist, E., Mendes, L., Dutey-Magni, P., Sachdeva, A., Brawley, C., . . . Attard, G. (2023). Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.. Res Sq. |
| 2023 | Mahal, B. A., Kwak, L., Xie, W., Eastham, J. A., James, N. D., Sandler, H. M., . . . D'Amico, A. V. (2023). Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis.. JAMA Network Open, 6(11), E2340787. Scopus11 WoS10 Europe PMC11 |
| 2023 | Rana, H. Q., Stopfer, J. E., Weitz, M., Kipnis, L., Koeller, D. R., Culver, S., . . . Taplin, M. -E. (2023). Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial.. JCO Oncology Practice, 19(11), 1069-1079. Scopus8 WoS8 Europe PMC9 |
| 2023 | Sweeney, C. J., Martin, A. J., Stockler, M. R., Begbie, S., Cheung, L., Chi, K. N., . . . ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. (2023). Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.. Lancet Oncol, 24(4), 323-334. Scopus155 WoS149 Europe PMC122 |
| 2023 | Gil da Costa, R. M., Levesque, C., Bianchi-Frias, D., Chatterjee, P., Lam, H. -M., Santos, C., . . . Nelson, P. S. (2023). Pharmacological NF-κB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities. Molecular Oncology, 17(12), 2709-2727. Scopus9 WoS9 Europe PMC6 |
| 2023 | Ravi, P., Wang, V., Fichorova, R. N., McGregor, B., Wei, X. X., Basaria, S., & Sweeney, C. J. (2023). IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer.. Endocr Relat Cancer, 30(11), 8 pages. Scopus5 WoS5 Europe PMC4 |
| 2023 | Fankhauser, C. D., Jandari, A., Collette, L., Tandstad, T., Jiang, D. M., De Giorgi, U., . . . Gillessen, S. (2023). Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma. European Urology Open Science, 56, 25-28. Scopus3 WoS3 Europe PMC3 |
| 2023 | Quinn, Z., Leiby, B., Sonpavde, G., Choudhury, A. D., Sweeney, C., Einstein, D., . . . Kelly, W. K. (2023). Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate Resistant Prostate Cancer. Clinical Cancer Research, 29(1), 50-59. Scopus23 WoS21 Europe PMC16 |
| 2023 | Gillessen, S., Bossi, A., Davis, I. D., de Bono, J., Fizazi, K., James, N. D., . . . Suzuki, H. (2023). Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology, 83(3), 267-293. Scopus96 WoS96 Europe PMC83 |
| 2023 | Matsubara, N., de Bono, J., Sweeney, C., Chi, K. N., Olmos, D., Sandhu, S., . . . Sternberg, C. N. (2023). Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer.. Clin Genitourin Cancer, 21(2), 230-237.e1. Scopus5 WoS5 Europe PMC6 |
| 2023 | Gillessen, S., Bossi, A., Davis, I. D., de Bono, J., Fizazi, K., James, N. D., . . . Suzuki, H. (2023). Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal of Cancer, 185, 178-215. Scopus121 WoS106 Europe PMC102 |
| 2023 | Antonelli, L., Ardizzone, D., Ravi, P., Bagrodia, A., Mego, M., Daneshmand, S., . . . Fankhauser, C. D. (2023). Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.. Eur J Cancer, 182, 144-154. Scopus6 WoS5 Europe PMC6 |
| 2023 | Riaz, I. B., Naqvi, S. A. A., He, H., Asghar, N., Siddiqi, R., Liu, H., . . . Bryce, A. H. (2023). First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis.. JAMA oncology, 9(5), 635-645. Scopus79 WoS71 Europe PMC67 |
| 2023 | Pomykala, K. L., Hadaschik, B. A., Sartor, O., Gillessen, S., Sweeney, C. J., Maughan, T., . . . Herrmann, K. (2023). Next Generation Radiotheranostics Promoting Precision Medicine.. Annals of oncology : official journal of the European Society for Medical Oncology, 34(6), 507-519. Scopus44 WoS47 Europe PMC36 |
| 2023 | Weiner, A. B., Liu, Y., Hakansson, A., Zhao, X., Proudfoot, J. A., Ho, J., . . . Schaeffer, E. M. (2023). A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.. Cancer, 129(14), 2169-2178. Scopus18 WoS18 Europe PMC19 |
| 2023 | Beije, N., Abida, W., Antonarakis, E. S., Castro, E., de Wit, R., Fizazi, K., . . . de Bono, J. S. (2023). PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.. European urology, 84(3), S0302-2838(23)02716-1. Scopus20 WoS21 Europe PMC19 |
| 2023 | Sutera, P. A., Shetty, A. C., Hakansson, A., Van der Eecken, K., Song, Y., Liu, Y., . . . Ost, P. (2023). Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.. Ann Oncol, 34(7), 605-614. Scopus20 WoS19 Europe PMC17 |
| 2023 | Sutera, P., Song, Y., Van der Eecken, K., Shetty, A. C., English, K., Hodges, T., . . . Tran, P. T. (2023). Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.. Eur Urol, 84(6), 531-535. Scopus19 WoS21 Europe PMC18 |
| 2023 | Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Supplementary Data from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. |
| 2023 | Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Supplementary Figure from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. |
| 2023 | Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Data from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. |
| 2023 | Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Data from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. |
| 2023 | Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S2 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. |
| 2023 | Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., . . . Swanton, C. (2023). Supplementary Figure from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. |
| 2023 | Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S1 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. |
| 2023 | Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S3 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. |
| 2023 | Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., . . . Swanton, C. (2023). Supplementary Figure from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. |
| 2023 | Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Supplementary Data from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. |
| 2023 | Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Data from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. |
| 2023 | Quinn, Z., Leiby, B., Sonpavde, G., Choudhury, A. D., Sweeney, C., Einstein, D., . . . Kelly, W. K. (2023). Data from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. |
| 2023 | Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Supplementary Figure from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. |
| 2023 | Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Table S2 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. |
| 2023 | Quinn, Z., Leiby, B., Sonpavde, G., Choudhury, A. D., Sweeney, C., Einstein, D., . . . Kelly, W. K. (2023). Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. |
| 2023 | Quinn, Z., Leiby, B., Sonpavde, G., Choudhury, A. D., Sweeney, C., Einstein, D., . . . Kelly, W. K. (2023). Data from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. |
| 2023 | Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., . . . Swanton, C. (2023). Supplementary Data from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. |
| 2023 | Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., . . . Swanton, C. (2023). Data from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. |
| 2023 | Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Data from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. |
| 2023 | Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Table S2 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. |
| 2023 | Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Table S1 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. |
| 2023 | Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Supplementary Figure from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. |
| 2023 | Quinn, Z., Leiby, B., Sonpavde, G., Choudhury, A. D., Sweeney, C., Einstein, D., . . . Kelly, W. K. (2023). Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. |
| 2023 | Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2023). Supplementary Figure from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. |
| 2023 | Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S1 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. |
| 2023 | Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S4 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. |
| 2023 | Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S2 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. |
| 2023 | Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., . . . Swanton, C. (2023). Supplementary Data from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. |
| 2023 | Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Table S1 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. |
| 2023 | Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S4 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. |
| 2023 | Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2023). Figure S3 from NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. |
| 2023 | Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., . . . Swanton, C. (2023). Data from Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. |
| 2023 | Hamid, A. A., Sayegh, N., Tombal, B., Hussain, M., Sweeney, C. J., Graff, J. N., & Agarwal, N. (2023). Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment.. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 43(43), e390166. Europe PMC37 |
| 2023 | Jackson-Spence, F., Young, M., Sweeney, C., & Powles, T. (2023). Top advances of the year: Genitourinary cancer.. Cancer, 129(17), 2603-2609. Scopus5 WoS4 Europe PMC3 |
| 2023 | Vale, C. L., Fisher, D. J., Godolphin, P. J., Rydzewska, L. H., Boher, J. -M., Burdett, S., . . . STOPCAP Collaboration. (2023). Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.. The Lancet. Oncology, 24(7), 783-797. Scopus62 WoS59 Europe PMC47 |
| 2023 | Lauritsen, J., Sauvé, N., Tryakin, A., Jiang, D. M., Huddart, R., Heng, D. Y. C., . . . Daugaard, G. (2023). Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database. British Journal of Cancer, 129(11), 1759-1765. Scopus4 WoS3 Europe PMC2 |
| 2022 | Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., . . . Swanton, C. (2022). Atezolizumab Treatment of Tumors With High Tumor Mutational Burden From MyPathway, a Multicenter, Open-label, Phase 2a Multiple Basket Study.. Cancer Discov, 12(3), 654-669. Scopus72 WoS71 Europe PMC68 |
| 2022 | Buyse, M., Saad, E. D., Burzykowski, T., Regan, M. M., & Sweeney, C. S. (2022). Surrogacy Beyond Prognosis:The Importance of “Trial-Level” Surrogacy. Oncologist, 27(4), 266-271. Scopus42 Europe PMC34 |
| 2022 | Weiner, A. B., Siebert, A. L., Fenton, S. E., Abida, W., Agarwal, N., Davis, I. D., . . . Sweeney, C. J. (2022). First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature.. European urology oncology, 5(4), 377-387. Scopus4 WoS5 Europe PMC4 |
| 2022 | Powles, T., Yuen, K. C., Gillessen, S., Kadel, E. E., Rathkopf, D., Matsubara, N., . . . Sweeney, C. J. (2022). Re: Atezolizumab with Enzalutamide versus Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase 3 Trial. Journal of Urology, 208(1), 214-215. |
| 2022 | Terbuch, A., Posch, F., Bauernhofer, T., Jost, P. J., Partl, R., Stranzl-Lawatsch, H., . . . Gillessen, S. (2022). Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 113(4), 825-832. Scopus3 WoS3 Europe PMC3 |
| 2022 | Morgans, A. K., Chen, Y. -H., Jarrard, D. F., Carducci, M., Liu, G., Eisenberger, M., . . . ECOG-ACRIN E3805 Investigators. (2022). Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.. The Prostate, 82(12), 1176-1185. Scopus9 WoS10 Europe PMC10 |
| 2022 | Riaz, I. B., & Sweeney, C. J. (2022). The role of chemotherapy in metastatic prostate cancer. Current opinion in urology, 32(3), 292-301. Scopus6 WoS5 Europe PMC5 |
| 2022 | Yoshikawa, Y., Stopsack, K. H., Wang, X. V., Chen, Y. H., Mazzu, Y. Z., Burton, F., . . . Sweeney, C. J. (2022). Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer. Molecular Oncology, 16(22), 3994-4010. Scopus8 WoS8 Europe PMC10 |
| 2022 | Baca, S. C., Singler, C., Zacharia, S., Seo, J. H., Morova, T., Hach, F., . . . Freedman, M. L. (2022). Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation. Nature Genetics, 54(9), 1364-1375. Scopus27 WoS26 Europe PMC45 |
| 2022 | Grist, E., Friedrich, S., Brawley, C., Mendes, L., Parry, M., Ali, A., . . . Attard, G. (2022). Accumulation of copy number alterations and clinical progression across advanced prostate cancer. Genome Medicine, 14(1), 102-1-102-15. Scopus21 WoS19 Europe PMC19 |
| 2022 | Vogl, U. M., Beer, T. M., Davis, I. D., Shore, N. D., Sweeney, C. J., Ost, P., . . . Gillessen, S. (2022). Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. European Journal of Cancer, 160, 24-60. Scopus14 WoS14 Europe PMC12 |
| 2022 | Martinez Chanza, N., Bernard, B., Barthelemy, P., Accarain, A., Paesmans, M., Desmyter, L., . . . Sweeney, C. J. (2022). Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 25(2), 199-207. Scopus10 WoS8 Europe PMC8 |
| 2022 | Powles, T., Yuen, K. C., Gillessen, S., Kadel, E. E., Rathkopf, D., Matsubara, N., . . . Sweeney, C. J. (2022). Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.. Nature medicine, 28(1), 144-153. Scopus184 WoS182 Europe PMC174 |
| 2022 | Brennan, V., Spektor, A., Sweeney, C., Choudhury, A., Rathkopf, D., Pomerantz, M., . . . King, M. (2022). Evaluating the Role of Stereotactic Body Radiation Therapy With Respect to Androgen Receptor Signaling Inhibitors for Oligometastatic Prostate Cancer. Advances in Radiation Oncology, 7(1), 8 pages. Scopus8 WoS7 Europe PMC4 |
| 2022 | Wei, X. X., Kwak, L., Hamid, A., He, M., Sweeney, C., Flanders, S. C., . . . Choudhury, A. D. (2022). Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry.. Prostate Cancer Prostatic Dis, 25(2), 314-319. Scopus9 WoS9 Europe PMC7 |
| 2022 | Turco, F., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., . . . Omlin, A. (2022). What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 82(1), 6-11. Scopus5 WoS7 Europe PMC6 |
| 2022 | Sweeney, C. J., Percent, I. J., Babu, S., Cultrera, J. L., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2022). Phase 1b/2 Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(11), 2237-2247. Scopus36 WoS35 Europe PMC35 |
| 2022 | Stockler, M. R., Martin, A. J., Dhillon, H. M., Davis, I. D., & Sweeney, C. J. (2022). Reply to L. Marandino et al.. Journal of Clinical Oncology, 40(19), 2176-2177. Scopus1 WoS1 |
| 2022 | Hussain, M., Carducci, M. A., Clarke, N., Fenton, S. E., Fizazi, K., Gillessen, S., . . . Sweeney, C. (2022). Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 69(26), JCO2200208. Scopus16 WoS16 Europe PMC14 |
| 2022 | Gillessen, S., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., . . . Omlin, A. (2022). Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 82(1), 115-141. Scopus83 WoS86 Europe PMC68 |
| 2022 | Turco, F., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., . . . Omlin, A. (2022). Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 2022] (European Urology, (S0302283822016505), (10.1016/j.eururo.2022.02.010)). European Urology, 82(1), e18-e19. |
| 2021 | Hamid, A. A., Huang, H. C., Wang, V., Chen, Y. H., Feng, F., Den, R., . . . Sweeney, C. J. (2021). Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Annals of Oncology, 32(9), 1157-1166. Scopus55 WoS55 Europe PMC56 |
| 2021 | Sweeney, C., Bracarda, S., Sternberg, C. N., Chi, K. N., Olmos, D., Sandhu, S., . . . de Bono, J. S. (2021). Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. The Lancet, 398(10295), 131-142. Scopus274 WoS258 Europe PMC241 |
| 2021 | Francini, E., Montagnani, F., Nuzzo, P. V., Gonzalez-Velez, M., Alimohamed, N. S., Rosellini, P., . . . Heng, D. Y. C. (2021). Association of Concomitant Bone Resorption Inhibitors with Overall Survival among Patients with Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate with Prednisone as First-Line Therapy. JAMA Network Open, 4(7), 13 pages. Scopus13 WoS13 Europe PMC13 |
| 2021 | Javle, M., Borad, M. J., Azad, N. S., Kurzrock, R., Abou-Alfa, G. K., George, B., . . . Burris, H. (2021). Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.. The Lancet. Oncology, 22(9), 1290-1300. Scopus348 WoS318 Europe PMC259 |
| 2021 | Francini, E., Ou, F. S., Rhoades, J., Wolfe, E. G., O’connor, E. P., Ha, G., . . . Choudhury, A. D. (2021). Circulating cell-free dna as biomarker of taxane resistance in metastatic castration-resistant prostate cancer. Cancers, 13(16), 12 pages. Scopus3 WoS3 Europe PMC3 |
| 2021 | Sweeney, C. J., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., . . . ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). (2021). Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy. European Urology, 80(3), 275-279. Scopus39 WoS41 Europe PMC33 |
| 2021 | Stockler, M. R., Martin, A. J., Davis, I. D., Dhillon, H. M., Begbie, S. D., Chi, K. N., . . . ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). (2021). Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. Journal of Clinical Oncology, 40(8), 837-846. Scopus36 WoS36 Europe PMC50 |
| 2021 | Sweeney, C. J., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., . . . Davis, I. D. (2021). Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. JOURNAL OF UROLOGY, 206(6), 1519-1520. |
| 2021 | Fankhauser, C. D., Tran, B., Pedregal, M., Ruiz-Morales, J. M., Gonzalez-Billalabeitia, E., Patrikidou, A., . . . Connors, J. M. (2021). A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. European Urology Focus, 7(5), 1130-1136. Scopus19 WoS14 Europe PMC13 |
| 2021 | McGregor, B., Zhang, L., Gray, K. P., Shaw, G., Evan, C., Francini, E., & Sweeney, C. (2021). Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. Prostate Cancer and Prostatic Diseases, 24(2), 341-348. Scopus8 WoS8 Europe PMC8 |
| 2021 | Beyer, J., Collette, L., Sauvé, N., Daugaard, G., Feldman, D. R., Tandstad, T., . . . International Germ Cell Cancer Classification Update Consortium. (2021). Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.. J Clin Oncol, 39(14), 1553-1562. Scopus147 WoS130 Europe PMC115 |
| 2021 | Morel, K. L., Sheahan, A. V., Burkhart, D. L., Baca, S. C., Boufaied, N., Liu, Y., . . . Ellis, L. (2021). EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nature Cancer, 2(4), 444-456. Scopus187 WoS178 Europe PMC170 |
| 2021 | Gillessen, S., Sauvé, N., Collette, L., Daugaard, G., de Wit, R., Albany, C., . . . International Germ Cell Cancer Classification Update Consortium. (2021). Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.. J Clin Oncol, 39(14), 1563-1574. Scopus177 WoS170 Europe PMC146 |
| 2021 | Morel, K. L., Hamid, A. A., Clohessy, J. G., Pandell, N., Ellis, L., & Sweeney, C. J. (2021). NF-κB blockade with oral administration of dimethylaminoparthenolide, delays prostate cancer resistance to androgen receptor inhibition and inhibits AR variants. Mol Cancer Res, 19(7), 1137-1145. Scopus17 WoS19 Europe PMC18 |
| 2021 | Hofmann, M. R., Hussain, M., Dehm, S. M., Beltran, H., Wyatt, A. W., Halabi, S., . . . Sharifi, N. (2021). Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology, 155, 165-171. Scopus11 WoS14 Europe PMC13 |
| 2021 | Feng, F. Y., Huang, H. C., Spratt, D. E., Zhao, S., Sandler, H. M., Simko, J. P., . . . Tran, P. T. (2021). Validation of a 22-Gene Genomic Classifier in Patients with Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncology, 7(4), 544-552. Scopus114 WoS112 Europe PMC112 |
| 2021 | Tewari, A. K., Gillessen, S., & Sweeney, C. J. (2021). Metastatic Prostate Cancer: In Search of More Granularity.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(26), JCO2100643. Scopus7 WoS5 Europe PMC4 |
| 2021 | Lage, D. E., Michaelson, M. D., Lee, R. J., Greer, J. A., Temel, J. S., & Sweeney, C. J. (2021). Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 24(4), 1181-1188. Scopus10 WoS10 Europe PMC9 |
| 2021 | Rosenberg, J. E., Ballman, K. A., Halabi, S., Atherton, P. J., Mortazavi, A., Sweeney, C., . . . Morris, M. J. (2021). Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(22), 2486-2496. Scopus38 WoS34 Europe PMC39 |
| 2021 | Wang, V., Geybels, M., Jordahl, K. M., Gerke, T., Hamid, A., Penney, K., . . . Sweeney, C. J. (2021). A polymorphism in the promoter of the FRAS1 gene is associated with metastatic prostate cancer. The Prostate, 81(10), 683-693. Scopus5 WoS5 Europe PMC5 |
| 2021 | Guerrero-Ramirez, N. R., Mommer, L., Freschet, G. T., Iversen, C. M., McCormack, M. L., Kattge, J., . . . Weigelt, A. (2021). Global root traits (GRooT) database. GLOBAL ECOLOGY AND BIOGEOGRAPHY, 30(1), 25-37. WoS139 |
| 2021 | Feng, F. Y., Huang, H. -C., Spratt, D. E., Zhao, S. G., Sandler, H. M., Simko, J. P., . . . Tran, P. T. (2021). Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial (vol 7, pg 544, 2021). JAMA ONCOLOGY, 7(4), 639. WoS1 |
| 2020 | Bergmann, J., Weigelt, A., van Der Plas, F., Laughlin, D. C., Kuyper, T. W., Guerrero-Ramirez, N. R., . . . Mommer, L. (2020). The fungal collaboration gradient dominates the root economics space in plants. SCIENCE ADVANCES, 6(27), 9 pages. WoS421 Europe PMC281 |
| 2020 | Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., . . . Omlin, A. (2020). Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]. European Urology, 77(4), 508-547. Scopus335 Europe PMC265 |
| 2020 | Fankhauser, C. D., Sweeney, C. J., & Connors, J. M. (2020). Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer.. European urology, 77(3), 388-390. Scopus5 WoS5 Europe PMC3 |
| 2020 | Allott, E. H., Ebot, E. M., Stopsack, K. H., Gonzalez-Feliciano, A. G., Markt, S. C., Wilson, K. M., . . . Mucci, L. A. (2020). Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(5), 1086-1093. Scopus42 WoS43 Europe PMC39 |
| 2020 | Bernard, B., Burnett, C., Sweeney, C. J., Rider, J. R., & Sridhar, S. S. (2020). Impact of age at diagnosis of de novo metastatic prostate cancer on survival. Cancer, 126(5), 986-993. Scopus44 WoS41 Europe PMC38 |
| 2020 | Hearn, J. W. D., Sweeney, C. J., Almassi, N., Reichard, C. A., Reddy, C. A., Li, H., . . . Sharifi, N. (2020). HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncology, 6(4), 8 pages. Scopus63 WoS60 Europe PMC63 |
| 2020 | Kurzrock, R., Bowles, D. W., Kang, H., Meric-Bernstam, F., Hainsworth, J., Spigel, D. R., . . . Swanton, C. (2020). Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Annals of Oncology, 31(3), 412-421. Scopus106 WoS94 Europe PMC82 |
| 2020 | Xie, W., Regan, M. M., Buyse, M., Halabi, S., Kantoff, P. W., Sartor, O., . . . Sweeney, C. J. (2020). Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(26), 3032-3041. Scopus47 WoS52 Europe PMC42 |
| 2020 | Font-Tello, A., Kesten, N., Xie, Y., Taing, L., Varešlija, D., Young, L. S., . . . Long, H. W. (2020). FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nature Protocols, 15(8), 2503-2518. Scopus26 WoS25 Europe PMC25 |
| 2020 | Kucharczyk, M. J., So, J., Gravis, G., Sweeney, C., Saad, F., & Niazi, T. (2020). A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer. Radiotherapy and Oncology, 152, 80-88. Scopus10 WoS10 Europe PMC6 |
| 2020 | Tripathi, A., Supko, J. G., Gray, K. P., Melnick, Z., Regan, M. M., Taplin, M. -E., . . . Harshman, L. C. (2020). Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib.. Clin Cancer Res, 26(23), 6122-6131. Scopus17 WoS14 Europe PMC14 |
| 2020 | Vicier, C., Ravi, P., Kwak, L., Werner, L., Huang, Y., Evan, C., . . . Sweeney, C. J. (2020). Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer. Prostate, 81(1), 50-57. Scopus23 WoS22 Europe PMC22 |
| 2020 | Schmid, S., Omlin, A., Higano, C., Sweeney, C., Martinez Chanza, N., Mehra, N., . . . Gillessen, S. (2020). Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA network open, 3(10), 15 pages. Scopus94 WoS92 Europe PMC75 |
| 2020 | Bryce, A. H., Chen, Y. H., Liu, G., Carducci, M. A., Jarrard, D. M., Garcia, J. A., . . . Sweeney, C. J. (2020). Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. European urology oncology, 3(6), 717-724. Scopus21 WoS22 Europe PMC18 |
| 2020 | Sundahl, N., Gillessen, S., Sweeney, C., & Ost, P. (2020). When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities. European Urology, 79(5), 565-567. Scopus32 WoS33 Europe PMC27 |
| 2020 | Chiorean, E. G., Perkins, S. M., Strother, R. M., Younger, A., Funke, J. M., Shahda, S. G., . . . Matei, D. E. (2020). Phase I, pharmacogenomic, drug-interaction study of sorafenib and bevacizumab in combination with paclitaxel in patients with advanced refractory solid tumors.. Molecular cancer therapeutics, 19(10), 2155-2162. Scopus4 WoS4 Europe PMC4 |
| 2020 | Harshman, L. C., Wang, V. X., Hamid, A. A., Santone, G., Drake, C. G., Carducci, M. A., . . . Sweeney, C. J. (2020). Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805). Prostate, 80(16), 1381-1449. Scopus16 WoS17 Europe PMC15 |
| 2020 | Fankhauser, C., Wettstein, M., Pedregal, M., Clarke, N., & Sweeney, C. (2020). A Call for Standardized Reporting of Adverse Events. European Urology, 78(3), 481-482. Scopus2 Europe PMC3 |
| 2019 | Xie, W., Halabi, S., Tierney, J. F., Sydes, M. R., Collette, L., Dignam, J. J., . . . Regan, M. M. (2019). A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses. JNCI Cancer Spectrum, 3(1), 11 pages. Scopus86 WoS84 Europe PMC69 |
| 2019 | Gillessen, S., Omlin, A., Attard, G., de Bono, J., Efstathiou, E., Fizazi, K., . . . Tombal, B. (2019). Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of oncology : official journal of the European Society for Medical Oncology, 30(12), e3. Scopus13 Europe PMC11 |
| 2019 | Davis, I., Stockler, M., & Sweeney, C. (2019). Enzalutamide in Metastatic Prostate Cancer. Reply. The New England journal of medicine, 381(15), 1494-1495. Scopus3 WoS3 Europe PMC1 |
| 2019 | VanderWeele, D., Antonarakis, E., Carducci, M., Dreicer, R., Fizazi, K., Gillessen, S., . . . Hussain, M. (2019). Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37(32), 2961-2967. Scopus12 WoS13 Europe PMC12 |
| 2019 | Sweeney, C. J., & Beltran, H. (2019). The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data.. European urology, 76(6), 729-731. |
| 2019 | Sweeney, C., De Abreu Lourenco, R., Hamid, A., & Buyse, M. (2019). What does metastasis-free survival actually mean?. Journal of Clinical Oncology, 37(19), 1679-1680. Scopus1 WoS1 Europe PMC1 |
| 2019 | Hamid, A. A., Gray, K. P., Huang, Y., Bowden, M., Pomerantz, M., Loda, M., & Sweeney, C. J. (2019). Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.. European urology oncology, 2(5), 475-482. Scopus21 WoS24 Europe PMC19 |
| 2019 | McKay, R., Mills, H., Werner, L., Choudhury, A., Choueiri, T., Jacobus, S., . . . Taplin, M. E. (2019). Evaluating a video-based, personalized webpage in genitourinary oncology clinical trials: A phase 2 randomized trial. Journal of Medical Internet Research, 21(5), 17 pages. Scopus3 WoS3 Europe PMC2 |
| 2019 | Francini, E., Gray, K. P., Shaw, G. K., Evan, C. P., Hamid, A. A., Perry, C. E., . . . Sweeney, C. J. (2019). Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer and Prostatic Diseases, 22(3), 420-427. Scopus60 WoS62 Europe PMC53 |
| 2019 | Morel, K. L., Ormsby, R. J., Klebe, S., Sweeney, C. J., & Sykes, P. J. (2019). DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues In Vivo. Radiation research, 192(2), 231-239. Scopus10 WoS10 Europe PMC8 |
| 2019 | Morris, M. J., Loriot, Y., Sweeney, C. J., Fizazi, K., Ryan, C. J., Shevrin, D. H., . . . Higano, C. S. (2019). Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European Journal of Cancer, 114, 107-116. Scopus51 WoS42 Europe PMC33 |
| 2019 | Stoneham, S., Murray, M., Thomas, B., Williamson, M., Sweeney, C., & Frazier, L. (2019). AYA testis cancer: The unmet challenge. Pediatric Blood and Cancer, 66(8), 8 pages. Scopus4 WoS4 Europe PMC3 |
| 2019 | Salgado, R., Solit, D. B., Rimm, D. L., Bogaerts, J., Canetta, R., Lively, T., . . . Golfinopoulos, V. (2019). Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. European Journal of Cancer, 114, 128-136. Scopus9 WoS7 Europe PMC6 |
| 2019 | McGregor, B. A., Miller, R. E., O'Donnell, E., Albiges, L. K., Sweeney, C. J., & Markt, S. C. (2019). Body Mass Index and Outcomes in Germ-Cell Tumors. Clinical Genitourinary Cancer, 17(4), 283-290. Scopus2 WoS1 Europe PMC2 |
| 2019 | Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., . . . Sweeney, C. J. (2019). Enzalutamide with standard first-line therapy in metastatic prostate cancer. New England Journal of Medicine, 381(2), 121-131. Scopus1287 WoS1203 Europe PMC1033 |
| 2019 | Santos, J. M. O., Moreira-Pais, A., Neto, T., Peixoto da Silva, S., Oliveira, P. A., Ferreira, R., . . . Gil da Costa, R. M. (2019). Dimethylaminoparthenolide reduces the incidence of dysplasia and ameliorates a wasting syndrome in HPV16-transgenic mice. Drug Development Research, 80(6), 7 pages. Scopus14 WoS11 Europe PMC10 |
| 2019 | Logothetis, C. J., Saad, F., Sweeney, C., Taplin, M. E., & Fizazi, K. (2019). Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. European Urology, 75(1), 44-60. Scopus54 WoS51 Europe PMC40 |
| 2019 | Hamid, A. A., Markt, S. C., Vicier, C., McDermott, K., Richardson, P., Ho, V. T., & Sweeney, C. J. (2019). Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. Clinical Genitourinary Cancer, 17(1), 58-64.e1. Scopus10 WoS10 Europe PMC8 |
| 2019 | Vicier, C., Werner, L., Chipman, J., Harshman, L. C., Patil, D. H., Fichorova, R. N., . . . Sweeney, C. J. (2019). Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. Clinical Genitourinary Cancer, 17(1), 32-37. Scopus5 WoS6 Europe PMC4 |
| 2019 | Gerke, T., Beltran, H., Wang, X., Lee, G. S. M., Sboner, A., Karnes, R. J., . . . Sweeney, C. J. (2019). Low tristetraprolin expression is associated with lethal prostate cancer. Cancer Epidemiology Biomarkers and Prevention, 28(3), 584-590. Scopus8 WoS7 Europe PMC6 |
| 2019 | McKay, R. R., Werner, L., Jacobus, S. J., Jones, A., Mostaghel, E. A., Marck, B. T., . . . Taplin, M. E. (2019). A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer, 125(4), 524-532. Scopus12 WoS11 Europe PMC9 |
| 2019 | Withington, J., Cole, A. P., Meyer, C. P., Seisen, T., Schmid, M., Lipsitz, S. R., . . . Trinh, Q. D. (2019). Comparison of testis cancer-specific survival: an analysis of national cancer registry data from the USA, UK and Germany. BJU International, 123(3), 385-387. Scopus7 WoS6 Europe PMC5 |
| 2019 | Hamid, A. A., Gray, K. P., Shaw, G., MacConaill, L. E., Evan, C., Bernard, B., . . . Sweeney, C. J. (2019). Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. European Urology, 76(1), 89-97. Scopus219 WoS210 Europe PMC199 |
| 2019 | Vapiwala, N., Hofman, M., Murphy, D., Williams, S., & Sweeney, C. (2019). Strategies for evaluation of novel imaging in prostate cancer: Putting the horse back before the cart. Journal of Clinical Oncology, 37(10), 765-769. Scopus32 WoS33 Europe PMC24 |
| 2019 | Burdett, S., Boevé, L. M., Ingleby, F. C., Fisher, D. J., Rydzewska, L. H., Vale, C. L., . . . Tierney, J. F. (2019). Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. European Urology, 76(1), 115-124. Scopus251 WoS239 Europe PMC187 |
| 2019 | Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., . . . Hainsworth, J. (2019). Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. The Lancet Oncology, 20(4), 518-530. Scopus488 WoS434 Europe PMC377 |
| 2019 | Sweeney, C. (2019). Time for an Integrated Global Strategy to Decrease Deaths from Prostate Cancer. European Urology Focus, 5(2), 111-113. Scopus3 WoS3 Europe PMC3 |
| 2019 | Aldubayan, S. H., Pyle, L. C., Gamulin, M., Kulis, T., Moore, N. D., Taylor-Weiner, A., . . . Lessel, D. (2019). Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) with Susceptibility to Testicular Germ Cell Tumors. JAMA Oncology, 5(4), 514-522. Scopus56 WoS50 Europe PMC48 |
| 2019 | Mateo, J., Fizazi, K., Gillessen, S., Heidenreich, A., Perez-Lopez, R., Oyen, W. J. G., . . . de Bono, J. S. (2019). Managing Nonmetastatic Castration-resistant Prostate Cancer. European Urology, 75(2), 285-293. Scopus130 WoS126 Europe PMC104 |
| 2018 | Hainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., . . . Kurzrock, R. (2018). Reply to J.J. Tao et al. Journal of Clinical Oncology, 36(23), 2451. Scopus2 WoS2 Europe PMC1 |
| 2018 | Morel, K. L., Ormsby, R. J., Solly, E. L., Tran, L. N. K., Sweeney, C. J., Klebe, S., . . . Sykes, P. J. (2018). Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clinical and Experimental Metastasis, 35(7), 649-661. Scopus8 WoS7 Europe PMC5 |
| 2018 | Sweeney, C. J. (2018). Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?. European Urology, 74(4), 420-421. |
| 2018 | Francini, E., Gray, K. P., Xie, W., Shaw, G. K., Valença, L., Bernard, B., . . . Sweeney, C. J. (2018). Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate, 78(12), 889-895. Scopus164 WoS153 Europe PMC123 |
| 2018 | Komura, K., Yoshikawa, Y., Shimamura, T., Chakraborty, G., Gerke, T. A., Hinohara, K., . . . Kantoff, P. W. (2018). ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. Journal of Clinical Investigation, 128(7), 2979-2995. Scopus64 WoS62 Europe PMC60 |
| 2018 | Choudhury, A. D., Gray, K. P., Supko, J. G., Harshman, L. C., Taplin, M. E., Pace, A. F., . . . Sweeney, C. (2018). A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate, 78(14), 1053-1062. Scopus6 WoS6 Europe PMC3 |
| 2018 | Sartor, O., Vogelzang, N., Sweeney, C., Fernandez, D., Almeida, F., Iagaru, A., . . . Morris, M. (2018). Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist, 23(2), 193-202. Scopus70 WoS65 Europe PMC51 |
| 2018 | Vale, C., Fisher, D., White, I., Carpenter, J., Burdett, S., Clarke, N., . . . Tierney, J. (2018). What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Annals of Oncology, 29(5), 1249-1257. Scopus67 WoS59 Europe PMC55 |
| 2018 | Komura, K., Sweeney, C., Inamoto, T., Ibuki, N., Azuma, H., & Kantoff, P. (2018). Current treatment strategies for advanced prostate cancer. International Journal of Urology, 25(3), 220-231. Scopus212 WoS209 Europe PMC174 |
| 2018 | Harshman, L., Chen, Y., Liu, G., Carducci, M., Jarrard, D., Dreicer, R., . . . Sweeney, C. (2018). Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel. Journal of Clinical Oncology, 36(4), 376-382. Scopus103 WoS96 Europe PMC76 |
| 2018 | McNamara, M., Sweeney, C., Antonarakis, E. S., & Armstrong, A. J. (2018). The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer and Prostatic Diseases, 21(3), 306-318. Scopus30 WoS26 Europe PMC17 |
| 2018 | Harshman, L., Xie, W., Moreira, R., Bossé, D., Ruiz Ares, G., Sweeney, C., & Choueiri, T. (2018). Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. Cancer, 124(5), 925-933. Scopus37 WoS36 Europe PMC38 |
| 2018 | Francini, E., Yip, S., Ahmed, S., Li, H., Ardolino, L., Evan, C. P., . . . Sweeney, C. J. (2018). Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. Clinical Genitourinary Cancer, 16(2), 130-134. Scopus22 WoS19 Europe PMC15 |
| 2018 | Hainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., . . . Kurzrock, R. (2018). Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from mypathway, an open-label, phase IIA multiple basket study. Journal of Clinical Oncology, 36(6), 536-542. Scopus416 WoS375 Europe PMC363 |
| 2018 | Kyriakopoulos, C. E., Chen, Y. H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., . . . Sweeney, C. J. (2018). Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 chaarted trial. Journal of Clinical Oncology, 36(11), 1080-1087. Scopus932 WoS852 Europe PMC694 |
| 2018 | Xie, W., Regan, M., & Sweeney, C. (2018). Reply to Y. Zhu et al. Journal of Clinical Oncology, 36(5), 515-516. Europe PMC4 |
| 2018 | Gravis, G., Boher, J. M., Chen, Y. H., Liu, G., Fizazi, K., Carducci, M. A., . . . Sweeney, C. (2018). Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. European Urology, 73(6), 847-855. Scopus204 WoS199 Europe PMC163 |
| 2018 | Morgans, A. K., Chen, Y. H., Sweeney, C. J., Jarrard, D. F., Plimack, E. R., Gartrell, B. A., . . . Patrick-Miller, L. J. (2018). Quality of life during treatment with chemohormonal therapy: Analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. Journal of Clinical Oncology, 36(11), 1088-1095. Scopus73 WoS77 Europe PMC69 |
| 2018 | Deraska, P. V., O Leary, C., Reavis, H. D., Labe, S., Dinh, T. K., Lazaro, J. B., . . . Kozono, D. (2018). NF-κB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair. Cell Death Discovery, 4(1), 12 pages. Scopus21 WoS19 Europe PMC18 |
| 2018 | Dinh, K. T., Aizer, A. A., Muralidhar, V., Mahal, B. A., Chen, Y. W., Beard, C. J., . . . Nguyen, P. L. (2018). Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. American Journal of Medicine, 131(5), 517-523. Scopus11 WoS9 Europe PMC9 |
| 2018 | Gillessen, S., Attard, G., Beer, T., Beltran, H., Bossi, A., Bristow, R., . . . Omlin, A. (2018). Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 [Figure presented]. European Urology, 73(2), 178-211. Scopus418 WoS397 Europe PMC319 |
| 2018 | Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., . . . Ryan, S. (2018). Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet, 391(10125), 1023-1075. Scopus4208 Europe PMC3417 |
| 2018 | Wong, S., North, S., Sweeney, C., Stockler, M., & Sridhar, S. (2018). Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. Clinical Genitourinary Cancer, 16(1), 233-242. Scopus11 WoS11 Europe PMC11 |
| 2018 | O'Donnell, E., Markt, S., Miller, R., Bernard, B., Albiges, L., Beard, C., & Sweeney, C. (2018). Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors. Clinical Genitourinary Cancer, 16(1), 78-84. Scopus6 Europe PMC5 |
| 2017 | Qu, F., Xie, W., Nakabayashi, M., Zhang, H., Jeong, S., Wang, X., . . . Kantoff, P. (2017). Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clinical Cancer Research, 23(3), 726-734. Scopus95 WoS94 Europe PMC87 |
| 2017 | Miller, R., Markt, S., O'Donnell, E., Bernard, B., Albiges, L., Beard, C., & Sweeney, C. (2017). Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy. European Urology Focus, 3(6), 621-628. Scopus15 WoS14 Europe PMC12 |
| 2017 | Guinney, J., Wang, T., Laajala, T. D., Winner, K. K., Bare, J. C., Neto, E. C., . . . Costello, J. C. (2017). Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. The Lancet Oncology, 18(1), 132-142. Scopus111 WoS101 Europe PMC108 |
| 2017 | Matz, M., Coleman, M., Carreira, H., Salmerón, D., Chirlaque, M., Allemani, C., . . . Stuart-Panko, H. (2017). Erratum to “Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)” [Gynecol. Oncol. 144 (2017) 396–404](S009082581631575X)(10.1016/j.ygyno.2016.11.019). Gynecologic Oncology, 147(3), 725. Scopus2 |
| 2017 | Matz, M., Coleman, M., Sant, M., Chirlaque, M., Visser, O., Gore, M., . . . Robb, K. (2017). Erratum to “The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)” [Gynecol. Oncol. 144 (2017) 405–413](S0090825816314974)(10.1016/j.ygyno.2016.10.019). Gynecologic Oncology, 147(3), 726. Scopus2 Europe PMC1 |
| 2017 | Bonaventure, A., Harewood, R., Stiller, C. A., Gatta, G., Clavel, J., Stefan, D. C., . . . Ruta, M. (2017). Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. Lancet Haematology, 4(5), e202-e217. Scopus184 Europe PMC138 |
| 2017 | Matz, M., Coleman, M. P., Sant, M., Chirlaque, M. D., Visser, O., Gore, M., . . . Robb, K. I. (2017). The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecologic Oncology, 144(2), 405-413. Scopus111 WoS108 Europe PMC85 |
| 2017 | Matz, M., Coleman, M. P., Carreira, H., Salmerón, D., Chirlaque, M. D., Allemani, C., . . . Stuart-Panko, H. (2017). Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecologic Oncology, 144(2), 396-404. Scopus116 Europe PMC101 |
| 2017 | Harshman, L. C., Werner, L., Tripathi, A., Wang, X., Maughan, B. L., Antonarakis, E. S., . . . Kantoff, P. W. (2017). The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate, 77(13), 1303-1311. Scopus23 WoS22 Europe PMC23 |
| 2017 | Rydzewska, L. H. M., Burdett, S., Vale, C. L., Clarke, N. W., Fizazi, K., Kheoh, T., . . . Tierney, J. F. (2017). Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. European Journal of Cancer, 84, 88-101. Scopus141 WoS123 Europe PMC104 |
| 2017 | Hamid, A., & Sweeney, C. (2017). Prostate cancer: A new standard-of-care for advanced-stage disease. Nature Reviews Clinical Oncology, 14(10), 592-593. Scopus4 WoS4 Europe PMC3 |
| 2017 | Xie, W., Regan, M. M., Buyse, M., Halabi, S., Kantoff, P. W., Sartor, O., . . . Zapatero, A. (2017). Metastasis-free survival is a strong Surrogate of overall survival in localized prostate cancer. Journal of Clinical Oncology, 35(27), 3097-3104. Scopus383 WoS369 Europe PMC290 |
| 2017 | Pezaro, C. J., Omlin, A., Mastris, K., Attard, G., Beer, T. M., Chi, K. N., . . . Gillessen, S. (2017). Precision, complexity and stigma in advanced prostate cancer terminology: It is time to move away from 'castration-resistant' prostate cancer. Annals of Oncology, 28(8), 1692-1694. Scopus6 WoS6 Europe PMC5 |
| 2017 | Dorff, T. B., & Sweeney, C. J. (2017). Chemotherapy for oligometastatic prostate cancer. Current Opinion in Urology, 27(6), 553-558. Scopus6 WoS5 Europe PMC5 |
| 2017 | Labbé, D. P., Sweeney, C. J., Brown, M., Galbo, P., Rosario, S., Wadosky, K. M., . . . Ellis, L. (2017). TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clinical Cancer Research, 23(22), 7072-7083. Scopus85 WoS86 Europe PMC82 |
| 2017 | Bernard, B., Muralidhar, V., Chen, Y. H., Sridhar, S. S., Mitchell, E. P., Pettaway, C. A., . . . Sweeney, C. J. (2017). Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer, 123(9), 1536-1544. Scopus65 WoS65 Europe PMC47 |
| 2017 | Clement, J. M., & Sweeney, C. J. (2017). Evolving treatment of oligometastatic hormone-sensitive prostate cancer. Journal of Oncology Practice, 13(1), 9-18. Scopus15 WoS14 Europe PMC13 |
| 2017 | Perez-Gracia, J. L., Sanmamed, M. F., Bosch, A., Patiño-Garcia, A., Schalper, K. A., Segura, V., . . . Melero, I. (2017). Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 53, 79-97. Scopus89 WoS82 Europe PMC58 |
| 2017 | Murphy, D. G., Sweeney, C. J., & Tombal, B. (2017). “Gotta Catch ‘em All”, or Do We? Pokemet Approach to Metastatic Prostate Cancer. European Urology, 72(1), 1-3. Scopus56 WoS54 Europe PMC45 |
| 2017 | Morel, K. L., Ormsby, R. J., Bezak, E., Sweeney, C. J., & Sykes, P. J. (2017). Parthenolide Selectively Sensitizes Prostate Tumor Tissue to Radiotherapy while Protecting Healthy Tissues in Vivo. Radiation Research, 187(5), 501-512. Scopus35 WoS33 Europe PMC31 |
| 2017 | Mahal, B. A., Chen, Y. W., Muralidhar, V., Mahal, A. R., Choueiri, T. K., Hoffman, K. E., . . . Nguyen, P. L. (2017). Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Annals of oncology : official journal of the European Society for Medical Oncology, 28(5), 1098-1104. Scopus45 WoS48 Europe PMC43 |
| 2017 | Muralidhar, V., Mahal, B., Rose, B., Chen, Y., Nezolosky, M., Efstathiou, J., . . . Nguyen, P. (2017). Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clinical Genitourinary Cancer, 15(5), 563-569.e3. Scopus7 WoS6 Europe PMC6 |
| 2017 | Seyednasrollah, F., Koestler, D. C., Wang, T., Piccolo, S. R., Vega, R., Greiner, R., . . . Lin, H. (2017). A DREAM challenge to build prediction models for short-term discontinuation of docetaxel in metastatic castration- resistant prostate cancer. JCO Clinical Cancer Informatics, 2017(1), 1-15. Scopus18 WoS18 Europe PMC16 |
| 2017 | Paterson, C., Yew-Fung, C., Sweeney, C., Szewczyk-Bieda, M., Lang, S., & Nabi, G. (2017). Predictors of growth kinetics and outcomes in small renal masses (SRM ≤4 cm in size): Tayside Active Surveillance Cohort (TASC) Study. EJSO, 43(8), 1589-1597. WoS18 |
| 2016 | Morrison, M. M., Williams, M. M., Vaught, D. B., Hicks, D., Lim, J., McKernan, C., . . . Cook, R. S. (2016). Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth (vol 35, pg 1143, 2016). ONCOGENE, 35(9), 1206. WoS5 |
| 2016 | Briganti, A., De Santis, M., Giannarini, G., & Sweeney, C. J. (2016). Delivering Optimal Care for Metastatic Prostate Cancer: A Strengthening Alliance Between Urologists and Medical Oncologists. European Urology Focus, 2(5), 463-464. Scopus1 WoS1 Europe PMC1 |
| 2016 | Lorente, D., Fizazi, K., Sweeney, C., & de Bono, J. S. (2016). Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. European Urology Focus, 2(5), 488-498. Scopus43 WoS42 Europe PMC31 |
| 2016 | Sweeney, C., Chen, Y. H., Liu, G., Carducci, M., Jarrard, D., Eisenberger, M., . . . Dipaola, R. (2016). Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial. Annals of Oncology, 27, vi244. Scopus42 |
| 2016 | Taylor-Weiner, A., Zack, T., O'Donnell, E., Guerriero, J. L., Bernard, B., Reddy, A., . . . Van Allen, E. M. (2016). Genomic evolution and chemoresistance in germ-cell tumours. Nature, 540(7631), 114-118. Scopus146 WoS137 Europe PMC129 |
| 2016 | Mahal, B. A., Chen, Y. W., Muralidhar, V., Mahal, A. R., Choueiri, T. K., Hoffman, K. E., . . . Nguyen, P. L. (2016). National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. Cancer, 122(21), 3371-3377. Scopus27 WoS30 Europe PMC23 |
| 2016 | Sadow, C. A., Maurer, A. N., Prevedello, L. M., Sweeney, C. J., & Silverman, S. G. (2016). CT restaging of testicular germ cell tumors: the incidence of isolated pelvic metastases. European Journal of Radiology, 85(8), 1439-1444. Scopus4 WoS4 Europe PMC4 |
| 2016 | Chen, Y. W., Muralidhar, V., Mahal, B. A., Nezolosky, M. D., Beard, C. J., Choueiri, T. K., . . . Nguyen, P. L. (2016). Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy, 15(6), 695-700. Scopus14 WoS14 Europe PMC10 |
| 2016 | Markt, S. C., Lago-Hernandez, C. A., Miller, R. E., Mahal, B. A., Bernard, B., Albiges, L., . . . Sweeney, C. J. (2016). Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. Cancer, 122(20), 3127-3135. Scopus59 WoS59 Europe PMC46 |
| 2016 | Bernard, B., Gershman, B., Karnes, R., Sweeney, C., & Vapiwala, N. (2016). Approach to oligometastatic prostate cancer. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting, 35, 119-129. Scopus21 Europe PMC21 |
| 2016 | Zheng, D., Gui, B., Gray, K. P., Tinay, I., Rafiei, S., Huang, Q., . . . Jia, L. (2016). Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. Oncogene, 35(36), 4807-4815. Scopus30 WoS29 Europe PMC24 |
| 2016 | Dinh, K., Reznor, G., Muralidhar, V., Mahal, B., Nezolosky, M., Choueiri, T., . . . Nguyen, P. (2016). Association of androgen deprivation therapy with depression in localized prostate cancer. Journal of Clinical Oncology, 34(16), 1905-1912. Scopus119 WoS112 Europe PMC98 |
| 2016 | McKay, R. R., Zurita, A. J., Werner, L., Bruce, J. Y., Carducci, M. A., Stein, M. N., . . . Taplin, M. E. (2016). A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy. Journal of Clinical Oncology, 34(16), 1913-1920. Scopus35 WoS35 Europe PMC32 |
| 2016 | Komura, K., Jeong, S. H., Hinohara, K., Qu, F., Wang, X., Hiraki, M., . . . Sweeney, C. J. (2016). Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proceedings of the National Academy of Sciences of the United States of America, 113(22), 6259-6264. Scopus137 WoS129 Europe PMC112 |
| 2016 | Kryukov, G. V., Bielski, C. M., Samocha, K., Fromer, M., Seepo, S., Gentry, C., . . . Van Allen, E. M. (2016). Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors. Clinical Cancer Research, 22(9), 2183-2189. Scopus17 WoS16 Europe PMC12 |
| 2016 | McKay, R., De Velasco, G., Werner, L., Bellmunt, J., Harshman, L., Sweeney, C., . . . Choueiri, T. (2016). A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer, 122(15), 2389-2398. Scopus19 WoS16 Europe PMC15 |
| 2016 | Börnigen, D., Tyekucheva, S., Wang, X., Rider, J. R., Lee, G. S., Mucci, L. A., . . . Huttenhower, C. (2016). Computational reconstruction of NFκB pathway interaction mechanisms during prostate cancer. PLoS Computational Biology, 12(4), e1004820-1-e1004820-30. Scopus24 WoS23 Europe PMC19 |
| 2016 | Muralidhar, V., Catalano, P., Reznor, G., Mahal, B., Choueiri, T., Sweeney, C., . . . Nguyen, P. (2016). Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer. Journal of the National Comprehensive Cancer Network, 14(4), 421-428. Scopus11 WoS11 Europe PMC8 |
| 2016 | Ko, J. J., Bernard, B., Tran, B., Li, H., Asif, T., Stukalin, I., . . . Heng, D. Y. C. (2016). Conditional survival of patients with metastatic testicular germ cell tumors treated with first-line curative therapy. Journal of Clinical Oncology, 34(7), 714-720. Scopus41 WoS39 Europe PMC30 |
| 2016 | Cejas, P., Li, L., O'Neill, N. K., Duarte, M., Rao, P., Bowden, M., . . . Long, H. W. (2016). Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. Nature Medicine, 22(6), 685-691. Scopus62 WoS57 Europe PMC52 |
| 2016 | Nezolosky, M., Dinh, K., Muralidhar, V., Mahal, B., Chen, Y., Beard, C., . . . Nguyen, P. (2016). Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urologic Oncology: Seminars and Original Investigations, 34(2), 57.e15-57.e22. Scopus18 WoS7 Europe PMC14 |
| 2016 | Vale, C., Burdett, S., Rydzewska, L., Albiges, L., Clarke, N., Fisher, D., . . . Tierney, J. (2016). Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. The Lancet Oncology, 17(2), 243-256. Scopus364 WoS323 Europe PMC271 |
| 2016 | Muralidhar, V., Regan, M. M., Werner, L., Nakabayashi, M., Evan, C. P., Bellmunt, J., . . . Nguyen, P. L. (2016). Duration of androgen deprivation therapy for high-risk prostate cancer: application of randomized trial data in a tertiary referral cancer center. Clinical Genitourinary Cancer, 14(4), e299-e305. Scopus10 WoS8 Europe PMC4 |
| 2016 | Garcia, J. A., & Sweeney, C. (2016). Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer. New England Journal of Medicine, 374(3), 287. Scopus1 Europe PMC2 |
| 2016 | Feldman, D., Lorch, A., Kramar, A., Albany, C., Einhorn, L., Giannatempo, P., . . . Powles, T. (2016). Brain metastases in patients with germ cell tumors: prognostic factors and treatment options - an analysis from the Global Germ Cell Cancer Group. Journal of Clinical Oncology, 34(4), 345-351. Scopus79 WoS69 Europe PMC59 |
| 2016 | Lu, D., Sinnott, J. A., Valdimarsdottir, U., Fang, F., Gerke, T., Tyekucheva, S., . . . Fall, K. (2016). Stress-Related signaling pathways in lethal and nonlethal prostate cancer. Clinical Cancer Research, 22(3), 765-772. Scopus27 WoS25 Europe PMC23 |
| 2016 | Rudman, S. M., Gray, K. P., Batista, J. L., Pitt, M. J., Giovannucci, E. L., Harper, P. G., . . . Sweeney, C. J. (2016). Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. BJU International, 118(6), 919-926. Scopus9 WoS7 Europe PMC6 |
| 2016 | Dinh, K. T., Muralidhar, V., Mahal, B. A., Chen, Y. W., Nezolosky, M. D., Beard, C. J., . . . Nguyen, P. L. (2016). Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. Urology, 87, 125-132. Scopus19 WoS18 Europe PMC16 |
| 2016 | Sridhar, S. S., & Sweeney, C. J. (2016). It Is Time to Harmonize the Design and Conduct of Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer. European Urology, Online(2), 1-2. Scopus3 WoS3 Europe PMC1 |
| 2016 | Harshman, L. C., Wang, X., Nakabayashi, M., Xie, W., Valenca, L., Werner, L., . . . Kantoff, P. W. (2016). Re: Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients with Hormone-Sensitive Prostate Cancer Editorial Comment. JOURNAL OF UROLOGY, 195(6), 1780-1781. WoS1 |
| 2016 | Francini, E., & Sweeney, C. J. (2016). Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer. European Urology, 70(3), 410-412. Scopus31 WoS31 Europe PMC25 |
| 2016 | Miller, R. E., & Sweeney, C. J. (2016). Chemotherapy for metastatic castrate-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 19(2), 139-144. Scopus14 WoS11 Europe PMC9 |
| 2016 | Mahal, B., Muralidhar, V., Chen, Y., Choueiri, T., Hoffman, K., Hu, J., . . . Nguyen, P. (2016). Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. BJU International, 118(1), 95-101. Scopus48 WoS43 Europe PMC34 |
| 2016 | Muralidhar, V., Mahal, B., Nezolosky, M., Beard, C., Feng, F., Martin, N., . . . Nguyen, P. (2016). Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU International, 118(2), 279-285. Scopus12 WoS10 Europe PMC10 |
| 2016 | Giannatempo, P., Pond, G. R., Sonpavde, G., Albany, C., Loriot, Y., Sweeney, C. J., . . . Cary, C. (2016). Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. Journal of Urology, 196(1), 95-100. Scopus67 Europe PMC55 |
| 2016 | Dinh, K. T., Mahal, B. A., Ziehr, D. R., Muralidhar, V., Chen, Y. W., Viswanathan, V. B., . . . Nguyen, P. L. (2016). Risk of prostate cancer mortality in men with a history of prior cancer. BJU International, 117(6), E20-E28. Scopus20 WoS19 Europe PMC17 |
| 2015 | Hsieh, C., Botta, G., Gao, S., Li, T., Van Allen, E., Treacy, D., . . . Kantoff, P. (2015). PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Research, 75(10), 1944-1948. Scopus48 WoS46 Europe PMC44 |
| 2015 | Pal, S., Azad, A., Bhatia, S., Drabkin, H., Costello, B., Sarantopoulos, J., . . . Hutson, T. (2015). A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma. Clinical Cancer Research, 21(15), 3420-3427. Scopus36 WoS34 Europe PMC26 |
| 2015 | Chiorean, E. G., Hurwitz, H. I., Cohen, R. B., Schwartz, J. D., Dalal, R. P., Fox, F. E., . . . Sweeney, C. J. (2015). Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Annals of Oncology, 26(6), 1230-1237. Scopus69 WoS65 Europe PMC56 |
| 2015 | Valenca, L. B., Sweeney, C. J., & Pomerantz, M. M. (2015). Sequencing current therapies in the treatment of metastatic prostate cancer. Cancer Treatment Reviews, 41(4), 332-340. Scopus43 WoS40 Europe PMC36 |
| 2015 | Bernard, B., & Sweeney, C. J. (2015). Management of Metastatic Hormone-Sensitive Prostate Cancer. Current Urology Reports, 16(3), 8 pages. Scopus12 WoS12 Europe PMC9 |
| 2015 | Mahal, B., Cooperberg, M., Aizer, A., Ziehr, D., Hyatt, A., Choueiri, T., . . . Nguyen, P. (2015). Who bears the greatest burden of aggressive treatment of indolent prostate cancer?. American Journal of Medicine, 128(6), 609-616. Scopus15 WoS13 Europe PMC11 |
| 2015 | Zukotynski, K., Kim, C., Gerbaudo, V., Hainer, J., Taplin, M. -E., Kantoff, P., . . . Sweeney, C. (2015). ¹⁸F-FDG-PET/CT and ¹⁸F-NaF-PET/CT in men with castrate-resistant prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 5(1), 72-82. Europe PMC16 |
| 2015 | Nakshatri, H., Appaiah, H. N., Anjanappa, M., Gilley, D., Tanaka, H., Badve, S., . . . Bhat-Nakshatri, P. (2015). Nf-kB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT. Cell Death and Disease, 6(1), 11 pages. Scopus52 WoS49 Europe PMC40 |
| 2015 | Wood, M., Tirumani, S., Sweeney, C., Ramaiya, N., & Howard, S. (2015). Approach to risk stratification in testicular germ cell tumors: a primer for radiologists. Abdominal Imaging, 40(6), 1871-1886. Scopus4 WoS3 Europe PMC4 |
| 2015 | Ziehr, D., Mahal, B., Aizer, A., Hyatt, A., Beard, C., D'Amico, A., . . . Nguyen, P. (2015). Income inequality and treatment of African American men with high-risk prostate cancer. Urologic oncology, 33(1), 18.e7-18.e13. Scopus55 WoS50 Europe PMC48 |
| 2015 | Ziehr, D., Chen, M., Zhang, D., Braccioforte, M., Moran, B., Mahal, B., . . . Nguyen, P. (2015). Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU International, 116(3), 358-365. Scopus69 WoS60 Europe PMC52 |
| 2015 | Börnigen, D., Moon, Y., Rahnavard, G., Waldron, L., McIver, L., Shafquat, A., . . . Huttenhower, C. (2015). A reproducible approach to high-throughput biological data acquisition and integration. PeerJ, 3(3), e791-1-e791-35. Scopus11 WoS8 Europe PMC9 |
| 2015 | Sweeney, C. J. (2015). Insights into E3805: The CHAARTED trial. Future Oncology, 11(6), 897-899. Scopus9 WoS9 Europe PMC6 |
| 2015 | Muralidhar, V., Dinh, K., Mahal, B., Ziehr, D., Chen, Y., Viswanathan, V., . . . Nguyen, P. (2015). Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: implications for managing patients upstaged on prostate magnetic resonance imaging. Urologic Oncology, 33(7), 300.e19-300.e25. Scopus15 Europe PMC10 |
| 2015 | Lago-Hernandez, C., Feldman, H., O'Donnell, E., Mahal, B., Perez, V., Howard, S., . . . Sweeney, C. (2015). A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion. Annals of Oncology, 26(7), 1396-1401. Scopus38 WoS36 Europe PMC29 |
| 2015 | Basch, E., Autio, K., Smith, M., Bennett, A., Weitzman, A., Scheffold, C., . . . Scher, H. (2015). Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: Results from a phase 2 nonrandomized expansion cohort. European Urology, 67(2), 310-318. Scopus38 WoS32 Europe PMC32 |
| 2015 | Graff, R., Pettersson, A., Lis, R., Dupre, N., Jordahl, K., Nuttall, E., . . . Mucci, L. (2015). The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate, 75(9), 897-906. Scopus27 WoS25 Europe PMC26 |
| 2015 | McCall, K. C., Cheng, S. C., Huang, Y., Kohf, N. E., Tupper, T., Van den Abbeele, A. D., . . . Sweeney, C. J. (2015). [¹⁸F]-fluorodeoxyglucose positron emission tomography computed tomography of LAPC4-CR castration-resistant prostate cancer xenograft mod in soft tissue compartments. Translational Oncology, 8(3), 147-153. Scopus5 WoS5 Europe PMC4 |
| 2015 | Gillessen, S., Omlin, A., Attard, G., de Bono, J. S., Efstathiou, E., Fizazi, K., . . . Tombal, B. (2015). Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology, 26(8), 1589-1604. Scopus278 WoS247 Europe PMC215 |
| 2015 | Muralidhar, V., Ziehr, D., Mahal, B., Chen, Y., Nezolosky, M., Viswanathan, V., . . . Nguyen, P. (2015). Association between older age and increasing gleason score. Clinical Genitourinary Cancer, 13(6), 525-530e3. Scopus26 WoS23 Europe PMC19 |
| 2015 | Olson, T. A., Murray, M. J., Rodriguez-Galindo, C., Nicholson, J. C., Billmire, D. F., Krailo, M. D., . . . Frazier, A. L. (2015). Pediatric and adolescent extracranial germ cell tumors: The road to collaboration. Journal of Clinical Oncology, 33(27), 3018-3028. Scopus74 WoS62 Europe PMC50 |
| 2015 | Wang, X., Huang, Y., Christie, A., Bowden, M., Lee, G., Kantoff, P., & Sweeney, C. (2015). Cabozantinib inhibits abiraterone's upregulation of IGFIR phosphorylation and enhances its anti-prostate cancer activity. Clinical Cancer Research, 21(24), 5578-5587. Scopus18 WoS18 Europe PMC15 |
| 2015 | Harshman, L. C., Wang, X., Nakabayashi, M., Xie, W., Valenca, L., Werner, L., . . . Kantoff, P. W. (2015). Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. JAMA Oncology, 1(4), 495-504. Scopus130 WoS127 Europe PMC110 |
| 2015 | Sweeney, C. J., Chen, Y. H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., . . . DiPaola, R. S. (2015). Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New England Journal of Medicine, 373(8), 737-746. Scopus2446 WoS2291 Europe PMC1870 |
| 2015 | Sharmeen, F., Rosenthal, M. H., Wood, M. J., Tirumani, S. H., Sweeney, C., & Howard, S. A. (2015). Relationship between the pathologic subtype/initial stage and microliths in testicular germ cell tumors. Journal of Ultrasound in Medicine, 34(11), 1977-1982. Scopus12 WoS12 Europe PMC8 |
| 2015 | Bernard, B., & Sweeney, C. J. (2015). Diagnosis and Treatment of Testicular Cancer: A Clinician's Perspective. Surgical Pathology Clinics, 8(4), 717-723. Scopus8 Europe PMC4 |
| 2015 | Sweeney, C., Nakabayashi, M., Regan, M., Xie, W., Hayes, J., Keating, N., . . . Mahal, B. (2015). The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). Journal of the National Cancer Institute, 107(12), djv261-online. Scopus71 WoS45 Europe PMC47 |
| 2015 | Muralidhar, V., Chen, M., Reznor, G., Moran, B., Braccioforte, M., Beard, C., . . . Nguyen, P. (2015). Definition and validation of "favorable high-risk prostate cancer": implications for personalizing treatment of radiation-managed patients. International Journal of Radiation Oncology Biology Physics, 93(4), 828-835. Scopus41 WoS38 Europe PMC31 |
| 2015 | Dinh, K., Mahal, B., Ziehr, D., Muralidhar, V., Chen, Y., Viswanathan, V., . . . Nguyen, P. (2015). Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer. Journal of Urology, 194(2), 343-349. Scopus105 WoS101 Europe PMC80 |
| 2015 | Sweeney, C. J. (2015). The juxtaposition of population science and individual treatment recommendations for intermittent androgen deprivation therapy. JAMA Oncology, 1(9), 1270-1271. |
| 2015 | Dinh, K. T., Mahal, B. A. V., Ziehr, D. R., Muralidhar, V., Chen, Y. W., Viswanathan, V. B., . . . Paul, L. N. (2015). Incidence and predictors of upgrading and upstaging among 10,000 contemporary patients with low-risk prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, 33(7), 1 page. |
| 2015 | Allemani, C., Weir, H. K., Carreira, H., Harewood, R., Spika, D., Wang, X. S., . . . Ryan, S. (2015). Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet, 385(9972), 977-1010. Scopus2051 Europe PMC1587 |
| 2015 | Zukotynski, K. A., Kim, C. K., Gerbaudo, V. H., Hainer, J., Taplin, M. -E., Kantoff, P., . . . Sweeney, C. J. (2015). <SUP>18</SUP>F-FDG-PET/CT and <SUP>18</SUP>F-NaF-PET/CT in men with castrate-resistant prostate cancer. AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 5(1), 72-82. WoS20 |
| 2014 | Voskoboynik, M., Staffurth, J., Malik, Z., Sweeney, C., & Chowdhury, S. (2014). 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Expert Review of Anticancer Therapy, 14(11), 1253-1256. Scopus11 WoS6 Europe PMC5 |
| 2014 | Chiorean, E., Sweeney, C., Youssoufian, H., Qin, A., Dontabhaktuni, A., Loizos, N., . . . Amato, R. (2014). A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 73(3), 595-604. Scopus62 WoS53 Europe PMC45 |
| 2014 | Ravi, P., Gray, K. P., O'Donnell, E. K., & Sweeney, C. J. (2014). Ameta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor. Annals of Oncology, 25(2), 331-338. Scopus35 WoS28 Europe PMC21 |
| 2014 | Sharma, J., Gray, K., Evan, C., Nakabayashi, M., Fichorova, R., Rider, J., . . . Sweeney, C. (2014). Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. The Prostate, 74(3), 225-234. Scopus35 WoS30 Europe PMC26 |
| 2014 | Hahn, N., Yiannoutsos, C., Kirkpatrick, K., Sharma, J., & Sweeney, C. (2014). Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event. Clinical Genitourinary Cancer, 12(1), 33-40.e4. Scopus8 WoS5 Europe PMC6 |
| 2014 | Sun, T., Wang, X., He, H., Sweeney, C., Liu, S., Brown, M., . . . Kantoff, P. (2014). MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene, 33(21), 2790-2800. Scopus134 WoS120 Europe PMC106 |
| 2014 | Mahal, B., Aizer, A., Ziehr, D., Hyatt, A., Lago-Hernandez, C., Chen, Y., . . . Nguyen, P. (2014). The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer and Prostatic Diseases, 17(3), 273-279. Scopus62 WoS57 Europe PMC54 |
| 2014 | Mahal, B., Aizer, A., Ziehr, D., Hyatt, A., Sammon, J., Schmid, M., . . . Nguyen, P. (2014). Trends in disparate treatment of African American men with localized prostate cancer across national comprehensive cancer network risk groups. Urology, 84(2), 386-392. Scopus81 WoS78 Europe PMC75 |
| 2014 | Mahal, B., Ziehr, D., Aizer, A., Hyatt, A., Lago-Hernandez, C., Choueiri, T., . . . Nguyen, P. (2014). Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. Journal of Geriatric Oncology, 5(4), 352-358. Scopus19 WoS20 Europe PMC16 |
| 2014 | Mahal, B., Aizer, A., Ziehr, D., Hyatt, A., Choueiri, T., Hu, J., . . . Nguyen, P. (2014). Racial disparities in prostate cancer - specific mortality in men with low-risk prostate cancer. Clinical Genitourinary Cancer, 12(5), e189-e195. Scopus41 WoS43 Europe PMC37 |
| 2014 | Mahal, B., Ziehr, D., Aizer, A., Hyatt, A., Sammon, J., Schmid, M., . . . Nguyen, P. (2014). Getting back to equal: the influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 32(8), 1285-1291. Scopus81 WoS76 Europe PMC66 |
| 2014 | Choueiri, T., Jacobus, S., Bellmunt, J., Qu, A., Appleman, L., Tretter, C., . . . Rosenberg, J. (2014). Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. Journal of Clinical Oncology, 32(18), 1889-1894. Scopus243 WoS220 Europe PMC184 |
| 2014 | Hsieh, C., Fei, T., Chen, Y., Li, T., Gao, Y., Wang, X., . . . Kantoff, P. (2014). Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proceedings of the National Academy of Sciences of the United States of America, 111(20), 7319-7324. Scopus306 WoS296 Europe PMC295 |
| 2014 | Seible, D., Gu, X., Hyatt, A., Beard, C., Choueiri, T., Efstathiou, J., . . . Nguyen, P. (2014). Weight gain on androgen deprivation therapy: which patients are at highest risk?. Urology, 83(6), 1316-1321. Scopus17 WoS15 Europe PMC11 |
| 2014 | Flavin, R., Pettersson, A., Hendrickson, W., Fiorentino, M., Finn, S., Kunz, L., . . . Mucci, L. (2014). SPINK1 protein expression and prostate cancer progression. Clinical Cancer Research, 20(18), 4904-4911. Scopus65 WoS63 Europe PMC56 |
| 2014 | Sharma, J., Gray, K., Harshman, L., Evan, C., Nakabayashi, M., Fichorova, R., . . . Sweeney, C. (2014). Elevated IL-8, TNF-α, and MCP-I in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate, 74(8), 820-828. Scopus79 WoS76 Europe PMC68 |
| 2014 | Howard, S., Gray, K., O'Donnell, E., Fennessy, F., Beard, C., & Sweeney, C. (2014). Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor. American Journal of Roentgenology, 203(4), W415-W420. Scopus14 WoS14 Europe PMC14 |
| 2014 | Smith, M., Sweeney, C., Corn, P., Rathkopf, D., Smith, D., Hussain, M., . . . Scher, H. (2014). Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. Journal of Clinical Oncology, 32(30), 3391-3399. Scopus115 WoS102 Europe PMC99 |
| 2014 | Milowsky, M., Dittrich, C., Durán, I., Jagdev, S., Millard, F., Sweeney, C., . . . Sternberg, C. (2014). Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. European Journal of Cancer, 50(18), 3145-3152. Scopus102 WoS92 Europe PMC80 |
| 2013 | Nakabayashi, M., Hayes, J., Taplin, M., Lefebvre, P., Lafeuille, M., Pomerantz, M., . . . Kantoff, P. (2013). Clinical predictors of survival in men with castration-resistant prostate cancer: Evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer, 119(16), 2990-2998. Scopus34 WoS32 Europe PMC27 |
| 2013 | Sweeney, C. (2013). Prostate cancer therapy: Going forwards by going backwards. Lancet Oncology, 14(2), 104-105. Scopus3 WoS3 Europe PMC5 |
| 2013 | Nichols, C. R., Roth, B., Albers, P., Einhorn, L. H., Foster, R., Daneshmand, S., . . . Kollmannsberger, C. (2013). Active surveillance is the preferred approach to clinical stage i testicular cancer. Journal of Clinical Oncology, 31(28), 3490-3493. Scopus123 WoS110 Europe PMC83 |
| 2013 | Valencia, P., Pridgen, E., Perea, B., Gadde, S., Sweeney, C., Kantoff, P., . . . Farokhzad, O. (2013). Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine, 8(5), 687-698. Scopus70 WoS65 Europe PMC51 |
| 2013 | Smith, D., Smith, M., Sweeney, C., Elfiky, A., Logothetis, C., Corn, P., . . . Hussain, M. (2013). Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. Journal of Clinical Oncology, 31(4), 412-419. Scopus389 WoS360 Europe PMC310 |
| 2013 | Nguyen, P., Devlin, P., Beard, C., Orio, P., O'Leary, M., Wolfsberger, L., . . . Hatiboglu, G. (2013). High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: Case report and review of the literature. Brachytherapy, 12(1), 77-83. Scopus26 Europe PMC21 |
| 2013 | Sweeney, C. J. (2013). Preface. Hematology Oncology Clinics of North America, 27(6), 11-12. |
| 2012 | Hrkach, J., Von Hoff, D., Ali, M., Andrianova, E., Auer, J., Campbell, T., . . . Zale, S. (2012). Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Science Translational Medicine, 4(128), 128ra39-1-128ra39-11. Scopus1030 WoS970 Europe PMC717 |
| 2012 | Pettersson, A., Graff, R., Bauer, S., Pitt, M., Lis, R., Stack, E., . . . Mucci, L. (2012). The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: A cohort study and meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 21(9), 1497-1509. Scopus289 WoS273 Europe PMC240 |
| 2012 | Arvold, N. D., Catalano, P. J., Sweeney, C. J., Hoffman, K. E., Nguyen, P. L., Balboni, T. A., . . . Beard, C. J. (2012). Barriers to the implementation of surveillance for Stage I testicular seminoma. International Journal of Radiation Oncology Biology Physics, 84(2), 383-389. Scopus19 WoS16 Europe PMC16 |
| 2012 | Patel, Y., Carr, K., Magjuka, D., Mohammadi, Y., Dropcho, E., Reed, A., . . . Hahn, N. (2012). Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs: implications for future genomic research in minority populations. Cancer, 118(4), 1075-1082. Scopus8 WoS6 Europe PMC8 |
| 2012 | Millward, M., Price, T., Townsend, A., Sweeney, C., Spencer, A., Sukumaran, S., . . . Spear, M. (2012). Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Investigational New Drugs, 30(6), 2303-2317. Scopus134 WoS125 Europe PMC100 |
| 2012 | Sharma, J., Gray, K. P., Nakabayashi, M., Petrozziello, G., Evan, C., Fichorova, R., . . . Sweeney, C. (2012). Use of elevated insulin-like growth factor binding protein-1 (IGFBP-1) to predict outcomes in men with metastatic prostate cancer treated with androgen-deprivation therapy (ADT).. JOURNAL OF CLINICAL ONCOLOGY, 30(5), 1 page. |
| 2012 | Hutson, T. E., Dang, L. H., Lauer, R. C., Starodub, A., Hauke, R. J., Logan, T., . . . Sarantopoulos, J. (2012). Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group).. JOURNAL OF CLINICAL ONCOLOGY, 30(5), 1 page. WoS1 |
| 2012 | Sharma, J., Gray, K. P., Nakabayashi, M., Petrozziello, G., Evan, C., Fichorova, R., . . . Sweeney, C. (2012). Use of elevated baseline IL-8, CCL-2, and TNFα to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT). JOURNAL OF CLINICAL ONCOLOGY, 30(5), 1 page. |
| 2012 | Rudman, S. M., Gray, K. P., Kasperzyk, J., Pitt, M., Giovannucci, E., Loda, M., . . . Sweeney, C. (2012). Association of metabolic syndrome with reduced survival among men receiving androgen deprivation therapy for nonmetastatic prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, 30(5), 1 page. WoS3 |
| 2012 | Rudman, S. M., Gray, K. P., Kasperzyk, J., Pitt, M., Giovannucci, E., Loda, M., . . . Sweeney, C. (2012). Association of metabolic syndrome with reduced survival among men receiving androgen deprivation therapy for nonmetastatic prostate cancer.. J Clin Oncol, 30(5_suppl), 56. |
| 2012 | Sharma, J., Gray, K. P., Nakabayashi, M., Petrozziello, G., Evan, C., Fichorova, R., . . . Sweeney, C. (2012). Use of elevated baseline IL-8, CCL-2, and TNFα to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT).. J Clin Oncol, 30(5_suppl), 13. |
| 2011 | Smith, D. C., Smith, M. R., Small, E. J., Sweeney, C., Kurzrock, R., Gordon, M. S., . . . Hussain, M. (2011). Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. JOURNAL OF CLINICAL ONCOLOGY, 29(7), 1 page. WoS2 |
| 2011 | Hahn, N. M., Jung, J., Philips, S., Patel, Y. R., Carr, K. A., Mohammadi, Y., . . . Skaar, T. C. (2011). Use of germ-line single nucleotide polymorphisms (SNPs) in drug transporters (ABCG2/ABCB1) and tubulin (TUBB4) to predict survival in patients with metastatic castrate-resistant prostate cancer (CRPC) receiving docetaxel. JOURNAL OF CLINICAL ONCOLOGY, 29(7), 2 pages. |
| 2011 | Davis, T. L., Jung, J., Carr, K. A., Philips, S., Mohammadi, Y., Campbell, M. T., . . . Hahn, N. M. (2011). Androgen pathway constitutional polymorphism predictors of progression-free and overall survivals in advanced castrate-resistant prostate cancer (CRPC) patients treated with ketoconazole (KC). JOURNAL OF CLINICAL ONCOLOGY, 29(7), 1 page. |
| 2011 | Arvold, N. D., Catalano, P. J., Sweeney, C., Hoffman, K. E., Nguyen, P. L., Balboni, T. A., . . . Beard, C. (2011). Physician and patient factors influencing management recommendations in stage I testicular seminoma: A survey among radiation oncologists in the United States. JOURNAL OF CLINICAL ONCOLOGY, 29(7), 1 page. |
| 2011 | Guancial, E. A., Rosenberg, J. E., & Sweeney, C. J. (2011). Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2011, 171-176. |
| 2011 | Arvold, N. D., Catalano, P. J., Sweeney, C., Hoffman, K. E., Nguyen, P. L., Balboni, T. A., . . . Beard, C. (2011). Physician and patient factors influencing management recommendations in stage I testicular seminoma: A survey among radiation oncologists in the United States.. J Clin Oncol, 29(7_suppl), 225. |
| 2011 | Smith, D. C., Smith, M. R., Small, E. J., Sweeney, C., Kurzrock, R., Gordon, M. S., . . . Hussain, M. (2011). Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease.. J Clin Oncol, 29(7_suppl), 127. |
| 2011 | Davis, T. L., Jung, J., Carr, K. A., Philips, S., Mohammadi, Y., Campbell, M. T., . . . Hahn, N. M. (2011). Androgen pathway constitutional polymorphism predictors of progression-free and overall survivals in advanced castrate-resistant prostate cancer (CRPC) patients treated with ketoconazole (KC).. J Clin Oncol, 29(7_suppl), 54. |
| 2011 | Campbell, M. T., Jung, J., Philips, S., Mohammadi, Y., Carr, K. A., Davis, T. L., . . . Hahn, N. M. (2011). Germ-line single nucleotide polymorphism (SNP) predictors of progression-free survival and overall survival in patients with advanced prostate cancer treated with androgen-deprivation therapy (ADT).. JOURNAL OF CLINICAL ONCOLOGY, 29(7), 1 page. |
| 2011 | Hutson, T. E., Sarantopoulos, J., Logan, T., Sonpavde, G., Galsky, M. D., Sweeney, C., . . . Hahn, N. M. (2011). Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors.. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. |
| 2011 | Shanmugam, R., Kusumanchi, P., Appaiah, H., Cheng, L., Crooks, P., Neelakantan, S., . . . Sweeney, C. (2011). A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species. International Journal of Cancer, 128(10), 2481-2494. Scopus67 WoS66 Europe PMC54 |
| 2011 | Resta, L., Pili, R., Eisenberger, M., Spitz, A., King, S., Porter, J., . . . Sweeney, C. (2011). A Phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer Chemotherapy and Pharmacology, 67(2), 431-438. Scopus1 WoS1 Europe PMC1 |
| 2011 | Hussain, M., Smith, M. R., Sweeney, C., Corn, P. G., Elfiky, A., Gordon, M. S., . . . Smith, D. C. (2011). Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. WoS38 |
| 2011 | Hahn, N. M., Jung, J., Dantzer, J., Philips, S., Patel, Y. R., Carr, K. A., . . . Skaar, T. C. (2011). A case-control study examining associations of germ-line oxidative DNA repair single-nucleotide polymorphisms (SNPs) with lethal prostate cancer (PCa) risk.. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. |
| 2011 | Sharma, J., Yiannoutsos, C. T., Hahn, N. M., & Sweeney, C. (2011). Prognositic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer.. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. WoS3 |
| 2011 | Okera, M., Bae, K., Bernstein, E., Cheng, L., Lawton, C., Wolkov, H., . . . Sweeney, C. (2011). Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU International, 108(2B Sp Iss), E51-E58. Scopus18 WoS19 Europe PMC19 |
| 2011 | Hahn, N., Stadler, W., Zon, R., Waterhouse, D., Picus, J., Nattam, S., . . . Sweeney, C. (2011). Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier oncology group GU 04-75. Journal of Clinical Oncology, 29(12), 1525-1530. Scopus184 WoS162 Europe PMC133 |
| 2011 | Harrison, M., Hahn, N., Pili, R., Oh, W., Hammers, H., Sweeney, C., . . . Liu, G. (2011). A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal <sup>®</sup> dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational New Drugs, 29(6), 1465-1474. Scopus103 WoS96 Europe PMC72 |
| 2011 | Estabrook, N., Chin-Sinex, H., Borgmann, A., Dhaemers, R., Shapiro, R., Gilley, D., . . . Mendonca, M. (2011). Inhibition of NF-κB and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-rays. Free Radical Biology and Medicine, 51(12), 2249-2258. Scopus26 WoS28 Europe PMC22 |
| 2011 | Jonker, D., Rosen, L., Sawyer, M., de Braud, F., Wilding, G., Sweeney, C., . . . Galbraith, S. (2011). A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Annals of Oncology, 22(6), 1413-1419. Scopus75 WoS70 Europe PMC54 |
| 2011 | Tolcher, A., Sweeney, C., Papadopoulos, K., Patnaik, A., Chiorean, E., Mita, A., . . . Mita, M. (2011). Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clinical Cancer Research, 17(2), 363-371. Scopus88 WoS74 Europe PMC71 |
| 2011 | Chang, P., Szymanski, K., Dunn, R., Chipman, J., Litwin, M., Nguyen, P., . . . Sanda, M. (2011). Expanded prostate cancer index composite for clinical practice: Development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. Journal of Urology, 186(3), 865-872. Scopus160 WoS151 Europe PMC128 |
| 2011 | Flanagan, J., Gray, P., Hahn, N., Hayes, J., Myers, L., Carney-Doebbeling, C., & Sweeney, C. (2011). Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Annals of Oncology, 22(4), 801-807. Scopus61 WoS55 Europe PMC52 |
| 2010 | Shanmugam, R., Kusumanchi, P., Cheng, L., Crooks, P., Neelakantan, S., Matthews, W., . . . Sweeney, C. J. (2010). A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFκB and generating reactive oxygen species. Prostate, 70(10), 1074-1086. Scopus67 WoS63 Europe PMC56 |
| 2010 | Sweeney, C. J., Takimoto, C., Wood, L., Porter, J. M., Tracewell, W. G., Darwish, M., . . . Remick, S. C. (2010). A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemotherapy and Pharmacology, 66(2), 345-356. Scopus31 WoS27 Europe PMC21 |
| 2010 | Sweeney, C. J., Chiorean, E. G., Verschraegen, C. F., Lee, F. C., Jones, S., Royce, M., . . . Burris, H. A. (2010). A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. Journal of Clinical Oncology, 28(29), 4513-4520. Scopus42 WoS36 Europe PMC35 |
| 2010 | Chiorean, E. G., Malireddy, S., Younger, A. E., Jones, D. R., Waddell, M. J., Sloop, M. I., . . . Sweeney, C. J. (2010). A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 66(3), 441-448. Scopus8 WoS7 Europe PMC6 |
| 2010 | Heath, E. I., Chiorean, E. G., Sweeney, C. J., Hodge, J. P., Lager, J. J., Forman, K., . . . Lorusso, P. (2010). A phase i study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clinical Pharmacology and Therapeutics, 88(6), 818-823. Scopus92 WoS87 Europe PMC78 |
| 2010 | Hayes, J. H., Ollendorf, D. A., Pearson, S. D., Barry, M. J., Kantoff, P. W., Stewart, S. T., . . . McMahon, P. M. (2010). Active surveillance compared with initial treatment for men with low-risk prostate cancer: A decision analysis. JAMA, 304(21), 2373-2380. Scopus226 WoS207 Europe PMC179 |
| 2010 | Hahn, N. M., Stadler, W. M., Zon, R., Waterhouse, D. M., Picus, J., Nattam, S. R., . . . Sweeney, C. (2010). Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. WoS4 |
| 2010 | Shamash, J., Stebbing, J., Sweeney, C., Sonpavde, G., Harland, S., Dawkins, G., . . . Powles, T. (2010). A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. Cancer, 116(15), 3595-3602. Scopus21 WoS22 Europe PMC19 |
| 2010 | Rosen, P. J., Sweeney, C. J., Park, D. J., Beaupre, D. M., Deng, H., Leitch, I. M., . . . Yee, L. K. (2010). A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clinical Cancer Research, 16(9), 2677-2687. Scopus67 WoS62 Europe PMC55 |
| 2010 | Gordon, M. S., Sweeney, C. S., Mendelson, D. S., Eckhardt, S. G., Anderson, A., Beaupre, D. M., . . . Gore, L. (2010). Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clinical Cancer Research, 16(2), 699-710. Scopus154 WoS147 Europe PMC123 |
| 2010 | Sweeney, C., Dugan, W. M., Dreicer, R., Chu, F., Parks, G., Baker, K., . . . Yiannoutsos, C. T. (2010). A randomized placebo-controlled trial of daily high-dose oral risedronate in men with metastatic prostate cancer commencing androgen deprivation therapy (ADT). JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. WoS21 |
| 2010 | Chiorean, E. G., Matei, D., Younger, A., Funke, J. M., Waddell, M. J., Jones, D. R., . . . Sweeney, C. (2010). Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors.. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. WoS1 |
| 2009 | Shanmugam, R., Wei, Z., Crooks, P., Nakshatri, H., & Sweeney, C. (2009). Dimethylaminoparthenolide targets apoptotic machinery in glioblastoma through ROS generation and NF\#954;B inhibition. CANCER RESEARCH, 69, 1 page. |
| 2009 | Mendonca, M., Estabrook, N., Watson, C., Miller, D., Chin-Sinex, H., Borgman, A., . . . Sweeney, C. (2009). The parthenolide analog DMAPT induces X-ray sensitization of radiation resistant lung cancer cells through inhibition of NF-\#954;B dependent split dose recovery and DNA double strand break repair. CANCER RESEARCH, 69, 2 pages. |
| 2009 | Kadlubar, S., Anderson, J. P., Sweeney, C., Gross, M. D., Lang, N. P., Kadlubar, F. F., & Anderson, K. E. (2009). Phenotypic CYP2A6 variation and the risk of pancreatic cancer. Journal of the Pancreas, 10(3), 263-270. Scopus28 WoS24 Europe PMC22 |
| 2009 | Watson, C., Miller, D. A., Chin-Sinex, H., Losch, A., Hughes, W., Sweeney, C., & Mendonca, M. S. (2009). Suppression of NF-κB activity by parthenolide induces x-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer Cells. Radiation Research, 171(4), 389-396. Scopus30 WoS28 Europe PMC20 |
| 2009 | Hahn, N., Zon, R., Yu, M., Ademuyiwa, F., Jones, T., Dugan, W., . . . Sweeney, C. (2009). A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Annals of Oncology, 20(12), 1971-1976. Scopus18 WoS15 Europe PMC13 |
| 2009 | Gardiner, R., Sweeney, C., & Tilley, W. (2009). Testosterone Therapy in Castrate-Resistant Prostate Cancer: A Possible New Approach. European Urology, 56(2), 245-246. Scopus8 WoS7 Europe PMC6 |
| 2009 | Hahn, N., Powles, T., & Sweeney, C. (2009). Development of novel agents for bladder cancer. Update on Cancer Therapeutics, 3(4), 160-169. |
| 2009 | Hahn, N., Reckova, M., Cheng, L., Baldridge, L., Cummings, O., & Sweeney, C. (2009). Patient With Malignant Paraganglioma Responding to the Multikinase Inhibitor Sunitinib Malate. Journal of Clinical Oncology, 27(3), 460-463. Scopus37 WoS35 Europe PMC33 |
| 2009 | Clarke, S. J., Smith, J. T., Gebbie, C., Sweeney, C., & Olszewski, N. (2009). A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer.. J Clin Oncol, 27(15_suppl), 3025. |
| 2009 | Hahn, N. M., Stadler, W. M., Zon, R. T., Waterhouse, D. M., Picus, J., Nattam, S. R., . . . Sweeney, C. J. (2009). A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU-0475.. J Clin Oncol, 27(15_suppl), 5018. |
| 2008 | Chiorean, E., Porter, J., Foster, A., Al Omari, A., Yoder, C., Fife, K., . . . Sweeney, C. (2008). A phase 1 and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clinical Cancer Research, 14(4), 1131-1137. Scopus21 WoS20 Europe PMC17 |
| 2008 | Carpenter, J., Rawl, S., Porter, J., Schmidt, K., Tornatta, J., Ojewole, F., . . . Giesler, R. (2008). Oncology Outpatient and Provider Responses to a Computerized Symptom Assessment System. Oncology Nursing Forum, 35(4), 661-669. Scopus26 WoS22 Europe PMC21 |
| 2008 | Strother, M., & Sweeney, C. (2008). Lessons learned from development of docetaxel. Expert Opinion on Drug Metabolism & Toxicology, 4(7), 1007-1019. Scopus5 WoS4 Europe PMC2 |
| 2008 | Sonpavde, G., Ross, R., Powles, T., Sweeney, C. J., Hahn, N., Hutson, T. E., . . . Sternberg, C. N. (2008). Novel agents for muscle-invasive and advanced urothelial cancer. BJU International, 101(8), 937-943. Scopus13 WoS7 Europe PMC6 |
| 2008 | Yip-Schneider, M. T., Wu, H., Njoku, V., Ralstin, M., Holcomb, B., Crooks, P. A., . . . Schmidt, C. M. (2008). Effect of celecoxib and the novel anti-cancer agent, dimethylamino- parthenolide, in a developmental model of pancreatic cancer. Pancreas, 37(3), e45-e53. Scopus31 WoS28 Europe PMC24 |
| 2008 | Li, L., Yu, M., Jason, R. D., Shen, C., Azzouz, F., McLeod, H. L., . . . Flockhart, D. A. (2008). A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes. Journal of Biopharmaceutical Statistics, 18(6), 1150-1177. Scopus3 WoS4 Europe PMC5 |
| 2008 | Hahn, N. M., Zon, R. T., Jones, T., Ademuyiwa, F., Dugan, W. M., Whalen, C., . . . Sweeney, C. J. (2008). A multicenter phase II study of pemetrexed as second-line chemotherapy for the treatment of hormone refractory prostate cancer (HRPC); Hoosier Oncology Group GU-0367. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. WoS2 |
| 2008 | Chiorean, E. G., Sweeney, C. J., Verschraegen, C. F., Lee, F. C., Jones, S. F., Rabinowitz, I., . . . Burris, H. A. (2008). Tolerability/safety of sunitinib (SU) on schedule 2/1 in combination with capecitabine (C) in patients (pts) with advanced solid tumors (STs): A phase I dose-finding study. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. WoS1 |
| 2008 | Malireddy, S. R., Chiorean, E. G., Younger, A., Jones, D., Waddell, M., Margol, M., . . . Sweeney, C. J. (2008). A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. |
| 2008 | Harrison, M. R., Hahn, N., Pili, R., Oh, W. K., Kim, K., Wilding, G., . . . Liu, G. (2008). Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC). JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. WoS1 |
| 2008 | Schwertschlag, U. S., Chiorean, E. G., Anthony, S. P., Sweeney, C. J., Borad, M. J., Von Hoff, D. D., . . . Ramanathan, R. K. (2008). Phase 1 pharmacokinetic (PK) and pharmacodynamic(PD) evaluation of SF1126 a vascular targeted pan phosphoinositide 3-kinase (PI3K) inhibitor in patients with solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. WoS10 |
| 2008 | Youssoufian, H., Amato, R. J., Sweeney, C. J., Chiorean, E. G., Fox, F., Katz, T., & Rowinsky, E. K. (2008). Phase 1 study of IMC-3G3, an IgG1 monoclonal antibody targeting PDGFRα in patients with advanced solid malignancies. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. WoS4 |
| 2008 | Sweeney, C. J., Chriorean, E. G., Mita, M. M., Papadopoulos, K. P., Silver, B., Freed, M., . . . Tolcher, A. W. (2008). Phase I study of CT-322, first Adnectin protein therapeutic and potent inhibitor of VEGFR-2, in patients (pts) with advanced solid tumors (ST). JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. WoS7 |
| 2008 | Rosen, P. J., Sweeney, C. J., Park, D. J., Rasmussen, E., Shubhakar, P., Scripture, C., . . . Yee, L. K. (2008). AMG 102, an HGF/SF antagonist, in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. WoS10 |
| 2008 | Strother, R. M., Jones, D., Li, L., Younger, A., Einhorn, L. H., Williams, S., & Sweeney, C. J. (2008). Effect of the C3435T genetic polymorphism in MDR1 on etoposide pharmacokinetics. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. WoS1 |
| 2007 | Vegeler, R. C., Yip-Schneider, M. T., Ralstin, M., Wu, H., Crooks, P. A., Neelakantan, S., . . . Schmidt, C. M. (2007). Effect of Celecoxib and Novel Agent LC-1 in a Hamster Model of Lung Cancer. Journal of Surgical Research, 143(1), 169-176. Scopus5 Europe PMC4 |
| 2007 | Yip-Schneider, M. T., Wu, H., Ralstin, M., Yiannoutsos, C., Crooks, P. A., Neelakantan, S., . . . Schmidt, C. M. (2007). Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Molecular Cancer Therapeutics, 6(6), 1736-1744. Scopus43 WoS40 Europe PMC33 |
| 2007 | Masters, A. R., Sweeney, C. J., & Jones, D. R. (2007). The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 848(2), 379-383. Scopus46 WoS42 Europe PMC29 |
| 2007 | Hahn, N. M., Kelley, M. R., Klaunig, J. E., Koch, M. O., Li, L., & Sweeney, C. J. (2007). Constitutional polymorphisms of prostate cancer: Prognostic and diagnostic implications. Future Oncology, 3(6), 665-682. Scopus1 Europe PMC1 |
| 2007 | Mendonca, M. S., Chin-Sinex, H., Gomez-Millan, J., Datzman, N., Hardacre, M., Comerford, K., . . . Sweeney, C. (2007). Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-κB and split-dose repair. Radiation Research, 168(6), 689-697. Scopus37 WoS35 Europe PMC30 |
| 2007 | Guzman, M. L., Rossi, R. M., Neelakantan, S., Li, X., Corbett, C. A., Hassane, D. C., . . . Jordan, C. T. (2007). An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood, 110(13), 4427-4435. Scopus368 WoS345 Europe PMC298 |
| 2007 | Kyselova, Z., Mechref, Y., Al Bataineh, M. M., Dobrolecki, L. E., Hickey, R. J., Vinson, J., . . . Novotny, M. V. (2007). Alterations in the serum glycome due to metastatic prostate cancer. Journal of Proteome Research, 6(5), 1822-1832. Scopus209 WoS195 Europe PMC179 |
| 2007 | Schneider, B., Fukunaga, A., Murry, D., Yoder, C., Fife, K., Foster, A., . . . Sweeney, C. (2007). A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-α2b in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 59(2), 261-268. Scopus8 WoS8 Europe PMC7 |
| 2007 | Yip-Schneider, M. T., Wu, H., Ralstin, M., Yiannoutsos, C., Crooks, P. A., Neelakantan, S., . . . Schmidt, C. M. (2007). Erratum: Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo (Molecular Cancer Therapeutics (2007) 6, (1736-1744)). Molecular Cancer Therapeutics, 6(10), 2816. |
| 2007 | Sonpavde, G., Chi, K. N., Powles, T., Sweeney, C. J., Hahn, N., Hutson, T. E., . . . Kadmon, D. (2007). Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer, 110(12), 2628-2639. Scopus17 WoS16 Europe PMC14 |
| 2007 | Agus, D. B., Sweeney, C. J., Morris, M. J., Mendelson, D. S., McNeel, D. G., Ahmann, F. R., . . . Scher, H. I. (2007). Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. Journal of Clinical Oncology, 25(6), 675-681. Scopus92 WoS85 Europe PMC63 |
| 2007 | Slattery, M. L., Sweeney, C., Wolff, R., Herrick, J., Baumgartner, K., Giuliano, A., & Byers, T. (2007). Genetic variation in <i>IGF1</i>, <i>IGFBP3</i>, <i>IRS1</i>, <i>IRS2</i> and risk of breast cancer in women living in Southwestern United States. BREAST CANCER RESEARCH AND TREATMENT, 104(2), 197-209. WoS46 Europe PMC42 |
| 2006 | Vaughn, D. J., Powell, M., Catalano, P. J., Loehrer, P., Nichols, C., Sweeney, C., . . . Dipaola, R. S. (2006). The influence of body mass index (BMI) on outcome in patients with advanced germ cell tumors (GCT).. J Clin Oncol, 24(18_suppl), 14594. |
| 2006 | Sweeney, C. J., Roth, B. J., Kabbinavar, F. F., Vaughn, D. J., Arning, M., Curiel, R. E., . . . Kaufman, D. S. (2006). Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. Journal of Clinical Oncology, 24(21), 3451-3457. Scopus218 WoS191 Europe PMC170 |
| 2006 | Sweeney, C. J., Takimoto, C. H., Latz, J. E., Baker, S. D., Murry, D. J., Krull, J. H., . . . Rowinsky, E. K. (2006). Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer. Clinical Cancer Research, 12(2), 536-542. Scopus37 Europe PMC22 |
| 2006 | Mita, A. C., Sweeney, C. J., Baker, S. D., Goetz, A., Hammond, L. A., Patnaik, A., . . . Takimoto, C. H. (2006). Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. Journal of Clinical Oncology, 24(4), 552-562. Scopus116 Europe PMC82 |
| 2006 | Sweeney, C. (2006). The Case for Systemic Therapy Alone for Prostate Cancer. Journal of Urology, 176(6 SUPPL.), S42-S46. Scopus1 WoS1 Europe PMC1 |
| 2006 | Shanmugam, R., Jayaprakasan, V., Gokmen-Polar, Y., Kelich, S., Miller, K. D., Yip-Schneider, M., . . . Sweeney, C. J. (2006). Restoring chemotherapy and hormonetherapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate, 66(14), 1498-1511. Scopus55 WoS51 Europe PMC36 |
| 2006 | Gray, R., Manola, J., Saxman, S., Wright, J., Dutcher, J., Atkins, M., . . . DiPaola, R. S. (2006). Phase II clinical trial design: Methods in translational research from the genitourinary committee at the Eastern Cooperative Oncology Group. Clinical Cancer Research, 12(7 I), 1966-1969. Scopus27 WoS24 Europe PMC22 |
| 2006 | Hahn, N. M., Marsh, S., Fisher, W., Langdon, R., Zon, R., Browning, M., . . . Sweeney, C. J. (2006). Hoosier oncology group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clinical Cancer Research, 12(20 PART 1), 6094-6099. Scopus55 WoS52 Europe PMC46 |
| 2006 | Sweeney, C. J. (2006). ECOG 3805: CHAARTED - ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clinical Advances in Hematology and Oncology, 4(8), 588-589. Scopus15 Europe PMC16 |
| 2005 | Pan, C. X., Loehrer, P., Seitz, D., Helft, P., Juliar, B., Ansari, R., . . . Sweeney, C. (2005). A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. Oncology, 69(1), 63-70. Scopus30 Europe PMC25 |
| 2005 | Li, J., Juliar, B., Yiannoutsos, C., Ansari, R., Fox, E., Fisch, M. J., . . . Sweeney, C. J. (2005). Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: A phase II Hoosier Oncology Group study. Journal of Clinical Oncology, 23(6), 1185-1191. Scopus93 Europe PMC69 |
| 2005 | Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2005). Can tumor angiogenesis be inhibited without resistance?. EXS, (94), 95-112. Scopus65 Europe PMC36 |
| 2005 | Sweeney, C., Liu, G., Yiannoutsos, C., Kolesar, J., Horvath, D., Staab, M. J., . . . Wilding, G. (2005). A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clinical Cancer Research, 11(18), 6625-6633. Scopus169 Europe PMC131 |
| 2005 | Li, J., Juliar, B., Yiannoutsos, C., Ansari, R., Fox, E., Fisch, M. J., . . . Trump, D. L. (2005). Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: A phase II Hoosier Oncology Group study. Urologic Oncology Seminars and Original Investigations, 23(5), 382. Scopus1 |
| 2005 | Hahn, N. M., & Sweeney, C. J. (2005). Germ cell tumors: An update of recent data and review of active protocols in stage I and metastatic disease. Urologic Oncology Seminars and Original Investigations, 23(4), 293-302. Scopus7 Europe PMC2 |
| 2005 | Sweeney, C. J., Mehrotra, S., Sadaria, M. R., Kumar, S., Shortle, N. H., Roman, Y., . . . Nakshatri, H. (2005). The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Molecular Cancer Therapeutics, 4(6), 1004-1012. Scopus152 Europe PMC112 |
| 2005 | Yip-Schneider, M. T., Nakshatri, H., Sweeney, C. J., Marshall, M. S., Wiebke, E. A., & Schmidt, C. M. (2005). Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-κB pathway in pancreatic carcinoma cells. Molecular Cancer Therapeutics, 4(4), 587-594. Scopus111 Europe PMC86 |
| 2004 | Sweeney, C., Li, L., Shanmugam, R., Bhat-Nakshatri, P., Jayaprakasan, V., Baldridge, L. A., . . . Cheng, L. (2004). Nuclear factor-κB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clinical Cancer Research, 10(16), 5501-5507. Scopus157 Europe PMC123 |
| 2004 | Cheng, L., Zhang, S., Sweeney, C. J., Kao, C., Gardner, T. A., & Eble, J. N. (2004). Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Research, 24(4), 2135-2140. Scopus37 Europe PMC23 |
| 2004 | Pan, C. X., Kinch, M. S., Kiener, P. A., Langermann, S., Serrero, G., Sun, L., . . . Cheng, L. (2004). PC Cell-Derived Growth Factor Expression in Prostatic Intraepithelial Neoplasia and Prostatic Adenocarcinoma. Clinical Cancer Research, 10(4), 1333-1337. Scopus66 Europe PMC55 |
| 2004 | Sandler, A., Gordon, M., De Alwis, D. P., Pouliquen, I., Green, L., Marder, P., . . . Slapak, C. A. (2004). A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clinical Cancer Research, 10(10), 3265-3272. Scopus108 Europe PMC74 |
| 2004 | Curry, E. A., Murry, D. J., Yoder, C., Fife, K., Armstrong, V., Nakshatri, H., . . . Sweeney, C. J. (2004). Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Investigational New Drugs, 22(3), 299-305. Scopus119 Europe PMC84 |
| 2004 | Kaufman, H. L., Wang, W., Manola, J., DiPaola, R. S., Ko, Y. J., Sweeney, C., . . . Weiner, L. M. (2004). Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 22(11), 2122-2132. Scopus230 WoS199 Europe PMC172 |
| 2004 | Slattery, M. L., Samowtiz, W., Ma, K., Murtaugh, M., Sweeney, C., Levin, T. R., & Neuhausen, S. (2004). <i>CYP1A1</i>, cigarette smoking, and colon and rectal cancer. AMERICAN JOURNAL OF EPIDEMIOLOGY, 160(9), 842-852. WoS92 Europe PMC70 |
| 2003 | Madani, A., Kemmer, K., Sweeney, C., Corless, C., Ulbright, T., Heinrich, M., & Einhorn, L. (2003). Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Annals of Oncology, 14(6), 873-880. Scopus57 Europe PMC40 |
| 2003 | Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2003). The Snark is a Boojum: The continuing problem of drug resistance in the antiangiogenic era. Annals of Oncology, 14(1), 20-28. Scopus44 Europe PMC23 |
| 2003 | Sweeney, C. J., Miller, K. D., & Sledge, G. W. (2003). Resistance in the anti-angiogenic era: Nay-saying or a word of caution?. Trends in Molecular Medicine, 9(1), 24-29. Scopus45 Europe PMC27 |
| 2003 | Hanna, N., Sweeney, C., Fife, K., Dropcho, S., & Seitz, D. E. (2003). Phase I trial of carboplatin and paclitaxel with escalating doses of oral topotecan in patients with solid tumors. American Journal of Clinical Oncology Cancer Clinical Trials, 26(2), 200-202. Scopus3 WoS3 Europe PMC2 |
| 2003 | Paterson, R. F., Ulbright, T. M., MacLennan, G. T., Zhang, S., Pan, C. X., Sweeney, C. J., . . . Cheng, L. (2003). Molecular Genetic Alterations in the Laser-Capture-Microdissected Stroma Adjacent to Bladder Carcinoma. Cancer, 98(9), 1830-1836. Scopus91 Europe PMC75 |
| 2003 | Brandli, D. W., Ulbright, T. M., Foster, R. S., Cummings, O. W., Zhang, S., Sweeney, C. J., . . . Cheng, L. (2003). Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma. Cancer Research, 63(18), 6063-6068. Scopus46 Europe PMC33 |
| 2002 | Sanchez, K. M., Sweeney, C. J., Mass, R., Koch, M. O., Eckert, G. J., Geary, W. A., . . . Cheng, L. (2002). Evaluation of HER-2/neu expression in prostatic adenocarcinoma: A request for a standardized, organ specific methodology. Cancer, 95(8), 1650-1655. Scopus47 Europe PMC36 |
| 2002 | Zhang, S., Zeng, G., Kao, C., Gardner, T., Sweeney, C., Yang, N. S., . . . Cheng, L. (2002). Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system. Prostate, 53(1), 69-76. Scopus8 Europe PMC5 |
| 2002 | Curry, E. A., & Sweeney, C. J. (2002). Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer. Journal of Urology, 168(1), 193. Scopus13 Europe PMC8 |
| 2002 | Bhat-Nakshatri, P., Sweeney, C. J., & Nakshatri, H. (2002). Identification of signal transduction pathways involved in constitutive NF-kB activation in breast cancer cells. Oncogene, 21(13), 2066-2078. Scopus111 Europe PMC81 |
| 2002 | Sweeney, C. J., Monaco, F. J., Jung, S. H., Wasielewski, M. J., Picus, J., Ansari, R. H., . . . Einhorn, L. H. (2002). A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Annals of Oncology, 13(3), 435-440. Scopus30 Europe PMC20 |
| 2002 | Sweeney, C. J., Marshall, M. S., Barnard, D. S., Heilman, D. K., Billings, S. D., Cheng, L., . . . Yip-Schneider, M. T. (2002). Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detection and Prevention, 26(3), 238-244. Scopus20 Europe PMC10 |
| 2002 | Cheng, L., Gu, J., Ulbright, T. M., MacLennan, G. T., Sweeney, C. J., Zhang, S., . . . Eble, J. N. (2002). Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. Cancer, 94(1), 104-110. Scopus73 Europe PMC51 |
| 2002 | Seo, Y. R., Sweeney, C., & Smith, M. L. (2002). Selenomethionine induction of DNA repair response in human fibroblasts. Oncogene, 21(23), 3663-3669. Scopus119 Europe PMC70 |
| 2002 | Curry, E. A., & Sweeney, C. J. (2002). Resistance to Luteinizing Hormone Releasing Hormone Agonist Therapy for Metastatic Prostate Cancer. Journal of Urology, 168(1), 193. |
| 2001 | Miller, K. D., Sweeney, C. J., & Sledge, J. (2001). Redefining the target: Chemotherapeutics as antiangiogenics. Journal of Clinical Oncology, 19(4), 1195-1206. Scopus401 Europe PMC263 |
| 2001 | Sweeney, C. J., Zhu, J., Sandler, A. B., Schiller, J., Belani, C. P., Langer, C., . . . Johnson, D. H. (2001). Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A phase III trial in patients with metastatic nonsmall cell lung carcinoma. Cancer, 92(10), 2639-2647. Scopus250 Europe PMC191 |
| 2001 | Yip-Schneider, M. T., Sweeney, C. J., Jung, S. H., Crowell, P. L., & Marshall, M. S. (2001). Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. Journal of Pharmacology and Experimental Therapeutics, 298(3), 976-985. Scopus97 Europe PMC58 |
| 2001 | Sweeney, C. J., Miller, K. D., Sissons, S. E., Nozaki, S., Heilman, D. K., Shen, J., & Sledge, G. W. (2001). The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Research, 61(8), 3369-3372. Scopus327 Europe PMC220 |
| 2001 | Sweeney, C. (2001). History of testicular cancer chemotherapy: Maximizing efficacy, minimizing toxicity. Seminars in Urologic Oncology, 19(3), 170-179. Scopus9 Europe PMC5 |
| 2000 | Sweeney, C. J., Hermans, B. P., Heilman, D. K., Foster, R. S., Donohue, J. P., & Einhorn, L. H. (2000). Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer. Journal of Clinical Oncology, 18(2), 358-362. Scopus107 Europe PMC75 |
| 2000 | Sweeney, C. J., & Sandler, A. B. (2000). Chemotherapy in non-small cell lung cancer. Investigational New Drugs, 18(2), 157-186. Scopus6 Europe PMC4 |
| 2000 | Yip-Schneider, M. T., Barnard, D. S., Billings, S. D., Cheng, L., Heilman, D. K., Lin, A., . . . Sweeney, C. J. (2000). Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis, 21(2), 139-146. Scopus281 Europe PMC212 |
| 2000 | Hermans, B. P., Sweeney, C. J., Foster, R. S., Einhorn, L. E., & Donohue, J. P. (2000). Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. Journal of Urology, 163(6), 1721-1724. Scopus89 Europe PMC60 |
| 2000 | Sweeney, C., & Farrow, D. C. (2000). Differential survival related to smoking among patients with renal cell carcinoma. EPIDEMIOLOGY, 11(3), 344-346. WoS17 Europe PMC17 |
| 2000 | Farrow, D. C., Vaughan, T. L., Sweeney, C., Gammon, M. D., Chow, W. H., Risch, H. A., . . . Blot, W. J. (2000). Gastroesophageal reflux disease, use of H<sub>2</sub> receptor antagonists, and risk of esophageal and gastric cancer. CANCER CAUSES & CONTROL, 11(3), 231-238. WoS161 Europe PMC142 |
| 1999 | Yip-Schneider, M. T., Lin, A., Barnard, D., Sweeney, C. J., & Marshall, M. S. (1999). Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression.. International Journal of Oncology, 15(2), 271-279. Scopus71 Europe PMC52 |
| 1999 | Sweeney, C. J., Williams, S. D., Finch, D. E., Bihrle, R., Foster, R. S., Collins, M., . . . Roth, B. J. (1999). A phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer, 86(3), 514-518. Scopus65 Europe PMC48 |
| 1998 | Michael, H., Hull, M. T., Foster, R. S., Sweeney, C. J., & Ulbright, T. M. (1998). Nephroblastoma-like tumors in patients with testicular germ cell tumors. American Journal of Surgical Pathology, 22(9), 1107-1114. Scopus37 Europe PMC27 |
| 1998 | Sweeney, C. J., & Sandler, A. B. (1998). Treatment of advanced (stages III and IV) non-small-cell lung cancer.. Current Problems in Cancer, 22(2), 85-132. Scopus15 Europe PMC7 |
| 1998 | McCarthy, L. J., Porcu, P., Fausel, C. A., Sweeney, C. J., & Danielson, C. F. M. (1998). Thrombotic thrombocytopenic purpura and simvastatin. Lancet, 352(9136), 1284-1285. Scopus44 Europe PMC26 |
| 1998 | Sweeney, C. J., Ghassemi, M., Agger, W. A., & Persing, D. H. (1998). Coinfection with Babesia microti and Borrelia burgdorferi in a Western Wisconsin resident. Mayo Clinic Proceedings, 73(4), 338-341. Scopus25 Europe PMC15 |
| 1997 | Chand, V., Sweeney, C., & Agger, W. A. (1997). Mental neuropathy in patients with AIDS-associated malignant lymphoma. Clinical Infectious Diseases, 24(3), 521-522. Scopus9 Europe PMC7 |
| 1997 | Sweeney, C. J., & Agger, W. A. (1997). Aids-related lymphomas with neurologic manifestations. Western Journal of Medicine, 167(1), 40-44. Scopus1 Europe PMC1 |
| 1995 | Sweeney, C. J., & Witte, R. S. (1995). Thrombocytopenia and pancreatic carcinoma. Wisconsin Medical Journal, 94(11), 611-615. Scopus1 |
| 1994 | FAUSTMAN, E. M., & SWEENEY, C. (1994). EFFECTS OF ETHYLNITROSOUREA ON EXPRESSION OF PROTOONCOGENE PP60(C-SRC) AND HIGH-MOLECULAR-WEIGHT NEUROFILAMENT PROTEIN IN RODENT EMBRYO CENTRAL-NERVOUS-SYSTEM CELLS IN-VITRO. TOXICOLOGY AND APPLIED PHARMACOLOGY, 128(2), 182-188. WoS5 Europe PMC3 |
| 1992 | SWEENEY, C., KIRBY, Z., & FAUSTMAN, E. M. (1992). EXPRESSION OF DEVELOPMENTALLY RELEVANT PROTEINS BY RODENT EMBRYO CNS CELLS INVIVO AND INVITRO - PROTO-ONCOGENE-PP60(C-SRC) AND HIGH-MOLECULAR-WEIGHT NEUROFILAMENT PROTEIN. CELL BIOLOGY AND TOXICOLOGY, 8(2), 113-128. WoS7 Europe PMC3 |
| Year | Citation |
|---|---|
| 2006 | Moore, A. M., Sweeney, C. J., Wick, M. R., & Loehrer, P. J. (2006). Thymoma and Thymic Carcinoma. In Textbook of Uncommon Cancer, Third Edition (pp. 237-256). Wiley. DOI |
| Year | Citation |
|---|---|
| 2025 | Sun, D., He, S., Brown, D. W., Tukachinsky, H., Hughes, J. D., Polisecki, E., . . . Xu, C. (2025). Evaluation of a variant origin prediction (VOP) algorithm to distinguish clonal hematopoiesis (CH) variants from tumor-derived variants and to predict metastatic castrate resistant prostate cancer (mCRPC) clinical responses.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 43 (pp. 1 page). CA, San Francisco: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS1 |
| 2025 | Tripathi, A., Chen, Y. -H., Jarrard, D. F., Garcia, J. A., Dreicer, R., Liu, G., . . . Sweeney, C. (2025). Impact of PSA nadir on long-term survival in metastatic hormone-sensitive prostate cancer: Final 10-year analysis of the ECOG-ACRIN E3805 CHAARTED trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 43 (pp. 1 page). CA, San Francisco: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS1 |
| 2025 | Fisher, D. J., Vale, C. L., Rydzewska, L. H., Godolphin, P., Agarwal, N., Attard, G., . . . Tierney, J. F. (2025). Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 43 (pp. 1 page). LIPPINCOTT WILLIAMS & WILKINS. DOI WoS6 |
| 2025 | Tokuyama, N., Hammouda, K., Pathak, T., Mirtti, T., Fu, P., Gupta, S., . . . Madabhushi, A. (2025). Computational pathology to predict docetaxel benefit in patients with metastatic hormone-sensitive prostate cancer from the CHAARTED trial (ECOG-ACRIN E3805). In JOURNAL OF CLINICAL ONCOLOGY Vol. 43 (pp. 1560). LIPPINCOTT WILLIAMS & WILKINS. DOI WoS1 |
| 2024 | Wei, X. X., Chahoud, J., Emamekhoo, H., Mckay, R. R., Marshall, C. H., Einstein, D., . . . Taplin, M. E. (2024). A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumours and DNA damage repair (DDR) alterations: Cohort 3 results. In ANNALS OF ONCOLOGY Vol. 35 (pp. S992-S993). SPAIN, Barcelona: ELSEVIER. DOI |
| 2024 | Halabi, S., Luo, B., Guo, S., Rydzewska, L. H. M., Godolphin, P. J., Parmar, M. K., . . . Sweeney, C. (2024). A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC). In ANNALS OF ONCOLOGY Vol. 35 (pp. S975). SPAIN, Barcelona: ELSEVIER. DOI |
| 2024 | Grist, E., Dutey-Magni, P., Mendes, L., Parry, M. A., Sachdeva, A., Proudfoot, J., . . . Attard, G. (2024). Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials. In ANNALS OF ONCOLOGY Vol. 35 (pp. S961-S962). SPAIN, Barcelona: ELSEVIER. DOI WoS6 |
| 2024 | Morgans, A. K., Roy, S., Barata, P. C., Brown, J. R., Jia, A., Zaorsky, N. G., . . . Spratt, D. E. (2024). Interaction of age and benefit of treatment intensification in advanced prostate cancer: An aggregate meta-analysis of 14 randomized trials.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 42 (pp. 1 page). CA, San Francisco: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2024 | Markowski, M. C., Ren, Y., Croucher, D., Royce, T. J., Yamashita, R., Tierney, M., . . . Sweeney, C. (2024). Prognostic validation of a digital pathology-based multi-modal artificial intelligence (MMAI) biomarker in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the CHAARTED trial (ECOG-ACRIN EA3805). In JOURNAL OF CLINICAL ONCOLOGY Vol. 42 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. WoS1 |
| 2024 | Morgans, A. K., Sweeney, C., Wallis, C. J. D., Halabi, S., Armstrong, A. J., Adorjan, P., . . . Grimm, M. -O. (2024). Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS. In JOURNAL OF CLINICAL ONCOLOGY Vol. 42 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. |
| 2024 | Mc Laughlin, R. A., Thomas, H., Davis, I. D., Zielinski, R. R., Thomson, A., Tan, T. H., . . . Sweeney, C. (2024). Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304). In JOURNAL OF CLINICAL ONCOLOGY Vol. 42 (pp. 1 page). LIPPINCOTT WILLIAMS & WILKINS. Scopus5 WoS4 |
| 2024 | Hamid, A., Vergara, M., Park, J., Chinsky, T. M., Aldubayan, S., Grist, E., . . . Sweeney, C. (2024). Whole exome correlates in metastatic hormone sensitive prostate cancer (mHSPC): Results from E3805 CHAARTED. In JOURNAL OF CLINICAL ONCOLOGY Vol. 42 (pp. 1 page). LIPPINCOTT WILLIAMS & WILKINS. |
| 2023 | Hamid, A., Chinsky, T. M., Vergara, M., Grist, E., Attard, G., Van Allen, E. M., . . . Sweeney, C. (2023). Landscape and impact of germline pathogenic variants (PVs) in metastatic hormone sensitive prostate cancer (mHSPC): Ancillary study of E3805 CHAARTED. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). IL, Chicago: LIPPINCOTT WILLIAMS & WILKINS. |
| 2023 | Horvath, L. G., Davis, I. D., Martin, A., Zielinski, R., Thomson, A., Tan, T. H., . . . Sweeney, C. (2023). Effects of enzalutamide on overall survival plus /- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304). In ANNALS OF ONCOLOGY Vol. 34 (pp. S968-S969). SPAIN, Barcelona: ELSEVIER. DOI WoS1 |
| 2023 | Deek, M., Sutera, P., Jing, Y., Pryor, D., Day, H., Huynh, M. A., . . . Sweeney, C. (2023). MULTI-INSTITUTIONAL ANALYSIS OF METASTASIS DIRECTED THERAPY WITH OR WITHOUT ANDROGEN DEPRIVATION THERAPY IN OLIGOMETASTATIC CASTRATION SENSITIVE PROSTATE CANCER. In JOURNAL OF UROLOGY Vol. 209 (pp. E381). LIPPINCOTT WILLIAMS & WILKINS. WoS1 |
| 2023 | Antonelli, L., Ardizzone, D., Ravi, P., Sweeney, C., Bagrodia, A., Mego, M., . . . Fankhauser, C. D. (2023). RISK OF RESIDUAL TERATOMA AFTER COMPLETE RESPONSE FOLLOWING FIRST-LINE CHEMOTHERAPY IN MEN WITH METASTATIC NON-SEMINOMATOUS GERM CELL TUMOR AND IGCCCG INTERMEDIATE/POOR PROGNOSIS: A MULTI-INSTITUTIONAL RETROSPECTIVE COHORT STUDY. In JOURNAL OF UROLOGY Vol. 209 (pp. E450). LIPPINCOTT WILLIAMS & WILKINS. |
| 2023 | Niazi, T., McBride, S. M., Williams, S., Davis, I. D., Stockler, M. R., Martin, A. J., . . . Sweeney, C. (2023). DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. WoS1 |
| 2023 | Gennusa, V., Saieva, C., Lee-Ying, R. M., Nuzzo, P. V., Spinelli, G. P., Zanardi, E., . . . Francini, E. (2023). Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS- Meet-URO 26 study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. |
| 2023 | Ravi, P., Huang, J., Xie, W., Whelpley, B., Kelly, E., McGregor, B. A., . . . Choudhury, A. D. (2023). Outcomes with metastasis-directed therapy (MDT) and fixed-duration systemic therapy in oligometastatic hormone-sensitive prostate cancer (omHSPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. WoS1 |
| 2023 | Weiner, A. B., Liu, Y., Hakansson, A. K., Zhao, X., Proudfoot, J. A., Zhang, J. J. H., . . . Schaeffer, E. M. (2023). Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. |
| 2023 | Lee-Ying, R. M., Saieva, C., Nuzzo, P. V., Malgeri, A., Fotia, G., Zanardi, E., . . . Francini, E. (2023). Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS - Meet-URO 26 study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. |
| 2023 | Gordoa, T. A., Goodman, M. M., Vulsteke, C., Roubaud, G., Zhang, J., Parikh, M., . . . Sweeney, C. (2023). Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. DOI Scopus4 WoS4 Europe PMC3 |
| 2023 | Sutera, P., Shetty, A., Hakansson, A., Van der Eecken, K., Song, Y., Liu, Y., . . . Ost, P. (2023). Transcriptomic Heterogeneity of Metastatic Disease Timing within Metastatic Castration-Sensitive Prostate Cancer. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 117 (pp. E261-E262). CA, San Diego: ELSEVIER SCIENCE INC. |
| 2023 | Halabi, S., Roy, A., Guo, S., Rydzewska, L., Godolphin, P. J., Parmar, M. K., . . . Sweeney, C. (2023). Assessing PSA. In ANNALS OF ONCOLOGY Vol. 34 (pp. S994-S995). SPAIN, Barcelona: ELSEVIER. DOI |
| 2023 | Sutera, P., Deek, M. P., Jing, Y., Pryor, D. I., Huynh, M. A., Koontz, B. F., . . . Sweeney, C. (2023). Multi -Institutional Analysis of Metastasis Directed Therapy with or without Androgen Deprivation Therapy in Oligometastatic Castration Sensitive Prostate Cancer. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 117 (pp. E442-E443). CA, San Diego: ELSEVIER SCIENCE INC. DOI Scopus5 WoS6 Europe PMC6 |
| 2023 | Phillips, R., Proudfoot, J., Davicioni, E., Spratt, D. E., Feng, F. Y., Simko, J., . . . Tran, P. T. (2023). Validation of a Genomic Classifier in the NRG Oncology/ RTOG 0521 Phase Ill Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 117 (pp. S34-S35). CA, San Diego: ELSEVIER SCIENCE INC. |
| 2023 | Xie, W., Ravi, P., Buyse, M. E., Halabi, S., Kantoff, P. W., Sartor, O., . . . Sweeney, C. (2023). ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era. In ANNALS OF ONCOLOGY Vol. 34 (pp. S958-S959). SPAIN, Barcelona: ELSEVIER. DOI WoS1 |
| 2023 | Morgans, A. K., Sweeney, C., Wallis, C., Halabi, S., Armstrong, A. J., Mohamed, A. F., . . . Grimm, M. -O. (2023). Health-related quality of life (HRQoL) deterioration-free survival (DetFS) by prostate-specific antigen (PSA) decline in darolutamide (DARO)-treated patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from ARAMIS. In ANNALS OF ONCOLOGY Vol. 34 (pp. S962). SPAIN, Barcelona: ELSEVIER. DOI |
| 2023 | Ravi, P., Xie, W., Buyse, M. E., Halabi, S., Kantoff, P. W., Sartor, O., . . . Sweeney, C. (2023). Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): An individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium. In ANNALS OF ONCOLOGY Vol. 34 (pp. S954). SPAIN, Barcelona: ELSEVIER. DOI |
| 2023 | Phillips, R., Proudfoot, J. A., Davicioni, E., Liu, Y., Spratt, D. E., Feng, F. Y., . . . Tran, P. T. (2023). Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). IL, Chicago: LIPPINCOTT WILLIAMS & WILKINS. WoS1 |
| 2023 | Sutera, P., Shetty, A., Hakansson, A. K., Van der Eecken, K., Song, Y., Liu, Y., . . . Ost, P. (2023). Transcriptomic heterogeneity of metastatic disease timing within metastatic castrationsensitive prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). IL, Chicago: LIPPINCOTT WILLIAMS & WILKINS. |
| 2023 | Halabi, S., Guo, S. S., Roy, A., Rydzewska, L., Godolphin, P., Hussain, M. H. A., . . . Sweeney, C. (2023). The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 1 page). IL, Chicago: LIPPINCOTT WILLIAMS & WILKINS. |
| 2022 | Davis, I. D., Martin, A. J., Zielinski, R. R., Thomson, A., Tan, T. H., Sandhu, S., . . . Sweeney, C. (2022). Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. WoS39 |
| 2022 | Niazi, T., McBride, S. M., Williams, S., Davis, I. D., Stockler, M. R., Martin, A. J., . . . Sweeney, C. (2022). DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. WoS3 |
| 2022 | Morgans, A. K., Sweeney, C., Wallis, C. J. D., Halabi, S., Armstrong, A. J., Verholen, F., . . . Grimm, M. -O. (2022). Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. |
| 2022 | Friedman, C., Swanton, C., Spigel, D., Bose, R., Burris, H., Yu, W., . . . Kurzrock, R. (2022). MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors. In ANNALS OF ONCOLOGY Vol. 33 (pp. S571). ELECTR NETWORK: ELSEVIER. DOI |
| 2022 | Vale, C. L., Fisher, D., Godolphin, P., Rydzewska, L. H., Boher, J. -M., Burdett, S., . . . Tierney, J. F. (2022). Defining more precisely the effects of docetaxel plus ADT for men with mHSPC: Meta-analysis of individual participant data from randomized trials.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. WoS20 |
| 2021 | Meric-Bernstam, F., Hainsworth, J., Bose, R., Burris, H. A., Friedman, C. F., Kurzrock, R., . . . Sweeney, C. (2021). MyPathway HER2 basket study: Pertuzumab (P) plus trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39 (pp. 3 pages). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS32 |
| 2021 | Hainsworth, J., Friedman, C. F., Kurzrock, R., Spigel, D. R., Burris, H., Sweeney, C. J., . . . Swanton, C. (2021). Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort.. In CANCER RESEARCH Vol. 81 (pp. 2 pages). PA, Philadelphia: AMER ASSOC CANCER RESEARCH. WoS1 |
| 2021 | Lage, D. E., Michaelson, D. M., Sweeney, C., Barrett, E. D., Olivier, K. M., Lee, R. J., . . . Nipp, R. D. (2021). Symptom burden, functional status, and clinical outcomes of hospitalized patients with advanced genitourinary cancers.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 39 (pp. 2 pages). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS1 |
| 2021 | Sternberg, C. N., Bracarda, S., de Bono, J. S., Sweeney, C., Chi, K. N., Olmos, D., . . . Matsubara, N. (2021). Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC). In ANNALS OF ONCOLOGY Vol. 32 (pp. S635-S636). ELECTR NETWORK: ELSEVIER. DOI WoS2 |
| 2021 | Sutera, P., Van der Eecken, K., Kishan, A. U., Hamid, A., Grist, E., Attard, G., . . . Deek, M. P. (2021). Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics. In International journal of radiation oncology, biology, physics Vol. 111 (pp. e294-e295). ELSEVIER SCIENCE INC. DOI |
| 2020 | de Bono, J. S., Bracarda, S., Sternberg, C. N., Chi, K. N., Olmos, D., Sandhu, S., . . . Sweeney, C. (2020). IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC). In ANNALS OF ONCOLOGY Vol. 31 (pp. S1153-S1154). ELECTR NETWORK: ELSEVIER. DOI WoS31 |
| 2020 | Niazi, T., Williams, S., Davis, I. D., Stockler, M. R., Martin, A., Bracken, K., . . . Sweeney, C. (2020). DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. In ANNALS OF ONCOLOGY Vol. 31 (pp. S548-S549). ELECTR NETWORK: ELSEVIER. DOI |
| 2020 | Smith, M. R., Agarwal, N., Todenhoefer, T., Trepiakas, R., Lee, J. -L., Lithio, A., . . . Sweeney, C. (2020). CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. |
| 2020 | Sweeney, C. J., Gillessen, S., Rathkopf, D., Matsubara, N., Drake, C., Fizazi, K., . . . Powles, T. (2020). IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). In CANCER RESEARCH Vol. 80 (pp. 3 pages). Philadelphia, PA, USA: AMER ASSOC CANCER RESEARCH. DOI WoS40 |
| 2020 | Ravi, P., Martin, N. E., Quoc-Dien, T., Shaw, G., Pomerantz, M., Preston, M. A., . . . Sweeney, C. (2020). Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. |
| 2020 | Niazi, T., Williams, S., Davis, I. D., Stockler, M. R., Martin, A. J., Hague, W., . . . Sweeney, C. (2020). DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate-A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. WoS2 |
| 2020 | Shi, Z., Sweeney, C., Bracarda, S., Sternberg, C. N., Chi, K. N., Olmos, D., . . . De Bono, J. S. (2020). Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. WoS19 |
| 2020 | Francini, E., Ou, F. -S., Rhoades, J., Wolfe, E. G., O'Connor, E., Ha, G., . . . Choudhury, A. D. (2020). Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. |
| 2020 | Francini, E., Montagnani, F., Nuzzo, P. V., Gonzalez-Velez, M., Alimohamed, N. S., Cigliola, A., . . . Heng, D. Y. C. (2020). Clinical outcomes of abiraterone acetate plus prednisone (AA) plus bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. |
| 2020 | Agarwal, A., Nassar, A., Nagy, R., Curran, C., Abou Alaiwi, S., Lanman, R. B., . . . Sonpavde, G. (2020). Circulating tumor (ct)-DNA alterations in patients with testicular germ cell tumors. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. |
| 2020 | Berchuck, J. E., Silver, R., Bakouny, Z., Abou Alaiwi, S., Hamid, A., Sweeney, C., . . . Taplin, M. -E. (2020). Response to olaparib or carboplatin in a real-world cohort of men with DNA damage repair (DDR) deficient metastatic castration-resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. WoS5 |
| 2020 | Grist, E., Parry, M., Mendes, L., Lall, S., Kudahetti, S. C., Vidal, S. S., . . . Attard, G. (2020). Multiregion expression profiling of prostate cancer from men randomized in the STAMPEDE trial: Stage I results of a multistage biomarker analysis. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. |
| 2020 | Hamid, A., Wang, X. V., Chen, Y. -H., Feng, F. Y., Benjamin, D. R., Attard, G., . . . Sweeney, C. (2020). Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. WoS13 |
| 2020 | Jiang, D. M., Wong, B., Morgans, A. K., Sweeney, C., Fizazi, K., Chi, K. N., . . . Sridhar, S. S. (2020). Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. |
| 2020 | Yoshikawa, Y., Wang, X. V., Chen, Y. -H., Mazzu, Y. Z., Chakraborty, G., Jehane, L. E., . . . Sweeney, C. (2020). The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. WoS2 |
| 2020 | Trujillo, M. P., Ravi, P. K., Shaw, G. K., Markt, S. C., Hamid, A., Tewari, A., . . . Sweeney, C. (2020). A retrospective review of the survival outcomes of patients with nonseminomatous germ cell tumors (NSGCTs) with and without teratoma in the primary. In ANNALS OF ONCOLOGY Vol. 31 (pp. S603). ELECTR NETWORK: ELSEVIER. DOI WoS1 |
| 2020 | Beyer, J., Collette, L., Daugaard, G., De Wit, R., Tryakin, A., Albany, C., . . . Gillessen, S. (2020). Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). CA, San Francisco: AMER SOC CLINICAL ONCOLOGY. WoS11 |
| 2020 | Hamid, A., Funt, S. A., Markt, S. C., Bromberg, M., O'Donnell, D., Adra, N., . . . Sweeney, C. (2020). Causes and patterns of mortality in patients with lethal germ cell tumor (GCT). In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). CA, San Francisco: AMER SOC CLINICAL ONCOLOGY. |
| 2020 | Daniel Fankhauser, C., Tran, B., Ruiz Morales, J. M., Gonzalez-Billalabeitia, E., Seidel, C. A., Bokemeyer, C., . . . Connors, J. M. (2020). Benefit of prophylactic anticoagulation before and during first-line chemotherapy on patients with metastatic germ cell tumors. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). CA, San Francisco: LIPPINCOTT WILLIAMS & WILKINS. |
| 2020 | Cole, A. P., Nabi, J., Sun, M., Fletcher, S., Berry, D. L., Nguyen, P. L., . . . Quoc-Dien, T. (2020). A SMARTPHONE-BASED MOBILE HEALTH APP TO ADDRESS THE ADVERSE EFFECTS OF ANDROGEN DEPRIVATION THERAPY IN MEN WITH PROSTATE CANCER. In JOURNAL OF UROLOGY Vol. 203 (pp. E1219). DC, Washington: LIPPINCOTT WILLIAMS & WILKINS. |
| 2020 | Geng, J. -H., Pomerantz, M., Penney, K., Nabi, J., Sweeney, C., Mucci, L., & Kibel, A. (2020). IMPACT OF METABOLIC DISEASES AND DRUGS ON PROSTATE CANCER PATIENTS RECEIVING ANDROGEN DEPRIVATION THERAPY. In JOURNAL OF UROLOGY Vol. 203 (pp. E1222-E1223). DC, Washington: LIPPINCOTT WILLIAMS & WILKINS. |
| 2019 | Gillessen, S., Collette, L., Daugaard, G., de Wit, R., Tryakin, A., Albany, C., . . . Beyer, J. (2019). Redefining the IGCCCG classification in advanced non-seminoma. In ANNALS OF ONCOLOGY Vol. 30 (pp. 357-+). SPAIN, Barcelona: OXFORD UNIV PRESS. WoS11 |
| 2019 | Rosenberg, J. E., Ballman, K. V., Halabi, S., Watt, C., Hahn, O. M., Steen, P. D., . . . Morris, M. J. (2019). CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase Ill trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). IL, Chicago: AMER SOC CLINICAL ONCOLOGY. DOI WoS11 |
| 2019 | Hearn, J. W., Sweeney, C., Almassi, N., Reichard, C. A., Reddy, C. A., Hobbs, B., . . . Sharifi, N. (2019). HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS2 |
| 2019 | Nassar, A., Agarwal, A., Nagy, R., Curran, C., Abou Alaiwi, S., Lanman, R. B., . . . Sonpavde, G. (2019). Circulating tumor (ct)-DNA alterations in patients with testicular germ tumors.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2019 | Sweeney, C., Percent, I. J., Babu, S., Cultrera, J., Mehlhaff, B. A., Goodman, O. B., . . . Bendell, J. C. (2019). Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS10 |
| 2019 | Hamid, A., Werner, L., Huang, Y., Vicier, C., Morel, K., Ellis, L., & Sweeney, C. (2019). Prognostic impact of tristetraprolin (TTP) and PTEN loss and assessment of associated immune infiltrates in localized prostate cancer (PrCa).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2019 | Vicier, C., Xie, W., Hamid, A., Evan, C., & Sweeney, C. (2019). Impact of new systemic therapies on outcomes of patients with non-metastatic castration resistant prostate cancer (nmCRPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2019 | Jiang, D. M., Brundage, M. D., Sweeney, C., Fizazi, K., Bellmunt, J., Vaughn, D. J., . . . Sridhar, S. S. (2019). Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2019 | Vicier, C., Werner, L., Huang, Y., Hamid, A., Evan, C., Loda, M., & Sweeney, C. (2019). Immune infiltrate with CD8 low or PDL1 high associated with metastatic prostate cancer after radical prostatectomy (RP).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI WoS4 |
| 2019 | Vatnick, D. R., Aktar, S., Stopfer, J. E., Kipnis, L., Culver, S. K., Koeller, D. R., . . . Pomerantz, M. (2019). Genetic counseling processes and outcomes among prostate cancer patients (ProGen).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2019 | Sweeney, C., Martin, A. J., Zielinski, R. R., Thomson, A., Tan, T. H., Sandhu, S. K., . . . Davis, I. D. (2019). Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone -sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2018 | Tripathi, A., Xie, W., Sweeney, C., Choudhury, A. D., Pomerantz, M., Wei, X. X., . . . Harshman, L. C. (2018). Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY. DOI |
| 2018 | Zhang, L., Gray, K. P., Shaw, G., Evan, C., Francini, E., & Sweeney, C. (2018). Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY. DOI |
| 2018 | Aldubayan, S. H., Pyle, L. T., Loud, J. T., Greene, M. H., Sweeney, C., Nathanson, K., . . . Lessel, D. (2018). Inherited defects in checkpoint kinase 2 (CHEK2) to confer increased susceptibility to testicular germ cell tumors.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2018 | Bernard, B. D., Gray, K. P., Shaw, G., MacConaill, L. E., Evan, C., Hamid, A., . . . Sweeney, C. (2018). DNA damage and repair (DDR) gene variants and outcomes in localized and metastatic prostate cancer (mPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2018 | Hamid, A., Gray, K. P., Huang, Y., Bowden, M., Loda, M., Pomerantz, M., & Sweeney, C. (2018). Association of low PTEN expression by fluorescence immunohistochemistry (F-IHC) and lethal disease in men with surgically-treated prostate cancer (PrCa).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2018 | Tripathi, A., Supko, J., Gray, K., Melnick, Z., Taplin, M. -E., Choudhury, A., . . . Harshman, L. (2018). Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC). In ANNALS OF ONCOLOGY Vol. 29 (pp. 298). Munich, GERMANY: OXFORD UNIV PRESS. DOI WoS1 |
| 2018 | Morgans, A., Chen, Y. -H., Jerrard, D., Carducci, M., Dipaola, R., Wagner, L., . . . Sweeney, C. (2018). Association between patient reported quality of life (QOL) and survival: Analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. In ANNALS OF ONCOLOGY Vol. 29 (pp. 1 page). Munich, GERMANY: OXFORD UNIV PRESS. DOI |
| 2018 | de Velasco, G., Lora, D., Lorente, D., Choueiri, T. K., Sweeney, C., & Castellano, D. E. (2018). Impact of statins on outcomes in patients (pts) with metastatic castration resistant prostate cancer (mCRPC): Post-hoc analysis of data from COU-AA-301 and COU-AA-302 trials.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 2 pages). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS3 |
| 2018 | Williams, S., Davis, I. D., Sweeney, C., Stockler, M. R., Martin, A. J., Hague, W., . . . Nguyen, P. L. (2018). Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI WoS9 |
| 2018 | Hamid, A., Gray, K. P., Shaw, G., MacConaill, L. E., Evan, C., Bernard, B. D., . . . Sweeney, C. (2018). Tumor suppressor aberrations and outcomes in localized and metastatic hormone sensitive prostate cancer (PrCa).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2018 | Francini, E., Gray, K. P., Shaw, G., Evan, C., Hamid, A., Perry, C. E., . . . Sweeney, C. (2018). Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2018 | Hamid, A., Gray, K. P., Shaw, G., MacConaill, L. E., Evan, C., Bernard, B. D., . . . Sweeney, C. (2018). Clinical outcomes with cumulative tumor suppressor gene (TSG) alterations in castration sensitive (CSPC) and resistant (CRPC) prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY. DOI |
| 2018 | Wei, X. X., Hamid, A., He, M., Harshman, L. C., Choueiri, T. K., Sonpavde, G., . . . Choudhury, A. D. (2018). Delayed PSA responses in metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with sipuleucel-T.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY. DOI |
| 2018 | Bryce, A. H., Chen, Y. -H., Liu, G., Carducci, M. A., Jarrard, D. F., Garcia, J. A., . . . Sweeney, C. (2018). Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2018 | Komura, K., Sweeney, C., Inamoto, T., Ibuki, N., Azuma, H., & Kantoff, P. (2018). DNA REPLICATION STRESS BY THE LOSS OF MALE SPECIFIC HISTONE DEMETHYLASE 'KDM5D' IN AGGRESSIVE PROSTATE CANCER. In JOURNAL OF UROLOGY Vol. 199 (pp. E365). CA, San Francisco: ELSEVIER SCIENCE INC. |
| 2018 | Allott, E., Noonan, E., Gonzalez-Feliciano, A., Markt, S., Wilson, K., Ahearn, T., . . . Mucci, L. (2018). MOLECULAR TUMOR PROFILING TO IDENTIFY MECHANISMS LINKING STATINS WITH LOWER RISK OF LETHAL PROSTATE CANCER. In JOURNAL OF UROLOGY Vol. 199 (pp. E261-E262). CA, San Francisco: ELSEVIER SCIENCE INC. |
| 2018 | Oguntola, I., Olubeko, S., & Sweeney, C. (2018). SlimNets: An Exploration of Deep Model Compression and Acceleration. In 2018 IEEE HIGH PERFORMANCE EXTREME COMPUTING CONFERENCE (HPEC) (pp. 6 pages). MA, Waltham: IEEE. WoS8 |
| 2017 | Maria, B. A., Garcia, A. M., Lora, D., Bernard, B. D., David, L., Kopp, R. M., . . . De, V. (2017). Association of risk of febrile neutropenia (FN) with docetaxel in prostate cancer (PC) patients: A meta-analysis of published phase II-III trials.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 6 pages). IL, Chicago: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2017 | Gerke, T., Bornigen, D., Beltran, H., Tyekucheva, S., Huttenhower, C., Lee, G. -S., . . . Sweeney, C. (2017). Loss of the tumor suppressor zinc finger protein-36 and risk of lethal prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). DC, Washington: AMER ASSOC CANCER RESEARCH. DOI |
| 2017 | Morel, K. L., Sykes, P. J., Gokhale, P. C., Lee, G. -S. M., Tiv, H., & Sweeney, C. J. (2017). Dimethylaminoparthenolide (DMAPT), an oral nuclear factor kappa B inhibitor (NFκB), enhances radiation therapy and enhances epidermal growth factor tyrosine kinase inhibitor (EGFR TKI) activity. In CANCER RESEARCH Vol. 77 (pp. 2 pages). DC, Washington: AMER ASSOC CANCER RESEARCH. DOI |
| 2017 | Harshman, L. C., Xie, W., Moreira, R. B., Bosse, D., Ares, G. R., Sweeney, C., & Choueiri, T. K. (2017). Evaluation of disease-free survival as an intermediate metric for overall survival in localized renal cell carcinoma: A trial-level meta-analysis. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). IL, Chicago: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2017 | Jarrard, D., Chen, Y. -H., Liu, G., Carducci, M., Eisenberger, M., Wong, Y. -N., . . . Sweeney, C. (2017). IMPACT OF METFORMIN ON PROSTATE CANCER PC OUTCOMES IN THE E3805 CHAARTED TRIAL. In JOURNAL OF UROLOGY Vol. 197 (pp. E715). MA, Boston: ELSEVIER SCIENCE INC. DOI |
| 2017 | Klotz, L., Sweeney, C., Dicker, A., Vogelzang, N., Morris, M., Verholen, F., . . . Sartor, O. (2017). EFFICACY AND SAFETY OF RADIUM-223 BY RADICAL LOCAL THERAPY AT INITIAL DIAGNOSIS: A RETROSPECTIVE SUBGROUP ANALYSIS OF ALSYMPCA TRIAL. In JOURNAL OF UROLOGY Vol. 197 (pp. E454). MA, Boston: ELSEVIER SCIENCE INC. DOI WoS1 |
| 2017 | Komura, K., Jeong, S. H., Azuma, H., Lee, G. -S., Sweeney, C., & Kantoff, P. (2017). DECREASED EXPRESSION OF MALE SPECIFIC HISTONE DEMETHYLASE "KDM5D" IS PROGNOSTIC FOR DEVELOPMENT OF CASTRATION-RESISTANT PROSTATE CANCER. In JOURNAL OF UROLOGY Vol. 197 (pp. E343-E344). MA, Boston: ELSEVIER SCIENCE INC. DOI |
| 2017 | Harshman, L. C., Xie, W., Moreira, R. B., Gustavo, R., Sweeney, C., & Choueiri, T. K. (2017). Meta-analysis of disease free survival (DFS) as a surrogate for overall survival (OS) in localized renal cell carcinoma (RCC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 2 pages). LIPPINCOTT WILLIAMS & WILKINS. DOI WoS2 |
| 2017 | Morris, M. J., Loriot, Y., Fizazi, K., Sweeney, C., Ryan, C. J., & Shevrin, D. H. (2017). Effects of radium-223 (Ra-223) with docetaxel versus docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer (CRPC): A phase I/IIa clinical trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 2 pages). LIPPINCOTT WILLIAMS & WILKINS. DOI WoS4 |
| 2017 | Kamran, S. C., Seisen, T., Markt, S. C., Preston, M. A., Frazier, A. L., & Sweeney, C. (2017). Post-orchiectomy adjuvant therapy versus surveillance for stage IS testicular cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 1 page). LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2017 | Javle, M. M., Hainsworth, J. D., Swanton, C., Burris, H. A., Kurzrock, R., & Sweeney, C. (2017). Pertuzumab plus trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 2 pages). IL, Chicago: AMER SOC CLINICAL ONCOLOGY. DOI WoS35 |
| 2017 | Yang, D. D., Mahal, B. A. V., Sweeney, C., Quoc-Dien, T., Feng, F. Y. -C., & Nguyen, P. L. (2017). Identification of low prostate-specific antigen, high Gleason prostate cancer as a unique hormone-resistant entity with poor survival: A contemporary analysis of 640,000 patients.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2017 | Powles, T., Fizazi, K., Gillessen, S., Drake, C. G., Rathkopf, D. E., Narayanan, S., . . . Sweeney, C. (2017). A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS3 |
| 2017 | Sweeney, C., Gerke, T., Beltran, H., Sboner, A., Karnes, R. J., Klein, E. A., . . . Trock, B. (2017). Association of loss of tumor suppressor ZFP36 with lethal prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2017 | Hainsworth, J. D., Bose, R., Sweeney, C., Meric-Bernstam, F., Hurwitz, H., Swanton, C., . . . Spigel, D. R. (2017). Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS6 |
| 2017 | Francini, E., Gray, K. P., Evan, C., Kaymakcalan, M. D., Shaw, G. K., Kantoff, P. W., . . . Sweeney, C. (2017). Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) plus docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2017 | Howard, S., Rosenthal, M., Qin, L., Matalon, S., Bernard, B., Beard, C., & Sweeney, C. (2017). Quantifying Decreased Radiation Exposure From Modern CT Scan Technology and Surveillance Programs of Germ Cell Tumors. In American Journal of Clinical Oncology: Cancer Clinical Trials Vol. 34 (pp. 1-4). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI Scopus6 WoS6 Europe PMC4 |
| 2016 | Ko, J. J., Bernard, B. D., Ben, T., Li, H., Asif, T., Stukalin, I., . . . Heng, D. Y. C. (2016). Conditional survival of patients with metastatic testicular germ-cell tumors (MT-GCT) treated with first-line curative therapy.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2016 | Hurwitz, H., Hainsworth, J. D., Swanton, C., Perez, E. A., Sweeney, C., Burris, H. A., . . . Bose, R. (2016). Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI WoS14 |
| 2016 | Patrick-Miller, L. J., Chen, Y. -H., Carducci, M. A., Cella, D., DiPaola, R. S., Gartrell, B. A., . . . Sweeney, C. (2016). Quality of life (QOL) analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PrCa). In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI WoS4 |
| 2016 | Bernard, B. D., Albiges, L., Signoretti, S., Novak, J., Hirsch, M. S., Massard, C., . . . Adam, J. (2016). Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2016 | Harshman, L. C., Werner, L., Nakabayashi, M., Tripathi, A., Mckay, R. R., Wang, X., . . . Kantoff, P. W. (2016). The impact of statin use on abiraterone acetate (AA) treatment duration in patients with castration-resistant prostate cancer (CRPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2016 | Muralidhar, V., Mahal, B. A. V., Reznor, G., Choueiri, T. K., Sweeney, C., Martin, N. E., . . . Nguyen, P. L. (2016). Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2016 | Pomerantz, M., Wang, X. V., Kantoff, P. W., Xie, W., Kohli, M., Lee, G. -S. M., . . . Sweeney, C. (2016). Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa). In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2016 | Harshman, L. C., Gray, K. P., Polacek, L., Taplin, M. -E., Choudhury, A. D., Pomerantz, M. M., . . . Sweeney, C. (2016). An investigator-initiated phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before or after progression on docetaxel.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2016 | Davis, I. D., Stockler, M. R., Martin, A. J., Hague, W., Coskinas, X., Yip, S., . . . Sweeney, C. (2016). Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 3 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2016 | Williams, S. G., Davis, I. D., Sweeney, C., Stockler, M. R., Martin, A. J., Hague, W., . . . Nguyen, P. L. (2016). Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 3 pages). IL, Chicago: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2016 | Friedland, D., Barry, A., Ellis, P. G., Sweeney, C., McCutcheon, S., Lokay, K., . . . Krebs, M. (2016). Evaluating the impact of Via Pathways (VP) on the adoption of changing treatment paradigms in metastatic hormone-sensitive prostate cancer (mHSPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2016 | Morris, M. J., Loriot, Y., Sweeney, C., Fizazi, K., Ryan, C. J., Shevrin, D. H., . . . Higano, C. S. (2016). Updated results: A phase InIa randomized trial of radium-223+docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 3 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS9 |
| 2016 | Sweeney, C., Xie, W., Regan, M. M., Nakabayashi, M., Buyse, M. E., Clarke, N. W., . . . Williams, S. G. (2016). Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS3 |
| 2016 | Patrick-Miller, L. J., Chen, Y. -H., Carducci, M. A., Cella, D., DiPaola, R. S., Gartrell, B. A., . . . Sweeney, C. (2016). Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS2 |
| 2016 | Howard, S. A. H., Rosenthal, M., Qin, L., Bernard, B. D., Beard, C., & Sweeney, C. (2016). Quantifying decreased radiation exposure from modern CT scan surveillance programs of germ cell tumors.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2016 | Wong, S. E., North, S. A., Sweeney, C., Stockler, M. R., & Sridhar, S. S. (2016). Screen failure rates in contemporary phase II/III therapeutic trials in genitourinary malignancies. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2016 | Deraska, P. V., O'Leary, C., Lazaro, J. -B., Sweeney, C. J., D'Andrea, A. D., & Kozono, D. (2016). NF-κB inhibitor DMAPT blocks non-homologous end-joining repair of radiation-induced DSBs in NSCLC. In CANCER RESEARCH Vol. 76 (pp. 4 pages). LA, New Orleans: AMER ASSOC CANCER RESEARCH. DOI |
| 2016 | Hainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., . . . Kurzrock, R. (2016). Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY. DOI WoS6 |
| 2016 | Hainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., . . . Kurzrock, R. (2016). Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). IL, Chicago: AMER SOC CLINICAL ONCOLOGY. DOI WoS7 |
| 2016 | Bernard, B. D., Rider, J. R., Sweeney, C., & Sridhar, S. S. (2016). Age, race, and survival of men with de novo distant metastatic prostate cancer (M1PC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 3 pages). IL, Chicago: AMER SOC CLINICAL ONCOLOGY. DOI WoS3 |
| 2015 | O'Leary, C., Deraska, P., Sweeney, C., D'Andrea, A., & Kozono, D. (2015). NF-κB inhibition by DMAPT radiosensitizes non-small cell lung carcinoma by impairing DNA double strand break repair. In CANCER RESEARCH Vol. 75 (pp. 1 page). PA, Philadelphia: AMER ASSOC CANCER RESEARCH. DOI WoS1 |
| 2015 | Shore, N., Vogelzang, N., Fernandez, D., Morris, M., Iagaru, A., Brown, A., . . . Sartor, O. (2015). RADIUM-223 DICHLORIDE IN EXPANDED-ACCESS SETTING IN THE UNITED STATES: OVERALL AND CONCURRENT EXPERIENCE WITH ABIRATERONE OR ENZALUTAMIDE. In JOURNAL OF UROLOGY Vol. 193 (pp. E1088-E1089). LA, New Orleans: ELSEVIER SCIENCE INC. DOI |
| 2015 | O'Rourke, M., Canavan, M., Sweeney, C., Fletcher, J., Fearon, U., & Murphy, C. (2015). The role of dendritic cells in non-infectious anterior uveitis. In ACTA OPHTHALMOLOGICA Vol. 93 (pp. 3 pages). WILEY-BLACKWELL. DOI |
| 2015 | Hsieh, C. -L., Botta, G., Gao, S., Li, T., Van Allen, E. M., Treacy, D. J., . . . Kantoff, P. W. (2015). PLZF, a tumor suppressor genetically lost in metastatic castration resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. In CANCER RESEARCH Vol. 75 (pp. 2 pages). San Francisco, CA: AMER ASSOC CANCER RESEARCH. DOI |
| 2015 | Vale, C., Rydzewska, L. H., Tierney, J. F., Albiges, L., Clarke, N. W., Fisher, D. J., . . . Burdett, S. (2015). What is the current evidence for adding docetaxel or bisphosphonates to androgen deprivation therapy (ADT) in men with hormone sensitive prostate cancer? A systematic review and meta-analyses. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S719-S720). Vienna, AUSTRIA: ELSEVIER SCI LTD. DOI WoS2 |
| 2015 | Dinh, K. T., Mahal, B. A. V., Ziehr, D. R., Muralidhar, V., Chen, Y. -W., Viswanathan, V. B., . . . Paul, L. N. (2015). Incidence and predictors of prostate cancer death in men with other prior malignancies: An analysis from SEER Database. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Harshman, L. C., Nakabayashi, M., Xie, W., Wang, X., Valenca, L., Werner, L., . . . Kantoff, P. W. (2015). Statin use at the time of initiation of androgen deprivation therapy (ADT) and time to progression (TTP) in patients with hormone-sensitive prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Bernard, B. D., Markt, S. C., Albiges, L., Miller, R., Pettersson, A., Beard, C., & Sweeney, C. (2015). Sunlight and testicular germ cell tumor rates in the USA. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Kamran, S. C., Markt, S. C., Miller, R., O'Donnell, E., Bernard, B. D., Curreri, S. A., . . . Beard, C. (2015). A review of clinical stage 1 testicular cancer mortality in a high-volume center. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI WoS2 |
| 2015 | Harshman, L. C., Wang, X., Nakabayashi, M., Xie, W., Valenca, L. B., Werner, L., . . . Kantoff, P. W. (2015). Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2014 | Beard, C. J., Jeldres, C., Odem-Davis, K., Hoffman, K. E., Martin, N. E., Nguyen, P. L., . . . Nichols, C. R. (2014). Variation in Patterns of Care in the United States for Clinical Stage I Seminoma: Results From the National Cancer Data Base (1998-2011). In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 90 (pp. S469). San Francisco, CA: ELSEVIER SCIENCE INC. DOI |
| 2013 | Sweeney, C. J., Zukotynski, K., Wang, X., Wick, A., Fredericks, A., Lam, B., & Kantoff, P. (2013). Cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): preclinical evaluation and interim results of an investigator-sponsored phase 1 clinical study.. In CANCER RESEARCH Vol. 73 (pp. 1 page). Washington, DC: AMER ASSOC CANCER RESEARCH. DOI |
| 2012 | Morris, M. J., Hammers, H. J., Sweeney, C., Bloma, M., Aksnes, A. -K., O'Bryan-Tear, C. G., & Carrasquillo, J. A. (2012). A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra-223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. WoS1 |
| 2012 | Hutson, T. E., Dang, L. H., Lauer, R. C., Starodub, A., Hauke, R. J., Galsky, M. D., . . . Sarantopoulos, J. (2012). Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. |
| 2012 | de Bono, J. S., Smith, M. R., Rathkopf, D., Corn, P. G., Mukherji, D., Harzstark, A. L., . . . Sweeney, C. (2012). CABOZANTINIB (XL184) AT 40 MG IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): RESULTS OF A PHASE 2 NON-RANDOMIZED EXPANSION COHORT (NRE). In ANNALS OF ONCOLOGY Vol. 23 (pp. 296). Vienna, AUSTRIA: OXFORD UNIV PRESS. |
| 2012 | Rudman, S. M., Gray, K. P., Kasperzyk, J., Giovannucci, E., Pitt, M., Loda, M. F., . . . Sweeney, C. (2012). Association of metabolic syndrome with poorer prostate cancer and overall survival in men receiving androgen deprivation therapy (ADT) for biochemical relapse.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. |
| 2012 | Smith, M. R., Sweeney, C., Rathkopf, D. E., Scher, H. I., Logothetis, C., George, D. J., . . . Corn, P. G. (2012). Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE). In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. WoS5 |
| 2010 | Arvold, N. D., Catalano, P. J., Sweeney, C. J., Hoffman, K. E., Nguyen, P. L., Balboni, T. A., . . . Beard, C. J. (2010). Patterns of Care for Stage I Seminoma: A Survey of American Radiation Oncologists. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 78 (pp. S193). San Diego, CA: ELSEVIER SCIENCE INC. DOI |
| 2010 | Jain, R. K., Thorat, M. A., Mehta, R., Polar, Y., Morimiya, A., Sweeney, C., . . . Badve, S. (2010). Gene Expression Profiles of Classical and Spermatocytic Seminoma. In MODERN PATHOLOGY Vol. 23 (pp. 198A). Washington, DC: NATURE PUBLISHING GROUP. |
| 2010 | Jain, R. K., Thorat, M. A., Mehta, R., Polar, Y., Morimiya, A., Sweeney, C., . . . Badve, S. (2010). Gene Expression Profiles of Classical and Spermatocytic Seminoma. In LABORATORY INVESTIGATION Vol. 90 (pp. 198A). Washington, DC: NATURE PUBLISHING GROUP. |
| 2010 | Estabrook, N. C., Chin-Sinex, H., Watson, C. N., Shapiro, R. H., Dhaemers, R. M., Gilley, D., . . . Mendonca, M. S. (2010). DMAPT Induced X-ray Sensitization of Lung Cancer Cells Involves Inhibition of NF-κB Dependent Split Dose and DNA Double Strand Break Repair. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 78 (pp. S647). San Diego, CA: ELSEVIER SCIENCE INC. DOI |
| 2009 | Clarke, S. J., Smith, J. T., Gebbie, C., Sweeney, C., & Olszewski, N. (2009). A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. In JOURNAL OF CLINICAL ONCOLOGY Vol. 27 (pp. 2 pages). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. WoS17 |
| 2009 | Hahn, N. M., Stadler, W. M., Zon, R. T., Waterhouse, D. M., Picus, J., Nattam, S. R., . . . Sweeney, C. J. (2009). A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU-0475. In JOURNAL OF CLINICAL ONCOLOGY Vol. 27 (pp. 1 page). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. WoS7 |
| 2008 | Chiorean, E., Sweeney, C., Youssoufian, H., Fox, F., Katz, T., Rowinsky, E., & Amato, R. (2008). Phase I study of IMC-3G3, an IgG1 monoclonal antibody targeting platelet-derived growth factor alpha (PDGFRa) in patients with advanced solid malignancies. In EJC SUPPLEMENTS Vol. 6 (pp. 162). Geneva, SWITZERLAND: PERGAMON-ELSEVIER SCIENCE LTD. DOI |
| 2006 | Shanmugam, R., Neelakantan, S., Jayaprakasan, V., Crooks, P., Nakshatri, H., & Sweeney, C. J. (2006). Water soluble analogue of parthenolide LC-1 influences apoptosis in bladder cancer cell lines by modulating proapoptotic and anti-apoptotic genes and promotes p21 activity.. In CANCER RESEARCH Vol. 66 (pp. 2 pages). AMER ASSOC CANCER RESEARCH. |
| 2003 | Sweeney, C. J. (2003). Why cyclooxygenase-2 inhibition plus chemotherapy?. In American Journal of Clinical Oncology Cancer Clinical Trials Vol. 26 (pp. S122-S125). United States: Ovid Technologies (Wolters Kluwer Health). DOI Scopus14 Europe PMC8 |
| Year | Citation |
|---|---|
| 2024 | Hamid, A. A., Thomas, H., Martin, A., Soon, Y. Y., Horvath, L. G., Zielinski, R., . . . Sweeney, C. (2024). Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304). Poster session presented at the meeting of Abstracts of the European Society for Medical Oncology Congress (ESMO 2024), as published in Annals of Oncology. Barcelona, Spain: Elsevier. DOI |
| 2023 | Halabi, S., Roy, A., Guo, S. S., Rydzewska, L., Godolphin, P., Hussain, M. H. A., . . . Sweeney, C. (2023). Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. IL, Chicago: LIPPINCOTT WILLIAMS & WILKINS. WoS6 |
| 2023 | Cilento, M. A., Mah, C. Y., Martelotto, L., Sweeney, C. J., & Butler, L. M. (2023). Multiomic analysis workflow for biomarker discovery in human prostate cancer. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. |
| 2023 | Phillips, R., Proudfoot, J. A., Davicioni, E., Liu, Y., Spratt, D. E., Feng, F. Y., . . . Tran, P. T. (2023). Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. DOI WoS1 |
| 2023 | Lledo, D. S., Chu, X., Jarrard, D. F., Carducci, M. A., Dipaola, R. S., Wagner, L. I., . . . Morgans, A. K. (2023). Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2023 | Hamid, A., Chinsky, T. M., Vergara, M., Grist, E., Attard, G., Van Allen, E. M., . . . Sweeney, C. (2023). Landscape and impact of germline pathogenic variants (PVs) in metastatic hormone sensitive prostate cancer (mHSPC): Ancillary study of E3805 CHAARTED.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. DOI WoS1 |
| 2023 | Halabi, S., Roy, A., Guo, S. S., Rydzewska, L., Godolphin, P., Hussain, M. H. A., . . . Sweeney, C. (2023). Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. DOI WoS6 |
| 2023 | Halabi, S., Guo, S. S., Roy, A., Rydzewska, L., Godolphin, P., Hussain, M. H. A., . . . Sweeney, C. (2023). The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. DOI WoS1 |
| 2023 | Ravi, P., Kwak, L., Armstrong, J., Beckendorf, V., Chin, J., D'Amico, A. V., . . . Sweeney, C. (2023). Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. DOI WoS1 |
| 2023 | Sutera, P., Shetty, A., Hakansson, A. K., Van der Eecken, K., Song, Y., Liu, Y., . . . Ost, P. (2023). Transcriptomic heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2023 | Ravi, P., Kwak, L., Armstrong, J., Beckendorf, V., Chin, J., D'Amico, A. V., . . . Sweeney, C. (2023). Prognostic impact of PSA nadir (n) >= 0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. IL, Chicago: LIPPINCOTT WILLIAMS & WILKINS. WoS1 |
| 2023 | Lledo, D. S., Chu, X., Jarrard, D. F., Carducci, M. A., DiPaola, R. S., Wagner, L. I., . . . Morgans, A. K. (2023). Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa). Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. IL, Chicago: LIPPINCOTT WILLIAMS & WILKINS. |
| 2022 | Shi, Z., Nowicka, M., de Bono, J., Chi, K. N., Sweeney, C., Sternberg, C. N., . . . Sandhu, S. K. (2022). Molecular subtyping in prostate cancer associate with outcomes to abiraterone and ipatasertib treatment from the phase III IPATential150 trial. Poster session presented at the meeting of CANCER RESEARCH. New Orleans, LA: AMER ASSOC CANCER RESEARCH. |
| 2022 | Shi, Z., Nowicka, M., de Bono, J., Chi, K. N., Sweeney, C., Sternberg, C. N., . . . Sandhu, S. K. (2022). Molecular subtyping in prostate cancer associate with outcomes to abiraterone and ipatasertib treatment from the phase III IPATential150 trial.. Poster session presented at the meeting of CANCER RESEARCH. New Orleans, LA: AMER ASSOC CANCER RESEARCH. |
| 2022 | Sweeney, C., Chi, K. N., Bracarda, S., Sternberg, C. N., Olmos, D., Sandhu, S., . . . De Bono, J. S. (2022). Activation of the AKT pathway and outcomes in patients (pts) treated with or without ipatasertib (ipat) in metastatic castration-resistant prostate cancer (mCRPC): Next-generation sequencing (NGS) data from the phase III IPATential150 trial.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. WoS6 |
| 2022 | George, S., Gosain, R., Yendamuri, K., Boher, J. M., Mescam, G. G., Sweeney, C. J., & Hutson, A. (2022). Assessment of whether time to docetaxel impacts outcome when given in metastatic hormone-sensitive prostate cancer (MHSPC) setting. Poster session presented at the meeting of ANNALS OF ONCOLOGY. ELECTR NETWORK: ELSEVIER. WoS1 |
| 2022 | Halabi, S., Roy, A., Rydzewska, L., Godolphin, P., Parmar, M. K., Hussain, M., . . . Sweeney, C. J. (2022). Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). Poster session presented at the meeting of ANNALS OF ONCOLOGY. ELECTR NETWORK: ELSEVIER. |
| 2022 | Mckay, R. R., Agarwal, N., Matsubara, N., Rodriguez, J. M. P., Smith, M. R., Todenhofer, T., . . . Sweeney, C. J. (2022). CYCLONE 3: A phase III, randomized, double-blind, placebocontrolled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). Poster session presented at the meeting of ANNALS OF ONCOLOGY. ELECTR NETWORK: ELSEVIER. WoS1 |
| 2022 | Parry, M., Grist, E., Brawley, C., Proudfoot, J. A., Mendes, L., Lall, S., . . . Attard, G. (2022). Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial. Poster session presented at the meeting of ANNALS OF ONCOLOGY. ELECTR NETWORK: ELSEVIER. WoS3 |
| 2022 | Sweeney, C. J., Morel, K., Hamid, A., & Ellis, L. (2022). Combined loss of tristetraprolin (TTP) and PTEN leads to aggressive prostate cancer and hypersensitivity to nuclear factor kappa B (NFkB) inhibition.. Poster session presented at the meeting of CANCER RESEARCH. LA, New Orleans: AMER ASSOC CANCER RESEARCH. |
| 2022 | Sweeney, C. J., Morel, K., Hamid, A., & Ellis, L. (2022). Combined loss of tristetraprolin (TTP) and PTEN leads to aggressive prostate cancer and hypersensitivity to nuclear factor kappa B (NFkB) inhibition. Poster session presented at the meeting of CANCER RESEARCH. LA, New Orleans: AMER ASSOC CANCER RESEARCH. |
| 2022 | Mostaghel, E. A., Wang, X. V., Marck, B., Matsumoto, A. M., & Sweeney, C. (2022). Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2022 | McGregor, B. A., Wang, X. V., Hamnvik, O. -P. R., Cheung, Y. M., Wei, X. X., Ravi, P., . . . Sweeney, C. (2022). Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus /- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2022 | Smith, M. R., Agarwal, N., Todenhofer, T., Piulats, J. M., Lee, J. -L., Trepiakas, R., . . . Sweeney, C. (2022). CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS4 |
| 2022 | McBride, S. M., Niazi, T., Williams, S., Davis, I. D., Stockler, M. R., Martin, A. J., . . . Sweeney, C. (2022). DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2022 | Tripathi, A., Chen, Y. -H., Jarrard, D. F., Hahn, N. M., Garcia, J. A., Dreicer, R., . . . Sweeney, C. (2022). Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. WoS1 |
| 2022 | Halabi, S., Roy, A., Rydzewska, L., Godolphin, P., Parmar, M. K. B., Hussain, M. H. A., . . . Sweeney, C. (2022). Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. WoS3 |
| 2021 | Halabi, S., Roy, A., Yang, Q., Xie, W., Kelly, W. K., & Sweeney, C. (2021). Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS4 |
| 2021 | Mendes, L., Brawley, C. D., Grist, E., Ali, A., Vidal, S. S., Parry, M., . . . Attard, G. (2021). Proliferation index and survival in men with prostate cancer starting long-term androgen deprivation therapy in the STAMPEDE clinical trial.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2021 | Niazi, T., Williams, S., Davis, I. D., Stockler, M. R., Martin, A. J., Bracken, K., . . . Sweeney, C. (2021). DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2021 | Choudhury, A. D., Kwak, L., Cheung, A., Tripathi, A., Pace, A. F., Van Allen, E. M., . . . Bhatt, R. S. (2021). Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS11 |
| 2021 | De Bono, J. S., Sweeney, C., Bracarda, S., Sternberg, C. N., Chi, K. N., Olmos, D., . . . Shi, Z. (2021). PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS15 |
| 2021 | Lage, D. E., Michaelson, D. M., Lee, R. J., Greer, J. A., Temel, J. S., & Sweeney, C. (2021). Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Online: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2021 | Brennan, V., Spektor, A., Sweeney, C., Choudhury, A. D., Rathkopf, D. E., Pomerantz, M., . . . King, M. T. (2021). Evaluating the role of stereotactic body radiation therapy with respect to androgen receptor signaling inhibitors for metastatic prostate cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2020 | Morel, K. L., Sweeney, C. J., & Ellis, L. (2020). Targeting EZH2 and PI3K/mTOR for a novel combination therapeutic strategy in aggressive variant prostate cancer.. Poster session presented at the meeting of MOLECULAR CANCER RESEARCH. Boston, MA: AMER ASSOC CANCER RESEARCH. WoS1 |
| 2020 | Sengupta, S., Niazi, T., Williams, S., Davis, I. D., Stockler, M., Martin, A. J., . . . Sweeney, C. J. (2020). DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. |
| 2020 | Harshman, L. C., Wang, X. V., Yamamoto, H. S., Hamid, A., Drake, C. G., Carducci, M. A., . . . Sweeney, C. (2020). Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHAARTED trial (E3805). Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. CA, San Francisco: LIPPINCOTT WILLIAMS & WILKINS. WoS1 |
| 2019 | Francini, E., Montagnani, F., Vitale, N. P., Alimohamed, N. S., Candilejo, I. M., Rosellini, P., . . . Heng, D. Y. C. (2019). Efficacy of bone resorption inhibitors (BRI) plus abiraterone acetate plus prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2019 | Hamid, A., Beltran, H., Choudhury, A. D., & Sweeney, C. (2019). Genomic predictors of benefit of docetaxel (D) and next-generation hormonal therapy (NHT) in metastatic castration resistant prostate cancer (mCRPC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS2 |
| 2019 | Stockler, M. R., Martin, A. J., Dhillon, H., Davis, I. D., Chi, K. N., Chowdhury, S., . . . Sweeney, C. J. (2019). Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial. Poster session presented at the meeting of ANNALS OF ONCOLOGY. Barcelona, SPAIN: OXFORD UNIV PRESS. WoS4 |
| 2019 | Sheahan, A., Morel, K., Burkhart, D., Baca, S., Labbe, D., Roehle, K., . . . Ellis, L. (2019). Targeting EZH2 increases therapeutic efficacy of PD-1 blockade in models of prostate cancer. Poster session presented at the meeting of MOLECULAR CANCER THERAPEUTICS. AMER ASSOC CANCER RESEARCH. DOI |
| 2019 | Morel, K. L., Hamid, A. A., Ellis, L., & Sweeney, C. J. (2019). Dimethylaminoparthenolide-mediated inhibition of NF-κB decreases resistance to ADT by targeting AR variants in lethal prostate cancer. Poster session presented at the meeting of MOLECULAR CANCER THERAPEUTICS. AMER ASSOC CANCER RESEARCH. DOI |
| 2018 | Allott, E. H., Ebot, E. M., Gonzalez-Feliciano, A. G., Markt, S. C., Wilson, K. M., Ahearn, T. U., . . . Mucci, L. A. (2018). Molecular tumor profiling to identify mechanisms linking statin use with lower risk of lethal prostate cancer: Results from the Health Professionals Follow-up Study.. Poster session presented at the meeting of CANCER RESEARCH. Orlando, FL: AMER ASSOC CANCER RESEARCH. DOI |
| 2017 | Mahal, B. A., Yang, D. D., Sweeney, C., Trinh, Q. D., Feng, F. Y., & Nguyen, P. L. (2017). Identification of Low Prostate-Specific Antigen, High Gleason Prostate Cancer as a Unique Hormone-Resistant Entity With Poor Survival: A Contemporary Analysis of Over 600,000 Patients. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. San Diego, CA: ELSEVIER SCIENCE INC. DOI WoS3 |
| 2017 | Francini, E., Yip, S., Ahmed, N. S., Li, H., Ardolino, L., Evan, C. P., . . . Sweeney, C. J. (2017). Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT plus Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry. Poster session presented at the meeting of ANNALS OF ONCOLOGY. SPAIN, Madrid: OXFORD UNIV PRESS. |
| 2017 | Vale, C. L., Fisher, D. J., Carpenter, J., White, I. R., Burdett, S., Clarke, N. W., . . . Tierney, J. F. (2017). What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis. Poster session presented at the meeting of Abstracts of the 42nd European Society for Medical Oncology Congress (ESMO 2017), as published in Annals of Oncology. Madrid, SPAIN: Elsevier. DOI WoS3 |
| 2017 | Williams, S., Davis, I. D., Sweeney, C., Stockier, M. R., Martin, A. J., Hague, W., . . . Nguyen, P. L. (2017). Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2017 | Mckay, R. R., Werner, L., Jones, A., Choudhury, A. D., Pomerantz, M., Sweeney, C., . . . Taplin, M. -E. (2017). A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2017 | Wong, S., Sweeney, C., & Sridhar, S. S. (2017). Eligibility criteria requirements and adherence in advanced prostate cancer trials. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. DOI |
| 2017 | de Bono, J., Bracarda, S., Chi, K., Massard, C., Olmos Hidalgo, D., Sandhu, S., . . . Sweeney, C. J. (2017). Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC). Poster session presented at the meeting of ANNALS OF ONCOLOGY. SPAIN, Madrid: OXFORD UNIV PRESS. WoS1 |
| 2017 | Hurwitz, H., Raghav, K. P. S., Burris, H. A., Kurzrock, R., Sweeney, C., Meric-Bernstam, F., . . . Hainsworth, J. D. (2017). Pertuzumab plus trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS17 |
| 2017 | Kurzrock, R., Meric-Bernstam, F., Hurwitz, H., Hainsworth, J. D., Spigel, D. R., Bose, R., . . . Lam, E. T. (2017). Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS7 |
| 2017 | Sweeney, C. J., Geybels, M., Coseo-Markt, S., Wang, V., Penney, K., Gerke, T., . . . Mucci, L. (2017). A polymorphism in the promoter of the FRAS1 gene is associated with metastatic prostate cancer. Poster session presented at the meeting of ANNALS OF ONCOLOGY. Madrid, SPAIN: ELSEVIER. WoS1 |
| 2016 | Muralidhar, V., Regan, M. M., Werner, L., Nakabayashi, M., Evan, C., Bellmunt, J., . . . Nguyen, P. L. (2016). Duration of androgen deprivation therapy for high-risk prostate cancer: Application of randomized trial data in a tertiary referral cancer center. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI WoS2 |
| 2016 | Sweeney, C., Chen, Y. -H., Liu, G., Carducci, M., Jarrard, D., Eisenberger, M., . . . Dipaola, R. (2016). Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naive metastatic prostate cancer (PrCa): E3805 CHAARTED trial. Poster session presented at the meeting of ANNALS OF ONCOLOGY. DENMARK, Copenhagen: OXFORD UNIV PRESS. DOI WoS10 |
| 2016 | Xie, W., Sweeney, C., Regan, M., Nakabayashi, M., Buyse, M., Clarke, N., . . . Williams, S. (2016). Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP). Poster session presented at the meeting of Annals of Oncology. Copenhagen, Denmark: Elsevier. DOI Scopus4 WoS2 |
| 2015 | Giannatempo, P., Pond, G. R., Sonpavde, G., Albany, C., Loriot, Y., Sweeney, C., . . . Necchi, A. (2015). Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation (TMT): An international collaboration.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. |
| 2015 | Davis, I., Stockler, M., Martin, A., Hague, W., Coskinas, X., Yip, S., . . . Sweeney, C. (2015). Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET trial (ANZUP 1304). Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. WILEY-BLACKWELL. |
| 2015 | Williams, S., Davis, I., Sweeney, C., Stockler, M., Martin, A., Hague, W., . . . Nguyen, P. (2015). Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD (ANZUP1303). Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. WILEY-BLACKWELL. WoS1 |
| 2015 | Mahal, B. A., Muralidhar, V., Dinh, K. T., Chen, Y. W., Nezolosky, M. D., Choueiri, T. K., . . . Nguyen, P. L. (2015). Gleason 5+3=8 Prostate Cancer: Much More like Gleason 9?. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. San Antonio, TX: ELSEVIER SCIENCE INC. DOI |
| 2015 | Muralidhar, V., Dinh, K. T., Mahal, B. A., Ziehr, D. R., Chen, Y. W., Viswanathan, V. B., . . . Nguyen, P. L. (2015). Differential Postprostatectomy Cancer-Specific Mortality of Occult T3 Versus Clinical T3 Prostate Cancer: Implications for Radiation Managed Patients Upstaged on Prostate MRI. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. San Antonio, TX: ELSEVIER SCIENCE INC. |
| 2015 | Muralidhar, V., Ziehr, D. R., Mahal, B. A., Chen, Y. W., Nezolosky, M. D., Viswanathan, V. B., . . . Nguyen, P. L. (2015). Older Age and Increasing Gleason Score: Implications for Prostate Cancer Screening. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. San Antonio, TX: ELSEVIER SCIENCE INC. WoS1 |
| 2015 | Sweeney, C., Sartor, A. O., Vogelzang, N. J., Shore, N. D., Cislo, P., Bangerter, K., & Morris, M. J. (2015). Effect of radium-223 dichloride (Ra-223) on pain from US EAP.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2015 | Sweeney, C., Gray, K. P., Harshman, L. C., Taplin, M. -E., Pace, A. F., Dumas, K., . . . Kantoff, P. W. (2015). Phase 1 study with expansion cohorts of cabozantinib (C) plus abiraterone (A) in metastatic castration resistant prostate cancer (mCRPC): Investigator-sponsored study.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS42 |
| 2015 | Miller, R., Markt, S. C., O'Donnell, E., Bernard, B. D., Albiges, L., Lago-Hernandez, C., . . . Sweeney, C. (2015). Association of age 40 and older with adverse outcome in metastatic testicular cancer (TC). Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Coulson, H., Loda, M., O'Donnell, E., Sweeney, C., & Hirsch, M. (2015). Targeted Next Generation Sequencing of Testicular Germ Cell Tumors. Poster session presented at the meeting of LABORATORY INVESTIGATION. Boston, MA: NATURE PUBLISHING GROUP. |
| 2015 | Burris, H. A., Hurwitz, H., Perez, E. A., Spigel, D., Swanton, C., Hainsworth, J. D., . . . Sweeney, C. (2015). MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. WoS1 |
| 2015 | Sweeney, C. (2015). PRECISION MEDICINE IN PROSTATE CANCER: HOW CLOSE ARE WE?. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. Sydney, AUSTRALIA: WILEY. |
| 2015 | Sweeney, C. (2015). NEW INSIGHTS IN GCT. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. Sydney, AUSTRALIA: WILEY. |
| 2015 | Sweeney, C. (2015). IMMEDIATE DOCETAXEL IN METASTATIC PROSTATE CANCER. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. Sydney, AUSTRALIA: WILEY. |
| 2015 | Sartor, O., Coleman, R. E., Morris, M. J., Nilsson, S., Shore, N., Sweeney, C., . . . Parker, C. (2015). Baseline characteristics, number of radium-223 (Ra-223) injections, and overall survival (OS) in US Expanded Access Program (EAP) and ALSYMPCA. Poster session presented at the meeting of EUROPEAN JOURNAL OF CANCER. Vienna, AUSTRIA: ELSEVIER SCI LTD. DOI WoS16 |
| 2015 | Sartor, A. O., Fernandez, D. C., Morris, M. J., Iagaru, A., Brown, A., Almeida, F., . . . Vogelzang, N. J. (2015). Ra-223 experience in pretreated patients: EAP setting.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS3 |
| 2015 | Markt, S. C., Miller, R., O'Donnell, E., Albiges, L., Bernard, B. D., Lago-Hernandez, C., . . . Sweeney, C. (2015). BMI at diagnosis and adverse outcomes among men with malignant testicular germ cell tumors. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Gerke, T., Tyekucheva, S., Penney, K., Sweeney, C., Lis, R., Sesso, H. D., . . . Mucci, L. A. (2015). Discovery and validation of a 30-gene expression signature to identify prostate cancer patients who are candidates for active surveillance. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Morris, M. J., Higano, C. S., Scher, H. I., Sweeney, C., Antonarakis, E. S., Shevrin, D. H., . . . Carrasquillo, J. A. (2015). Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2015 | Van Allen, E. M., Kryukov, G., Bielski, C., Samocha, K., Fromer, M., Seepo, S., . . . Taplin, M. -E. (2015). Transgenerational genomic effect of chemotherapy exposure in testicular cancer survivors.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Sartor, A. O., Fernandez, D. C., Morris, M. J., Iagaru, A., Brown, A., Almeida, F., . . . Vogelzang, N. J. (2015). Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI WoS2 |
| 2015 | Coulson, H., Loda, M., O'Donnell, E., Sweeney, C., & Hirsch, M. (2015). Targeted Next Generation Sequencing of Testicular Germ Cell Tumors. Poster session presented at the meeting of MODERN PATHOLOGY. SPRINGERNATURE. |
| 2015 | Williams, S. G., Davis, I. D., Sweeney, C., Stockler, M. R., Martin, A. J., Marchesin, V., . . . Nguyen, P. L. (2015). Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | McKay, R. R., Werner, L., Harshman, L. C., Bellmunt, J., Sweeney, C., Rosenberg, J. E., . . . Choueiri, T. K. (2015). A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS6 |
| 2015 | Curreri, S. A., Markt, S. C., Miller, R., O'Donnell, E., Bernard, B. D., Kamran, S. C., . . . Beard, C. (2015). Bilateral testicular germ cell tumors. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Morris, M. J., Higano, C. S., Scher, H. I., Sweeney, C., Antonarakis, E. S., Shevrin, D. H., . . . Carrasquillo, J. A. (2015). Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS2 |
| 2015 | Pal, S. K., Azad, A., Bhatia, S., Drabkin, H. A., Costello, B. A., Sarantopoulos, J., . . . Hutson, T. E. (2015). Association of baseline IL-8 and ferritin with clinical outcome with everolimus and BNC105P in the DisrupTOR-1 trial. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Vogelzang, N. J., Fernandez, D. C., Morris, M. J., Iagaru, A., Brown, A., Almeida, F., . . . Sartor, A. O. (2015). Radium-223 dichloride (Ra-223) in US expanded access program (EAP).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI WoS4 |
| 2015 | Bernard, B. D., Markt, S. C., Albiges, L., Miller, R., Beard, C., & Sweeney, C. (2015). Melanoma risk in men with testicular germ cell tumors in the United States. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Morris, M. J., Sartor, A. O., Vogelzang, N. J., Shore, N. D., Cislo, P., Bangerter, K., & Sweeney, C. (2015). Effect of radium-223 dichloride (Ra-223) on pain from US EAP.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI WoS5 |
| 2015 | Davis, I. D., Stockler, M. R., Martin, A. J., Marchesin, V., Deignan, O., McDermott, R., . . . Sweeney, C. (2015). Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Albiges, L., Xie, W., Chen, Y. -H., Boher, J. -M., Valenca, L. B., Bernard, B. D., . . . Sweeney, C. (2015). Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2014 | Cortazar, J. M., Howitt, B. E., O'Donnell, E., Sweeney, C., Ulbright, T., & Hirsch, M. S. (2014). Hilar Soft Tissue Involvement by Testicular Germ Cell Tumors Is Associated with Advanced Stage Indicators. Poster session presented at the meeting of LABORATORY INVESTIGATION. San Diego, CA: NATURE PUBLISHING GROUP. |
| 2014 | Williams, S., Davis, I., Sweeney, C., Stockler, M., Martin, A., Long, A., . . . Nguyen, P. (2014). RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN ANDROGEN DEPRIVATION THERAPY WITH RADIATION THERAPY FOR HIGH RISK, CLINICALLY LOCALISED, PROSTATE CANCER: THE ANZUP ENZARAD STUDY. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. |
| 2014 | Sweeney, C., Gray, K. P., Harshman, L. C., Elfiky, A., Choueiri, T. K., Pomerantz, M., . . . Kantoff, P. W. (2014). Phase 1 dose-finding study of cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): An investigator-sponsored study.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS1 |
| 2014 | Sweeney, C., Chen, Y., Carducci, M., Liu, G., Jarrard, D., Eisenberger, M., . . . Dipaola, R. (2014). CHEMOHORMONAL THERAPY VERSUS HORMONAL THERAPY FOR HORMONE NAIVE HIGH VOLUME NEWLY METASTATIC PROSTATE CANCER (PRCA): ECOG LED PHASE III RANDOMIZED TRIAL. Poster session presented at the meeting of ANNALS OF ONCOLOGY. Madrid, SPAIN: OXFORD UNIV PRESS. DOI WoS2 |
| 2014 | Kaymakcalan, M. D., Stuver, S., Sweeney, C., Choueiri, T. K., & Elfiky, A. (2014). Patient risk factors and pegfilgrastim use in cabazitaxel-treated prostate cancer pateints in an academic setting.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2014 | Mahal, B. A., Aizer, A. A., Ziehr, D. R., Hyatt, A. S., Choueiri, T. K., Jim, H. C., . . . Nguyen, P. L. (2014). The Impact of Race on Prostate-Cancer Specific Mortality Among Men With Low-Risk Disease: Potential Implications for Active Surveillance. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. San Francisco, CA: ELSEVIER SCIENCE INC. DOI |
| 2014 | Sweeney, C., Chen, Y. -H., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., . . . DiPaola, R. S. (2014). Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. |
| 2014 | Mahal, B. A., Aizer, A. A., Ziehr, D. R., Hyatt, A. S., Sammon, J. D., Schmid, M., . . . Nguyen, P. L. (2014). Racial Disparities in the Management of African American Men With Intermediate- to High-Risk Prostate Cancer. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. San Francisco, CA: ELSEVIER SCIENCE INC. DOI WoS1 |
| 2014 | Sweeney, C., Chen, Y. -H., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., . . . DiPaola, R. S. (2014). Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrca): An ECOG-led phase III randomized trial. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. |
| 2014 | Mahal, B. A., Ziehr, D. R., Hyatt, A., Aizer, A. A., Sammon, J. D., Schmid, M., . . . Paul, L. N. (2014). The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2014 | Cortazar, J. M., Howitt, B. E., O'Donnell, E., Sweeney, C., Ulbright, T., & Hirsch, M. S. (2014). Hilar Soft Tissue Involvement by Testicular Germ Cell Tumors Is Associated with Advanced Stage Indicators. Poster session presented at the meeting of MODERN PATHOLOGY. San Diego, CA: NATURE PUBLISHING GROUP. |
| 2014 | Zukotynski, K., Kim, C., Gerbaudo, V., Hainer, J., Van Den Abbeele, A., Seltzer, S., & Sweeney, C. (2014). Prognostic value of baseline evaluation of FDG and NaF PET/CT in castrate-resistant prostate cancer (CRPC): Early results from a prospective phase 1 trial. Poster session presented at the meeting of JOURNAL OF NUCLEAR MEDICINE. MO, St Louis: SOC NUCLEAR MEDICINE INC. |
| 2014 | Howard, S. A. H., Gray, K. P., O'Donnell, E., Fennessy, F. M., Beard, C., & Sweeney, C. (2014). Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2014 | O'Donnell, E., Feldman, H., Lago-Hernandez, C., Hirsch, M. S., Beard, C., Van Allen, E. M., . . . Sweeney, C. (2014). Tumor genomic mutation profiling of germ cell tumors using "Profile".. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2014 | Davis, I., Stockler, M., Martin, A., Long, A., Yip, S., Coskinas, X., & Sweeney, C. (2014). RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN FIRST LINE ANDROGEN DEPRIVATION THERAPY FOR METASTATIC PROSTATE CANCER: THE ANZUP ENZAMET STUDY. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. |
| 2013 | Choueiri, T. K., Jacobus, S. J., Qu, A. Q., Sweeney, C., Appleman, L. J., Tretter, C. P. G., . . . Ross, R. W. (2013). A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2013 | Milowsky, M. I., Dittrich, C., Martinez, I. D., Jagdev, S., Millard, F. E., Sweeney, C., . . . Sternberg, C. N. (2013). Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated <i>FGFR3</i>. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI WoS19 |
| 2013 | Hutson, T. E., Dang, L. H., Lauer, R. C., Starodub, A., Hauke, R. J., Galsky, M. D., . . . Sarantopoulos, J. (2013). Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC). Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2013 | Elfiky, A., Kaymakcalan, M., Stuver, S., Sweeney, C., Jacobson, J. O., & Weingart, S. (2013). Developing and promoting evidence-based use of granulocyte colony stimulating factors (GCSF) in the palliative chemotherapy setting. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Diego, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2013 | O'Donnell, E., Gray, K. P., Ravi, P., & Sweeney, C. (2013). A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic nonseminomatous germ cell tumor (NSGCT). Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2013 | Sarantopoulos, J., Dang, L. H., Lauer, R. C., Starodub, A., Hauke, R. J., Galsky, M. D., . . . Hutson, T. E. (2013). A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients: Updated phase I results of the Disruptor-1 trial. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. WoS1 |
| 2013 | Scher, H. I., Smith, M. R., Sweeney, C., Corn, P. G., Logothetis, C., Vogelzang, N. J., . . . Basch, E. M. (2013). An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. |
| 2013 | Yoo, S. M., Werner, L., Nakabayashi, M., Sweeney, C., Hirsch, M. S., Kantoff, P. W., & Pomerantz, M. M. (2013). Clinicopathologic features and clinical outcomes associated with Gleason upgrading from biopsy to radical prostatectomy. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. |
| 2013 | O'Donnell, E., Gray, K. P., Hirsch, M. S., Ravi, P., Beard, C., & Sweeney, C. (2013). A 10-year retrospective review of germ cell tumors not cured with cisplatin-based chemotherapy. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2013 | Morris, M. J., Hammers, H. J., Sweeney, C., Antonarakis, E. S., Cho, S. Y., Pandit-Taskar, N., . . . Carrasquillo, J. A. (2013). Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. WoS10 |
| 2013 | Chi, K. N., Sweeney, C., Jacobs, C., Stewart, P. S., & Hahn, N. M. (2013). The Pacific trial: A randomized phase II study of OGX-427 in men with metastatic castration-resistant prostate cancer (mCRPC) and PSA progression while receiving abiraterone acetate (AA).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. WoS1 |
| 2013 | Strock, J., Gray, K. P., Nakabayashi, M., Evan, C., O'Donnell, E., Pomerantz, M., . . . Sweeney, C. (2013). Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Orlando, FL: AMER SOC CLINICAL ONCOLOGY. DOI WoS3 |
| 2013 | O'Donnell, E., Gray, K. P., Hirsch, M. S., Kantoff, P. W., Beard, C., & Sweeney, C. (2013). Smoking history and disease outcomes in patients with malignant germ cell tumors.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. |
| Year | Citation |
|---|---|
| 2025 | Williams, C., Morel, K., Kumorkiewicz-Jamro, A., Johnstone, D., Le, H., Sweeney, C., & Wardill, H. (2025). Radioprotective effects of parthenolide lotion against skin injury caused by radiation (REPAIR-1): protocol for a phase 0, non-randomised, double-blind, interventional pilot study. DOI |
| 2024 | Bührer, E., D'Haese, D., Daugaard, G., de Wit, R., Albany, C., Tryakin, A., . . . Beyer, J. (2024). Impact of Teratoma on Survival Probabilities of Patients with Metastatic Non-Seminomatous Germ Cell Cancer. DOI |
| 2024 | Pommier, P., Xie, W., RAVI, P., CARRIE, C., DIGNAM, J. J., Feng, F., . . . Sweeney, C. (2024). Prognostic Factors in Post-Prostatectomy Salvage Radiotherapy Setting with and Without Hormonotherapy: An Individual Patient Data Analysis of Randomized Trials from Icecap Database. DOI |
| 2024 | Soon, Y. Y., Marschner, I. C., Schou, M., Sweeney, C., Davis, I., Stockler, M. R., & Martin, A. J. (2024). Challenges of Estimating Treatment Effects after a Positive Interim Analysis. DOI |
| 2022 | Morel, K., Hamid, A., Falcón, B., Nanda, J., Linder, S., Bergman, A., . . . Ellis, L. (2022). Loss of tristetraprolin activates NF-κB induced phenotypic plasticity and primes transition to lethal prostate cancer. DOI |
| 2021 | Freedman, M., Baca, S., Singler, C., Zacharia, S., Seo, J. -H., Morova, T., . . . Gusev, A. (2021). Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation. DOI |
| 2019 | Sheahan, A., Morel, K., Burkhart, D., Baca, S., Labbé, D., Roehle, K., . . . Ellis, L. (2019). Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer. DOI |
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2025 | Co-Supervisor | Advancing treatment options for triple-negative breast cancer through NF-kB inhibition | Doctor of Philosophy | Doctorate | Full Time | Miss Huimin Shao |
| 2025 | Co-Supervisor | Investigating the role of the extracellular matrix protein complex FRAS1/FREM2 on the metastatic progression of breast and prostate cancer | Doctor of Philosophy | Doctorate | Full Time | Ms Christina Jos . |
| 2024 | Principal Supervisor | Investigating Context Specific Gene Regulation in Cancer | Doctor of Philosophy | Doctorate | Full Time | Ms Malvika Kharbanda |
| 2024 | Co-Supervisor | Investigating a role for NF-KB inhibition in overcoming therapeutic resistance to EGFR TKIs in lung cancer | Doctor of Philosophy | Doctorate | Full Time | Miss Basira Najafzadeh Sotoubadi |
| 2023 | Co-Supervisor | Identifying novel metabolic drivers of lethal prostate cancer | Doctor of Philosophy | Doctorate | Full Time | Dr Michael Cilento |
| 2023 | Co-Supervisor | Defining and describing different clinical phenotypes of local and metastatic prostate cancer using Prostate Specific Membrane Antigen PET | Doctor of Philosophy | Doctorate | Part Time | Dr Mrunal Devendra Hiwase |
Connect With Me
External Profiles
